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ABSTRACT 
Fetal growth is influenced by the in utero environment and genetic factors inherited 
from both parents. Poor fetal growth leading to low birth weight is associated with 
insulin resistance and type-2 diabetes in later life.  
The fetal programming of adult disease hypothesis suggests that growth-restricted 
fetuses make enduring physiological adaptations that predispose to diabetes in later 
life. The fetal insulin hypothesis suggests that poor fetal growth and diabetes are two 
phenotypes of genetically determined insulin resistance. Under these circumstances, 
an insulin resistant fetus cannot optimise insulin-mediated growth and is predisposed 
to diabetes in later life. Environmental and genetic influences come together through 
epigenetic modifications, for example DNA methylation, that alter gene expression 
without altering the nucleotide sequence.  
The first aim of this thesis was to investigate whether men who fathered pregnancies 
complicated by fetal growth restriction had an insulin resistant phenotype at the time 
of the index pregnancy. A case-control study showed that men who fathered growth-
restricted offspring have pre-clinical insulin resistance and are more likely to smoke 
than fathers of normal grown offspring. This observation supports the concept that an 
insulin resistant genotype inherited from a father could manifest as poor fetal growth 
in offspring.  
I then investigated the mechanisms through which paternal insulin resistance might 
be inherited by a growth-restricted fetus. I studied DNA extracted from the cord 
blood of growth-restricted offspring using whole exome sequencing to identify novel 
gene variants and those known to be associated with type-2 diabetes. I validated 
findings with Sanger sequencing and Taqman genotyping in all family members. 
 Using the Illumina Human 450 BeadChip, I found marked differences in genome 
wide DNA methylation of fetal cord blood and placental samples from growth 
restricted compared with normal grown offspring. 
 Future work is aimed at investigating the functional consequences of genetic and 
epigenetic differences to identify targets for treatment and prophylaxis against fetal 
growth restriction and diabetes. 
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Chapter 1:  INTRODUCTION                                                           
 
1.1 Fetal growth 
In utero growth from a single cell to a fully formed neonate is the most fundamental 
yet complex process we undergo. Fetal growth and development are driven by genes 
inherited from both mother and father and the interplay of those genes with the in 
utero environment. Of particular importance is the interaction between maternal and 
fetal genes at the utero-placental interface, as these dictate placental development. 
Failure of the placenta to invade the uterine placental bed is a common cause of 
reduced fetal growth in the developed world. In the developing world, environmental 
factors such as maternal malnutrition and disease more commonly influence fetal 
growth (Bodsky D et al., 2004; Maulik 2006b & 2006c). 
When the gene-environment interaction is sub-optimal, a fetus will adapt to optimise 
its growth potential. Fetal adaptations are however inevitably a compromise and 
result in reduced birth weight. Furthermore, as in utero growth is so rapid and 
profound, fetal adaptations may have a commensurately profound and enduring 
effect on its’ life-long health. This thesis explores how genes and environment 
interact to result in severely compromised fetal growth.  
 
1.2 Consequences of poor fetal growth  
Given optimal conditions, a fetus follows a growth trajectory in-utero that allows it 
to  fulfil  its  own  unique  growth  potential  and  reach  its  expected  birth  weight.  In 
contrast, fetal growth restriction (FGR) occurs when a fetus is unable to reach its 
growth potential (Pallotto E et al., 2006).  FGR should be considered a syndrome, 
with  multi-factorial  origins  which  can  broadly  be  divided  into  maternal,  fetal  or 
placental causes (Figure 1.1).      Chapter 1: Introduction     
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Fig 1.1 Known causes of fetal growth restriction and normal role of placenta 
 
 
1.3 Fetal Growth Restriction  
FGR is the second leading cause of perinatal morbidity and mortality affecting 
around 5% of all babies (which equates to over 8 million worldwide each year) 
(Neerhof MG, 1995 & Bernstein IM et al., 2000).  It poses a significant health and 
socio-economic problem in both developed and developing countries. Problems 
relate to immediate in-utero and birth complications, increased neonatal problems, 
childhood and adolescent development problems and disease in later life. 
 1.3.1 Immediate consequences of fetal growth restriction 
Stillbirth accounts for up to 1 in 200 pregnancies in the United Kingdom (CEMACH, 
2009) of which a significant proportion will be affected by growth restriction. A 
fetus with growth restriction has an increased risk of intrauterine death (OR 7; 95% 
CI 3.3-15.1) (Froen JF et al., 2004), with the severity of FGR related to stillbirth risk 
independently of gestational age (Piper JM et al., 1996 and Divon MY, 1998). 
     Chapter 1: Introduction     
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Perinatal mortality is also increased in FGR offspring up to 10 fold compared to 
similar gestational aged babies (Lackman F et al., 2001 and McIntire DD et al., 
1999). Within growth restricted fetuses those with more severe pathology (as 
determined by fetal ultrasound patterns of reversed or absent Doppler blood flow 
patterns) have been shown to have the highest perinatal mortality (Hackett GA et al., 
1997 and Simchen MJ et al., 2000). 
1.3.2 Long term consequences of poor fetal growth 
Poor fetal growth and subsequent low birth weight are risk factors for the future 
development of impaired glucose tolerance (IGT), metabolic syndrome, type 2 
diabetes (T2DM) and cardiovascular disease (Hales CN et al., 1991 and Barker DJP 
et al., 1993).  Through the reporting of birth weight records, of men and women in 
middle and later life living in Hertfordshire, it was identified that the incidence of 
impaired glucose tolerance or T2DM in these men (mean age 64 years) fell from 
40% if born at less than 2.5kg to less than 14% if born at more than 4.3kg  (Figure 
1.2). In these same men, blood pressure also inversely correlated with reported birth 
weight (Barker DJ et al., 1993). This trend was maintained when reported weight at 
age 1 was assessed in these men in relation to IGT and T2DM.  
  
Figure 1.2 Reproduced data from Hertfordshire cohort of men aged 64 with metabolic 
syndrome or T2DM in relation to birth weight (Barker DJ et al., 1993) 
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Many subsequent studies have confirmed the link between birth size and future 
cardio-metabolic disease.  An inverse correlation was seen between a measure of 
leanness the ‘ponderal index’ (calculated from birth weight/length
3) at birth and 
subsequent insulin concentrations in 1333 Swedish men aged 50 and presence of 
diabetes in these men at aged 60 (Lithell HO et al., 1996).  
A prospective study of 1258 men from South Wales revealed those born in the 
lowest birth weight quartile had the highest incidence of coronary heart disease 
during a 10 year follow up (Frankel S et al., 1997).  
 
1.4 Role of fetal insulin in growth 
Fetal insulin, a growth factor, acting mainly in the third trimester, is one of the key 
determinants of fetal growth (Constância M et al., 2012). An example of the 
importance of insulin in fetal growth can be seen in gestational diabetes where 
fetuses are often macrosomic. High maternal glucose levels pass easily across the 
placenta to cause elevated fetal glucose levels, which results in over-production of 
insulin by the fetus and increased fetal growth (Pedersen, 1952).  
In diabetic pregnancies with good maternal blood glucose control, macrosomia is 
less commonly seen compared with poorly controlled gestational diabetes (Naylor 
CD et al., 1993).  In normal pregnancy a direct correlation can be seen between 
maternal blood glucose and offspring birth weight (Tallarigo L et al., 1986 and 
Sermer N et al., 1995), providing evidence that glucose homeostasis mechanisms are 
vital in fetal growth. 
One of the ways fetal insulin is thought to be regulated is by insulin growth factor-1 
(Constância M et al., 2012). In humans, fetal serum IGF-1 levels have been shown to 
correlate with birth weight with lower levels observed in FGR babies (Maulik D, 
2006). Low levels of IGF-1 and elevated levels of IGF binding protein-1 (IGFBP-1) 
have consistently been observed in FGR infants (Wang HS et al, 1991).     Chapter 1: Introduction     
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Transgenic mice overexpressing IGFBP-1 demonstrate poor growth (Crossey PA et 
al., 2002) and abnormal trophoblast differentiation and provide further evidence that 
insulin and its regulators has a role in placental development and fetal growth.  
 
1.5 The fetal insulin hypothesis 
The importance of insulin and insulin pathways as mediators of fetal growth is 
explored further in the fetal insulin hypothesis (Hattersley AT and Tooke JE, 1999). 
In the reverse of the situation previously described, where fetuses are macrosomic as 
a result of maternal hyperglycaemia, the fetal insulin hypothesis provides a 
mechanism whereby genetically inherited fetal insulin resistance leads to poor 
growth and low birth weight.  If fetal insulin mediated growth can reflect maternal 
glycaemia then fetal genetic factors which regulate the ability of the fetus to secrete 
insulin and the ability of fetal tissues to be sensitive to the effects of insulin (i.e. the 
degree of insulin resistance) must also influence fetal growth. 
 A genetic defect in either the sensing of the maternal glucose by the fetal pancreas, 
or insulin secretion by the fetal pancreas, or the action of the insulin on the insulin-
dependent tissues, would all result in reduced fetal growth (Figure 1.3). It is this 
mechanism of fetal insulin resistance and or beta cell dysfunction that underlies the 
hypothesis and provides insight into how a growth restricted fetus may also be 
predisposed to later T2DM development. 
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Figure 1.3 The fetal insulin hypothesis. In response to maternal glucose, fetal genetics 
influence glucose and insulin sensing by fetal pancreas and alter insulin response which is 
critical in fetal growth. Reproduced from: Frayling T M, and Hattersley A T Br Med Bull 
2001; 60:89-101 
 
1.6 Evidence of a genetic influence on fetal growth 
Despite growth restriction being the extreme phenotype, evidence that further 
supports a genetic influence in fetal growth is based on studies performed across the 
spectrum of birth weight. There is a strong correlation in family birth weights 
between siblings (Tanner JM et al., 1972). Estimates of heritability suggest fetal 
genes explain around 30% of the normal variation in birth weight and birth length 
(Lunde A et al., 2007). 
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1.6.1 Imprinted genes 
Genomic imprinting is a process through which the expression of a gene is dependent 
on the sex of the parent from which it was inherited (Morrison IM et al., 1998). 
Imprinted genes have been implicated in growth disorders (Haycock PC et al., 2009). 
An example of an imprinted gene disorder resulting in a growth restricted phenotype 
is transient neonatal diabetes mellitus (TNDM). Paternal inheritance of an imprinted 
gene (PLAGL1) on chromosome 6 has been found in offspring affected by TNDM 
(Temple IK et al., 1996). 
 In addition to the diabetic phenotype, infants suffering from TNDM have markedly 
reduced birth weights (<1
st centile) (Shield JPH, 1996). This rare genotype is a good 
example of a gene mutation that can result in two apparently disparate phenotypes – 
diabetes and fetal growth restriction.  Over 60 imprinted genes have been identified 
(Morrison IM et al., 1998) and in many cases a phenotype has been identified which 
is associated with altered fetal growth (e.g. overgrowth in Prader-Willi syndrome and 
poor growth in TNDM and Silver-Russell syndrome). However, these are rare 
examples and it seems unlikely that imprinted genes have a significant role in the 
common variation seen in birth weight or the majority of cases of fetal growth 
restriction. 
 
 1.7 Monogenic diabetes, birth weight and T2DM risk 
Further evidence for a genetic influence in fetal growth arises through the study of 
monogenic conditions which occur as a result of a defective single gene (Lenderman 
HM, 1995). Maturity-onset diabetes of the young (MODY) is a form monogenic 
diabetes characterised by single autosomal dominant mutations in a range of 
individual genes accounting for 1-2% of non-insulin dependent diabetes in Europe 
(Lenderman HM, 1995).      Chapter 1: Introduction     
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Whilst MODY is a genetically heterogeneous collection of primarily autosomal 
dominant mutations on a number of genes, up to 80% of cases can be attributed to 
heterozygous mutations on one of four genes; GCK, HNF1α, HNF1β and HNF4α 
(Ellard S et al., 2008). About 14% of diagnosed cases are mutations within the gene 
for the enzyme gluckokinase (GCK) (Stride A et al., 2002).  
Glucokinase is a hexokinase enzyme that phosphorylates glucose to glucose-6-
phosphate which within beta cells is closely linked to insulin secretion (Meglasson 
MD et al., 1986). Mutations in this gene first provided evidence for the fetal insulin 
hypothesis and showed that genetic inheritance of a single gene mutation in GCK 
from father to offspring could result in low birth weight.  
Over 100 mutations within the gene have been described (Stride A et al., 2002).  
Heterozygous presentation usually results in mild hyperglycaemia often only 
detected during screening for gestational diabetes. This gene mutation was one of the 
first studied and able to provide a plausible mechanism for a single genotype causing 
pleiotropic effects that leads to both low birth weight and diabetes.  
Maternal GCK heterozygotes provide a hyperglycaemic environment to the fetus 
which in turn increases its insulin secretion with a resultant higher birth weight. Fetal 
GCK heterozygotes fail to secrete insulin efficiently for fetal growth with a resultant 
decrease in birth weight. In the presence of maternal-fetal heterozygotes the normal 
increase in insulin secretion (to the maternal hyperglycaemic environment) fails in 
the fetus, resulting in no difference in birth weight from wild-type controls.   
As shown in Figure 1.4, mother-offspring pairs carrying the glucokinase mutation 
showed that on average, birth weight is decreased by 533g if the GCK mutation is 
present in the fetus but not mother. Conversely, when the GCK mutation is present in 
the mother and not the fetus, birth weight is increased by 601g. When a mutation is 
present in both mother and offspring birth weight is unaffected (Hattersley et al., 
1998). GCK mutations cause impaired glucose sensing, which reduces an affected 
individual’s ability to secrete insulin and results in stable fasting hyperglycaemia 
throughout life (Froguel P et al., 1993).     
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Figure 1.4 The effect of mutations in the glucokinase gene on centile birth weight from 59 
offspring  pairs  (M+  mother  with  mutation:  F+  fetus  with  mutation)  (Frayling  T  M, 
Hattersley a T Br Med Bull 2001; 60:89-101). 
 
1.7.1 GCK mutations and evidence provided through animal models 
In mice, fetuses heterozygous for a GCK mutation resulted in significantly lower 
birth weight replicating what has been identified in humans (Terauchi Y et al., 2000).  
Metabolites of the insulin pathway could also be investigated more easily than in 
humans.  Low birth weight in the presence of gluckokinase mutation was also 
associated with insulin receptor substrate 1 (IRS-1) deficiency. IRS-1 is the major 
substrate of the insulin receptor tyrosine kinase and peripheral insulin resistance has 
been shown in IRS-1 deficient mice (Tamemoto H et al., 1994). The study confirmed 
the human subject data but also went on to provide direct evidence of a link to 
insulin and lower birth weight in the offspring.     Chapter 1: Introduction     
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1.7.2 Other MODY genes that support a negative influence on fetal growth  
A similar birth weight profile has also been seen in conjunction with mutations in 
other genes associated with MODY including HNF1β. Neonates studied with HNF1β 
mutations were on average 900g lighter than negative controls (Edghill EL et al., 
2006). 
Aside from the gluckokinase mutation almost all known MODY mutations lie in 
transcription factor genes responsible for gene expression and tissue development. In 
these mutations the exact mechanisms leading to diabetes is less clear but it is 
apparent that there is a defect in insulin sensing and subsequent beta cell function. 
The different phenotypes or time of disease onset in MODY may be explained by the 
different mechanisms of beta cell dysfunction that are occurring. Not all mutations 
may be able to have an impact in-utero and only those that do are likely to influence 
birth weight.  
However, monogenic forms of diabetes form only a small proportion (2-5%) of all 
diabetes cases, and are unlikely to explain the majority of growth restriction or 
susceptibility to T2DM. T2DM is characterized by both insulin secretory dysfunction 
and peripheral insulin resistance (Taylor S et al., 1994).  
T2DM development is more complex than monogenic forms of diabetes with 
individual susceptibility influenced by genetic variation and environmental 
exposures encountered during life (Stumvoll M et al., 2005). However, there is 
evidence for a genetic influence in T2DM. Siblings of parents who have diabetes 
have  a 3- 4 fold risk of developing T2DM over the general population (Kobberling J 
et al., 1982) and T2DM is more concordant  in monozygotic as opposed to dizygotic 
twins (Newman B et al., 1987). Whilst environment is also shared in most of these 
instances, further evidence of a genetic basis is drawn from studies where despite 
environmental similarities risk of diabetes development is altered by genetic 
admixture. An example of this is the Pima Indian community where Caucasian 
genetic admixture altered the risk of developing diabetes (Williams RC et al., 2000).  
     Chapter 1: Introduction     
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1.8 Genetic influence of T2DM risk alleles  
Genome wide association studies (GWAS) which provide strong, reproducible 
associations between common genetic variants and disease state have yielded some 
useful information about genetic risk loci in T2DM. Currently there are around 40 
published loci reproducibly associated single nucleotide polymorphisms (SNPs) 
(McCarthy M et al., 2010).  
However, the influence of each of these genes is modest. The largest effect in 
relation to T2DM is seen with TCFL7 (transcription factor 7-like-2), with a per allele 
odds ratio of 1.4. The 15% of population who carry two risk alleles are twice more 
likely to develop T2DM than the 40% population who do not carry the alleles 
(Zeggini E et al, 2007). It has been shown that individual smaller effect sizes can 
combine to generate higher individual risk of developing T2DM (Weedon MN et al., 
2006). 
Genetic mutations in monogenic diabetes have been shown to have a large effect size 
on fetal growth (Table 1.1) with common variants found in polygenic T2DM having 
smaller effects (Table 1.2). It is unclear if these influences may be additive. Given 
the potential genetic basis for both T2DM and the observed and potentially 
interlinked association between MODY; genetic loci that predispose to T2DM 
(particularly those implicated in the rarer inherited monogenic diseases associated 
with low birth weights, such as MODY) are of interest in FGR.         
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Table 1.1  Genes known to cause monogenic diabetes and subsequent birth weight effect (when assessed in small sample cohorts with specific heterozygous 
mutations) and the relationship of these genes with common T2DM risk loci and birth weight. The example of GCK shows that despite a heterozygous 
genotype resulting in decreased birth weight, when the recognised T2DM risk allele is present, birth weight is increased and thought to be driven by maternal 
genotype.
Gene  Genetic defect  Adult 
clinical  trait 
BW decrease 
(g) 
BW increase 
(g) 
Reference 
GCK (rs1799884) 
 
Fasting glucose    64
c  Weedon et al. 2005 
  Het mutation    531
d    Frayling et al., 2001 
HNF1α    No
b      Hegele et al. 1999 
HNF1β (rs757219)  T2DM  No    Winckler et al.2007 
  Het mutation    900     
HNF4α (rs1884614)  T2DM  No    Hanson et al. 2005 
  Het mutation      790
e  Pearson et al. 2007 
KCNJ11 (rs5215/19)  T2DM  No
a     
  Het mutation         TNDM
f    Slingerland et al. 2006 
 
a Once maternal genotype accounted for       
 
b Specific mutation in Oji-Cree population predisposes to early onset T2DM 
c Driven by maternal genotype 
 d Neutral if present in fetus and mother    
e According to recalled birth weight  
f With resultant low birth weight            
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Table 1.2  Common T2DM risk SNP loci where an effect on birth weight has been assessed in a large sample cohorts 
 
Gene  Common 
T2DM SNP 
Adult Clinical 
trait 
Per risk 
size on 
Weight 
allele effect 
Birth             
(g)* 
 References   
      Decrease    Increase      
CDKAL1   rs10946398  T2DM  21    Andersson et al. 2010   
CDKN2A-2B   rs10811661  T2DM    11  Freathy et al. 2009  Andersson et al. 2010 
HHEX-IDE   rs1111875  T2DM  14    Andersson et al. 2010   
IGF2BP2   rs440290  T2DM    4  Freathy et al. 2009  Andersson et al. 2010 
SLC30A8   rs13266634  T2DM    12  Freathy et al. 2009  Andersson et al. 2010 
ADCY5   rs9883204  T2DM  30    Freathy et al. 2010   
CCNL1   rs900400  No known risk  42    Freathy et al. 2010   
TCFL7   rs7903146  T2DM    18  Freathy et al. 2007  Andersson et al. 2010 
WFS1   
rs10010131 
T2DM  NA
a    Freathy et al. 2010   
FTO   rs8050136  T2DM  NA    Freathy et al. 2010   
PPARG  rs1801282  T2DM  NA    Freathy et al. 2010   
NOTCH2  rs10923931  T2DM  NA    Freathy et al. 2010   
THADA  rs7578597  T2DM  NA    Freathy et al. 2010   
JAZF1  rs864745  T2DM  NA    Freathy et al. 2010   
             
*BW (birth weight) Adjusted for sex and gestational age      
 
a Once maternal genotype accounted for    
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1.8.1 Overlap between rare glucose metabolism disorders and T2DM risk alleles  
There is overlap between rare gene mutations resulting in disorders of glucose 
metabolism and common variants of these genes that are also implicated in T2DM 
risk.  
 
Common variants on the most widely studied MODY gene GCK have not been 
robustly identified in T2DM populations (Lotfi K et al, 1997) but a mutation 
upstream from the promoter region has been associated with increased fasting 
glucose (Weedon MN et al, 2005). 
  
Of the four common MODY genes, mutations in the HNF1α gene account for about 
50% of recognised MODY cases (Stride A et al., 2002). This gene codes for a key 
member of a transcription factor network that is essential for the development and 
function of the pancreatic cell making it a reasonable target to implicate in T2DM 
risk (Odom DT et al., 2004).  A variant of HNF1α, resulting in a p.G319S change, is 
known to predispose to T2DM in the Oji-Cree population of Canada (Hegele RA et 
al., 1999) but common variants in Caucasian populations have not replicated this 
finding (Urhammer SA et al., 1997).  Despite the p. I27L polymorphism (rs1169288) 
being shown to predict future T2DM in elderly obese men (HR 1.2 [95% CI 1.1–
1.3], P = 0.0002) (Holmkvist J, 2006), large scale studies of common variants of the 
HNF1α gene have failed to find an association with T2DM risk (Weedon MN et al., 
2005 & Winckler W et al., 2005). 
 
A gene variant in HNF1β is a rarer cause of MODY. It is a gene important for the 
development of the pancreas and is associated with characteristic phenotypes like 
cystic kidney disease, liver dysfunction, and abnormal urogenital tract development 
(Winkler Wet al., 2007). Polymorphisms in HNF1β (rs757210) have been reported in 
association with type 2 diabetes in Caucasians but would seem overall to contribute 
very modestly to T2DM risk (Winckler W, 2007). 
     Chapter 1: Introduction         
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The hepatocyte nuclear factor (HNF)-4α regulates expression of genes involved in 
glucose metabolism and insulin secretion, including activation of expression of the 
insulin gene [Bartoov-Shifman R et al., 2002]. In a Danish population a common 
variant (rs1884614) near the P2 promoter in HNF4 has been shown to be associated 
with an increased risk of T2DM (OR 1.14) as well as a subtle increase in post-OGTT 
plasma glucose levels (Hansen SK et al., 2005). These findings have also been 
replicated in other populations albeit with lower odds ratios (Love-Gregory LD et al., 
2004 & Silander K et al., 2004).  
  
As better understanding of genes involved in MODY pathogenesis emerges, new 
genes and avenues of research have opened up with regards to T2DM risk.  Other 
rarer genes thought to now fall within the MODY spectrum include: PDX; INS; 
CEL; NEUROD1; WFS1 and KCNJ11, and have been studied in relation to T2DM 
risk. A common polymorphism of KCNJ11 (p.E23K) is associated with T2DM in 
Caucasians (Hani EH et al., 1998). Studies of the p.E23K variant show associations 
with impaired glucose induced insulin release and increased BMI (Nielsen EM et al., 
2003). 
 
Mutations in the gene WFS1,cause Wolfram syndrome, which is characterized by 
diabetes insipidus and juvenile-onset non-autoimmune diabetes mellitus (Inoue H et 
al., 1998). In a pooled analysis of UK populations comprising 9,533 cases and 
11,389 controls, SNPs in WFS1 were strongly associated with T2DM diabetes risk 
(Sandhu MS et al., 2007). 
 
As discussed previously, lower birth weight is a recognised phenomenon in those 
with MODY gene mutations. Several of these genes have polymorphic variations 
that increase adult risk of T2DM. This understanding makes it possible that 
polygenic loci within MODY genes may be responsible for both a growth restricted 
phenotype and T2DM presentation.      Chapter 1: Introduction         
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1.9 Birth Weight Genome Wide Association Studies (GWAS)  
The GWAS approach taken to identify T2DM risk alleles has also been taken in 
relation to birth weight. To date there has been limited success in identifying robust 
and reproducible associations. 
A meta-analysis performed by The Early Growth Genetics (EGG) Consortium 
identified two robust genetic associations with birth weight (Freathy RM et al., 
2010). One was contained within a cluster of correlated SNPs near the CCNL1 and 
LEKR1 genes (rs900400). Each risk allele present in a fetus for SNP rs900400 was 
associated with a 42g [95% confidence interval 35–48 g] lower birth weight.   
However, it is unclear how these SNPs function to influence fetal growth. 
SNP rs900400 was also associated with lower birth weight in a study of preterm 
neonates, arguing against a gestational age effect (Ryckman KK et al., 2012).  
The second cluster of SNPs identified with birth weight centred on the ADCY5 gene. 
Each additional fetal risk allele for SNP rs9883204 is associated with 30 g (95% CI: 
23–38 g) lower birth weight (Freathy RM et al., 2010). SNP rs9883204 is in linkage 
disequilibrium with SNP rs11708067 which is also known to predispose to T2DM 
(Dupuis J et al., 2010). 
In  both  instances,  despite  the  evidence  of  their  involvement  in  fetal  growth,  the 
causal mechanisms that influence fetal growth are not yet known. The ADCY5 locus 
has pleiotropic effects on glucose regulation and T2DM in adulthood as well as fetal 
growth and provides some evidence of a genetic association between lower birth 
weight and subsequent T2DM.      Chapter 1: Introduction         
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1.10 Candidate approach linking T2DM risk alleles and birth weight 
In conjunction with GWAS, candidate gene approaches have also been undertaken 
attempting to identify T2DM risk alleles that may be influencing birth weight. As 
TCFL7 has been robustly associated with T2DM, it was hypothesised that it may 
play an important role in fetal growth. However, GWAS and candidate approaches 
have failed to confirm any birth weight association with TCF7L2. In a meta-analysis 
of 24,053 individuals fetal inheritance of the T2DM risk allele SNP rs7903146 
resulted in an 18g (95% CI 7-29g) increase in birth weight (Freathy RM et al., 2007). 
However, following adjustment for maternal genotype, no birth weight differences 
could be identified.  
The candidate approach has been more successful for other T2DM risk alleles. 
19,200 individuals were assessed for the presence of risk alleles within the genes 
CDKAL1 (SNP rs10946398) and HHEX-IDE (SNP rs1111875). Birth weight was 
decreased by 21g and 14g per risk allele present respectively (Freathy RM et al., 
2009). It is likely that maternal risk alleles provide an opposing effect that increases 
birth weight. These findings have been replicated in other cohorts from around the 
world (Zhao J et al., 2009 & Pulizzi N et al., 2009). However, these and other large 
studies have on the whole failed to identify any association between birth weight and 
other T2DM common variants in PPARG, KCNJ11, SLC30A8, IGF2BP2 or 
CDKN2A/2B. 
Interestingly, although effect size alone is small it was shown that carrying four risk 
alleles for both CDKAL1 and HHEX-IDE resulted in a birth weight decrease of 80g 
in the 4% of population carrying all versus the 8% carrying none (Freathy RM et al., 
2009). This suggests that multiple gene variants have a synergistic or additive effect 
that can significantly influence fetal growth and birth weight. 
 
 
     Chapter 1: Introduction         
33 
   
1.11 The paternal influence on fetal growth 
1.11.1 Epidemiological studies 
Epidemiological work provides evidence for a paternal influence on fetal growth 
leading to low birth weight. Studies of Pima Indians support a genetic influence on 
low birth weight and T2DM transmitted from the father (Lindsay RS et al., 2000). 
Pima Indians are unusual in that their diabetes rate is one of the highest in the world. 
In this study, 50% of adult men and women had diabetes. The data revealed that men 
who had diabetes, when the mother did not, fathered children whose  birth weight 
was lower than those who were not diabetic or when the mother was diabetic 
(Lindsey RS et al., 2000) (Figure 1.5). 
 
Figure 1.5 Offspring birthweight in parents with diabetes. Reproduced from Lindsay RS et 
al., 2000 
Further epidemiological studies have validated these findings in different populations 
confirming that men who develop diabetes in later life were more likely to have 
fathered low birth weight offspring (Davey Smith G et al., 2004; Wannamethee SG 
et al., 2004, and Hypponen E et al., 2003).These fathers are also at increased risk of 
cardiovascular disease
 (Davey Smith G et al., 2007). 
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1.11.2 Phenotypic studies 
Phenotypic and functional measures have also shown a correlation between father 
and offspring. A study of infants born in Southampton showed a correlation between 
a father’s birth weight and height and the birth weight, length and placental weight of 
his offspring (Godfrey KM et al., 1997).  
It has also been shown that men who fathered small for gestational age infants were 
more likely to be obese and have larger waist circumferences, but in this study no 
measure of insulin resistance was made (McCowan LM et al., 2011). 
The  Exeter  Family  Study  of  Childhood  Health  (EFSOCH)  studied  almost  1000 
normal  grown  offspring  and  their  fathers,  and  identified    that  paternal  insulin 
resistance was inversely correlated with fetal insulin concentrations
 (Shields BM et 
al., 2006) but they did not find an association between offspring birth weight and 
paternal insulin resistance (Knight B et al., 2006).  
 
1.12 The environmental influences on fetal growth 
Genotypic  differences  do  not  account  for  all  the  influence  on  fetal  growth.  The 
maternal  environment  is  also  important.  Furthermore,  the  placenta  acts  as  the 
interface  between  mother  and  fetus  providing  essential  nutrients  and  oxygen. 
Placental  dysfunction  is  thought  to  underlie  a  significant  proportion  of  FGR.  A 
normally functioning placenta relies on a complex series of changes at the vascular 
interface that produces a low resistance, high capacitance utero-placental circulation 
allowing  for  effective  oxygen  and  nutrient  transfer  between  mother  and  fetus. 
Maintenance  of  placental  function  is  energy  intensive.  Under  physiological 
conditions,  the  placenta  consumes  as  much  as  40%  of  O2  and  70%  of  glucose 
supplied to the uterus (Meschia G, 1987 & Carter AM, 2000). In the presence of a 
sub-optimal  placental  environment  one  of  the  consequences  will  be  poor  fetal 
growth.      Chapter 1: Introduction         
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1.12.1 Placental dysfunction and fetal growth 
The placenta is of both maternal and paternal origin and shares the same genotype as 
the fetus. Placental function is directly linked to fetal development and health, and as 
such  placental  dysfunction  is  implicated  in  many  pregnancy-associated  diseases 
including;  pre-eclampsia  and  recurrent  miscarriage  as  well  as  underlying  a 
significant proportion of fetal growth restriction. The growth of the placenta and 
fetus are intrinsically linked, suggesting a common  in-utero environment benefits 
both.  However,  fetal  growth,  especially  towards  the  later  stages  of  pregnancy 
outstrips that of the placenta with placental growth plateauing in mid-gestation while 
fetal growth continues exponentially at a rate of 1.5%/day to term (Molteni RA et al., 
1978). 
Immune interactions have also been shown to have a role in placental function. In 
animals, maternal uterine Natural Killer cells (uNK) remodel maternal decidual 
blood vessels for a healthy pregnancy (Leonard S et al., 2006). Adverse immune 
interactions between placental antigens, which are specific haplotypes of HLA-C and 
inherited from both mother and father, and receptors on maternal uNK (KIR) have been 
associated with the placental syndromes; pre-eclampsia (Hiby S et al., 2004) and 
recurrent miscarriage (Hiby S et al., 2008). 
 
The development of a low resistance, high capacitance circulation is dependent on 
efficient spiral artery remodelling at the materno-fetal placental interface.  Deficient 
spiral artery remodelling within the first trimester during embryonic organogenesis 
seems to be highly associated with the subsequent development of placental 
insufficiency. Spiral arteries have been shown to be 8 times less likely to be 
remodelled at high altitude, presumably secondary to low oxygen levels, and birth 
weight has been shown to decrease with increasing altitude (Zamudio S, 2003). The 
failure of spiral arteries to develop and cause a reduction in vascular resistance may 
lead to reduced oxygen tension in the placenta and is hypothesised to limit the 
differentiation of the invading trophoblast (Tissot van Patot et al., 2010).      Chapter 1: Introduction         
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Placentas of FGR pregnancies are characterized by reduced syncytiotrophoblast 
surface area, increased thickness of the exchange barrier formed by the trophoblast 
and fetal capillary endothelium and an increase in placental apoptosis (Ishihara N et 
al., 2002 and Mayhew TM et al., 2000). This complex series of maladaptations affect 
the overall ability of the placenta to provide sufficient oxygen and nutrients to the 
fetus which in turn affect the ability of the fetus to reach its growth potential in-
utero. Depending on the degree of placental dysfunction, some fetuses may be able 
to adapt to the environment and not exhibit reduced growth whilst others will fail to 
thrive. However, direct cause and effect is not clear and despite being intrinsically 
linked to eventual poor growth, the underlying mechanisms that cause placental 
dysfunction and compromised fetal growth may differ. 
1.12.2 Maternal nutrition - The ‘thrifty phenotype’ hypothesis 
The ‘thrifty phenotype’ suggests that the maternal in-utero environment is the 
driving force between poor fetal growth and later development of T2DM (Barker 
DJP et al., 1993). In the ‘thrifty phenotype’ exposure to poor nutrition in-utero 
produces permanent changes in glucose-insulin metabolism and sensing.  
Those in-utero adaptations predispose an individual to T2DM and metabolic 
syndrome through increased insulin resistance and decreased insulin sensitivity. 
Insulin resistance as seen in T2DM is seen as a persistent effect from fetal life in 
response to adverse conditions and having to maintain glucose levels to the brain at 
the expense of glucose transport to the muscles for growth (Philips DIW, 1996).  
One of the mechanisms through which the environment might influence the placenta 
and fetus is through epigenetic modifications. 
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1.13 Environmental influence on gene expression through epigenetic 
modifications  
Epigenetics refers to molecular mechanisms which establish and maintain mitotically 
stable patterns of  gene  expression that do not  alter the  genomic DNA sequence. 
Epigenetic mechanisms enable developing organisms to produce disparate cellular 
phenotypes from the same genotype (Jirtle RL et al., 2007). These modifications take 
the form of DNA methylation, chromatin remodelling and covalent modifications to 
histones which package DNA into chromatin and include; methylation, acetylation, 
phosphorylation and ubiquitination of histones (Feinberg AP, 1983).  
 
The  best  understood  example  of  epigenetic  modification  is  DNA  methylation,  a 
covalent  addition  of  a  methyl  (CH3)  group  to  the  nucleotide  cytosine.  It  is 
maintained during cell division in mammals only at the dinucleotide C-G by the 
enzyme DNA methyltransferase- 1 (Feinberg AP, 1983).   
 
Epigenetic  events  may  explain  the  relationship  between  an  individual’s  genetic 
background, the environment, aging and disease. Whilst a DNA sequence always 
remains the same, cells in a specific tissue have the ability to vary their epigenetic 
state and hence gene expression, through their life course. 
 
The subsequent development of T2DM following a pregnancy that resulted in FGR 
may follow modifications to genes that were made in-utero by a fetus attempting to 
optimise its growth.  
 
Individual genetic loci methylation levels can be investigated on candidate genes but 
recent technological advances have meant that the whole genome can be investigated 
using  high  throughput  methylation  arrays.  These  arrays  can  simultaneously 
investigate the methylation status of 27,000 or 450,000 individual CpG sites across 
the human genome.      Chapter 1: Introduction         
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1.14 Epigenetics and maternal diet 
Maternal  diet is  one of the ways  in  which the supply of nutrients  vital  to  DNA 
methylation may be affected. Famine provides an extreme example of disruption to 
the  supply  of  nutrients  essential  in  the  methylation  pathway.  The  Dutch  Hunger 
Winter famine of 1944-45 is  unusual  in  several ways;  first, that the  famine was 
imposed on a previously well-nourished population; second, that there was a sudden 
onset and relief from the famine; and third, that despite the adversities of the war, 
midwives and doctors continued to offer professional obstetric care and kept detailed 
records of the course of pregnancy, the delivery and the size and health of the baby at 
birth. (Roseboom T et al., 2006). These unique set of circumstances  allowed the 
study of under-nutrition restricted to pregnancy alone, unencumbered by the effects 
of chronic under nutrition with all its accompanying influences, such as vulnerability 
to infection. Individuals who were exposed to the famine in-utero have been shown 
to have lower birth weights (Lumey LH et al., 1992.) and, furthermore exposure to 
famine during any stage of gestation was associated with glucose intolerance later in 
life. More coronary heart disease, a more atherogenic lipid profile, disturbed blood 
coagulation  and more obesity among those exposed to famine in early gestation was 
also noted (Roseboom T et al., 2006).  
 
The environmental factor that influences CpG methylation is methionine, the source 
of  methyl  groups,  via  a  pathway  dependent  on  folic  acid  (Giovannucci  E  et  al., 
2004). Individuals born during the Dutch famine born 60 years ago were later found 
to  have  less  DNA  methylation  of  the  imprinted  IGF2  gene  compared  with  their 
unexposed same sex siblings (Heijmans BT et al., 2008). This observation supports 
the  hypothesis  that  exposure  to  adverse  environmental  factors  in-utero  could 
permanently alter epigenetic marks which might have a bearing in adult disease risk.     Chapter 1: Introduction         
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1.15 Placental methylation  
The human placenta has a strikingly different DNA methylation profile relative to 
other somatic tissues (Christensen BC et al., 2009). This includes low global DNA 
methylation compared to healthy somatic tissue (Gama-Sosa MA et al., 1983). The 
functional role of lower methylation is not fully understood but may include the 
regulation of genome ‘plasticity’ and gene regulation. Whilst the overall pattern of 
methylation seen in the placenta is of hypomethylation there is also evidence of a 
programmed and reproducible change in methylation that occurs with increasing 
gestational age. Global methylation increases as a placenta matures (Gama-Sosa MA 
et al., 1983 & Macaulay EC et al., 2011) and genes involved in immune regulation 
are highly prevalent amongst those whose methylation changes with gestation 
(Novakovic B et al, 2011). These dynamic changes may help explain the time-of-
exposure-dependent effects of certain environments or stresses on fetal health at 
different gestational ages (Laplante DP et al., 2004) but could also reflect a change in 
cell composition of placental tissue (Dancause KN et al., 2011). 
1.15.1 Methylation of imprinted genes in the placenta 
Imprinted genes are highly conserved and expressed in the placenta. These genes are 
effectively driven by epigenetic regulation theorized to be controlled by differential 
methylation of the relevant genes (Haycock PC et al., 2009). It has been 
hypothesized that sporadic loss-of-imprinting induced through methylation change 
could occur in human placentas and contribute to abnormal placental development 
and consequentially decreased fetal growth (Maccani MA et al., 2009). 
Within the placenta regulation of imprinted gene expression appears to be less stable 
than in the fetus itself. This allows the placenta to better adapt to changing 
physiological environments but with potential adverse consequences such as poor 
growth (Novakovic B et al., 2010 & Nelissen EC et al., 2011).  
 
Paternally expressed insulin-like growth factor 2 (IGF2) gene, is imprinted and is a 
major modulator of both placental and fetal growth (Constancia M et al., 2002). IGF-
2  is co-ordinately regulated by a differentially methylated CTCF binding region     Chapter 1: Introduction         
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known as imprinting control region 1 (ICR1) or differentially methylated region 2 
(DMR2) along with H19 promoter activation (Murrell A et al., 2004 & Engel N et 
al., 2004). In growth restricted placentas the ICR1 region has been found to be 
significantly hypomethylated compared with normal grown placentas, leading to 
reduced expression of IGF2 Decreased placental methylation at the H19/IGF2 
imprinting control region is associated with normotensive intrauterine growth 
restriction but not pre-eclampsia. (Bourque DK et al., 2010). Furthermore, previous 
studies have reported a reduction in IGF2 expression in placentas from pregnancies 
associated with FGR (McMinn J et al., 2006) and complete loss of placental IGF2 
expression is associated with fetal growth restriction in mice (Fowden AL et al., 
2006). 
Reduced placental IGF2 expression leads to a reduction in size of all placental layers 
and alters the diffusional exchange characteristics of the placenta (Sibley CP et al., 
2004).  In human pregnancies, reduced exchange surface area, and likely  reduced 
transfer  capacity  of  the  placenta,  has  been  noted  in  growth  restricted  placentas 
(Mayhew TM et al., 2003). 
1.15.2 Methylation of IGF2 control regions in placenta and cord blood 
Studies have investigated DNA methylation of the regulators of IGF2 in relation to 
other tissues and postnatal cord blood. The ICR1 region was found to be similarly 
methylated in placenta and cord blood (around 50% which would be expected for 
monoallelic expression) but reduced in the DMR2 region in placenta and normally 
methylated in cord blood (Guo L et al., 2008). 
However, these results have not been reproduced. A further investigation found no 
methylation difference in these regions between FGR and normal grown placentas or 
between cord blood samples (Tabano S et al., 2012).   
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1.16 DNA Methylation in placental diseases  
DNA hypomethylation at gene enhancer regions has been identified in a study that 
investigated the methylation status of placentae from pregnancies affected by pre-
eclampsia (PET). Using the Infinium Human Methylation 450 BeadChip®, 20 
placentas from preterm PET pregnancies across a range of gestational ages were 
compared to 20 pre-term placentae unaffected by pre-eclampsia. However, sub-group 
analysis revealed no identifiable DMPs between cases of PET with concurrent FGR 
and those with PET and appropriate fetal growth (Blair JD et al., 2013)  
In a study that used the Infinium HumanMethylation27 BeadChip® platform, the 
precursor to the 450 Beadchip, 206 term placentas identified 22 methylation loci that 
could act as markers for poor growth Functional pathway analysis for the 22 genes 
where a DMP was identified centred on placental implantation and materno-fetal 
interface factors (Banister C et al., 2011).. 
 
 
1.17 DNA methylation in umbilical cord blood  
DNA  methylation  has  been  investigated  in  umbilical  cord  blood.  Using  the 
HumanMethylation27 BeadChip a cohort of appropriately grown offspring (32-43 
weeks gestation) were found to have 25 differentially methylated positions in whole 
cord blood DNA that were thought to be related to gestational age (Schroeder DW et 
al., 2011).  
 
However on the same platform, no genome wide significant methylation differences 
were seen in cord blood related to birth weight in a term population (between 2.1kg 
and 5kg) (Adkins RM et al., 2012).  
 
In a small cohort of term  pregnancies  (n=5)  affected by fetal  growth restriction, 
CD34+ cells were isolated from umbilical cord blood and methylation differences 
were  found  that  were  identified  as  being  important  in  the  pathway  involving 
hepatocyte nuclear factor 4α (HNF4A) gene (Einstein F et al., 2010). As HNF4A is a     Chapter 1: Introduction         
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candidate gene for non-insulin dependent diabetes mellitus this observation opens up 
the possibility that differential methylation of genes important in diabetes might play 
a role in fetal growth.   
 
 
1.18 Animal models supporting a role for DNA methylation in FGR  
In an animal model of FGR induced through  utero-placental insufficiency 
(secondary to ligation of the uterine arteries), cytosine methylation in pancreatic islet 
cells was different at approximately 1400 loci in male rats at 7 weeks of age, before 
they went to develop diabetes. Of the top 53 genes almost half of those tested were 
associated together in a single functional network centred on a collection of 
important metabolic and cellular regulators (Thompson RF et al., 2011). The 
majority of changes occurred in evolutionarily conserved DNA sequences with some 
loci in proximity to genes manifesting changes in gene expression which were 
enriched near genes regulating vascularization, proliferation and insulin secretion 
(Stoffers DA et al., 2003 & Simmons RA et al., 2001). 
 
A rodent model of FGR induced through placental insufficiency, showed a decrease 
in the PDX1 gene transcription mediated through a cascade of epigenetic 
modifications culminating in silencing of the PDX1 gene (Park JH et al., 2008).  
Histone modifications in association with DNA methylation differences in the 
promoter region of the gene PDX1 were identified in growth restricted rodent 
offspring, eventuating in permanent gene silencing and a diabetic phenotype (Park 
JH et al., 2008).  In health PDX1 regulates pancreatic beta cell differentiation, but 
when silenced T2DM eventuates and this study offered a new insight in epigenetic 
mechanisms linking FGR to T2DM development (Brissova M et al., 2005). PDX1 
has also been implicated in insulin transcription, acting to recruit histone 
deacetylases (HDACs) to the insulin promoter region resulting in down regulation of 
insulin gene transcription under conditions of low glucose (Mosley AL et al., 2004). 
Epigenetic regulation of genes that influence insulin transcription offers novel 
insights into potential mechanistic pathways that link poor fetal growth with later 
risk of T2DM.      Chapter 1: Introduction         
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1.19 Inheritance of epigenetic modifications across generations  
It is believed that DNA methylation throughout the genome of the developing zygote 
is almost completely removed during the cleavage phase of development. In normal 
conditions, methylation then re-establishes itself and in normal conditions in a tissue 
specific fashion (Rakyan V et al., 2006). This patterning is not limited to the embryo, 
but also occurs in a specific fashion in the extra embryonic lineages (placenta), 
although the overall levels of methylation in the placenta are significantly lower than 
that in the somatic tissues of the fetus (Jaenisch R, 1997). 
The concept that epigenetic modifications can be inherited is controversial due to 
supposed resetting of methylation in gametes. There is, however, emerging evidence 
to support the concept that some methylation marks transmitted through the gamete 
are maintained. The Agouti viable yellow (A
vy) allele in mice is responsible for coat 
colour and, if over-produced, other phenotypic consequences such as obesity. 
Depending on the methylation status of this allele, coat colour can vary from yellow 
(fully methylated) to brown (not methylated) (Morgan HD et al., 1999). It has been 
shown that A
vy methylation can be transmitted and maintained through the female 
germline, even when accounting for other factors (Morgan HD et al., 1999) 
supporting trans-generational inheritance  
In male rats, exposure to a high-fat-diet (HFD) program has been shown to result in 
β-cell ‘dysfunction’ in rat F1 their female offspring (Ng SF et al., 2010). Chronic 
HFD consumption in Sprague–Dawley fathers induced increased body weight, 
adiposity, impaired glucose tolerance and insulin sensitivity. Relative to controls, 
their female offspring had an early onset of impaired insulin secretion and glucose 
tolerance that worsened with time. 
The offspring of these obese male rats showed an altered epigenetic expression of 
more than 600 pancreatic islet genes. The greatest difference in expression was found 
in a gene called Il13ra2. In the daughters of obese fathers, the level of methylation of 
this gene was around 25% of the level seen in the control daughters     Chapter 1: Introduction         
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This is the first report in mammals of intergenerational transmission of metabolic 
sequelae from father to offspring that might be mediated through an epigenetic 
mechanism.  It opens up the possibility that transmission of epigenetic, rather than 
genetic, modifications may be responsible for the growth restricted phenotype seen 
in infants and the diabetic susceptibility identified in their fathers.  
 
1.20 Genetic-epigenetic interactions in T2DM 
Emerging work centres on the complex interplay between genotype and epi-
genotype. It is well established that SNPs can affect methylation. Within the 450HM 
array, Illumina (Illumina Inc., San Diego) have published over 150,000 recognised 
potential SNP/ methylation interacting loci. 
However, it seems far from clear whether DNA methylation is an active or passive 
process in relation to genetic variation. Using fibroblasts, T-cells and lymphoblastoid 
cells from the umbilical cords of 204 babies it was shown that inter-individual DNA 
methylation changes were mechanistically associated to genetic variation and gene 
expression in complex and context dependent ways that could in fact be of passive or 
active nature (Gutierrez-Arcelus et al., 2013).  
Evidence supports both genetic and epigenetic factors in development of T2DM.  
Whilst over 40 genetic loci have been identified in T2DM their individual molecular 
function in disease development is on the whole unclear. In many cases it has not 
been possible to identify any link to the hallmarks of T2DM, namely insulin 
resistance and/or beta cell dysfunction. The possibility arises that methylation 
differences secondary to SNPs may be critical in the pathway to disease and provide 
a molecular explanation for the mechanism by which the T2DM risk alleles act.      Chapter 1: Introduction         
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It has been shown that genetic, epigenetic and non-genetic factors integrate to 
influence the expression of a candidate gene for T2DM in human skeletal muscle. A 
SNP near the gene NDUFB6 is able to introduce a CpG site which is associated with 
increased DNA methylation, decreased gene expression, and insulin resistance in the 
muscle of elderly, but not young, individuals (Ling C et al., 2007). 
A  comprehensive  study  of  T2DM  SNP  loci  in  conjunction  with  methylation 
differences has shown that 19 of 40 known SNPs associated with T2DM cause the 
introduction  or  removal  of  a  CpG  site.  These  CpG  positions  exhibit  differential 
methylation in human pancreatic islet cells. Furthermore, in a number of instances, 
surrounding CpG positions, methylation was also affected by the presence of the 
SNP (Dayeh TA et al., 2013) 
SERPINA3 (Serpin peptidase inhibitor clade A member 3), is a protease inhibitor 
involved  in  a  wide  range  of  biological  processes.  It  is  up-regulated  in  human 
placental diseases in association with a hypomethylation of the 5′ region of the gene 
(Chebil ST et al., 2012). 
It has been shown that the promoter of SERPINA3 is transcriptionally activated by 
three  transcription  factors  (TFs)  (SP1,  MZF1  and  ZBTB7B)  with  the  level  of 
induction being dependent on the SNP rs1884082, the T allele being consistently 
induced  to  a  higher  level  than  the  G,  with  or  without  added  TFs.  When  the 
SERPINA3 promoter is methylated, the response to ZBTB7B was allele specific (the 
G  allele  was  strongly  induced,  while  the  T  allele  was  strongly  down  regulated). 
Interestingly in a small case/control study of pregnancies, the presence of T allele 
seemed to predispose to growth restriction (Chebil St et al., 2012).  
This interaction between methylation and genotype which could lead to alteration of 
gene  expression  and,  therefore,  disease  provides  a  novel  insight  into  how 
communicating genetic and epigenetic mechanisms could be involved in placental 
disorders such as fetal growth restriction.       Chapter 1: Introduction         
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1.21 Rationale for study  
Fetal growth restriction is associated with future risk of T2DM and it is hypothesised 
that these disorders are two phenotypes of the same genotype expressed under 
different environmental conditions; in utero and as an adult with abundant nutrition. 
Epidemiological studies show diabetic fathers have smaller babies and that smaller 
babies are themselves more prone to diabetes as adults. This evidence supports the 
inheritance of risk alleles for fetal growth and T2DM from the father. However it is 
also possible that genes and in utero environment interact through epigenetic 
modifications that result in both FGR and T2DM. The pathophysiology of these 
interactions is still unclear. A more complete understanding may identify 
interventions before or during pregnancy, or in early neonatal life that might reduce 
future risk of T2DM. Primary prevention of T2DM started early in life is more likely 
to be effective at reducing morbidity and mortality of this globally endemic 
condition.  
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1.22 Hypothesis 
Fetal growth restriction secondary to placental dysfunction is mediated in part by 
genetic factors inherited from father to offspring.  
Fetal growth restriction secondary to placental dysfunction creates an environment 
that modifies the fetal epigenome and which predisposes the fetus to T2DM in later 
life. 
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1.23 Thesis Aims 
  To investigate the fetal insulin hypothesis in relation to a growth restricted 
cohort by the use of a case-control study.  Specifically to identify if there is a 
paternal phenotype in men who father fetal growth restricted offspring that 
predisposes to T2DM. 
  To discover, using whole exome sequencing, if novel genetic variants are 
present in FGR offspring, which could contribute to disease pathogenesis. 
Furthermore, to investigate known candidate genes (implicated in MODY 
and T2DM) in FGR offspring. To validate findings and establish patterns of 
inheritance. 
  To explore the DNA methylation profile in FGR offspring in placental tissue 
and cord blood using a whole genome approach. Furthermore, to assess 
potential functional significance of methylation differences using other 
bioinformatics tools. 
  To interrogate potential genetic-epigenetic interactions from the data gathered 
on these FGR offspring that provide plausible functional pathways in FGR. 
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Chapter 2: Research Methods and Materials 
 
2.1 Phenotype study  
The research focused on fetal growth restriction and characterisation of parental 
phenotype. A case control study was designed which is described in detail in sections 
2.1 to 2.6.  Physical, vascular and metabolic measurements were made on mothers 
and fathers as described in section 2.7 to 2.9. 
DNA was extracted from whole blood (parents) and cord blood and placenta 
(offspring) of participants in the phenotype study. The quality of extracted DNA was 
assessed as described in section 2.12 to 2.12.4. Exome sequencing and validation 
was performed on samples as described in sections 2.13 and 2.14.  DNA methylation 
was analysed using the Illumina Human methylation 450 array as described in 
sections 2.15 and 2.16.  
2.1.1 Case- control study design 
An unmatched case control study was undertaken of babies with fetal growth 
restriction (cases) and babies of appropriate fetal growth (controls). The study was 
carried out at University College London Hospital (UCLH) between September 2009 
and May 2011. Ethical approval for the study was granted by the Joint UCLH/UCL 
(alpha) Ethical Committee (09/H0715/28). All participants gave informed consent.  
 
2.1.2 Statistical methods:  
Multivariable logistic regression was used to analyse phenotype data with case or 
control as the outcome measure.  Prior to study commencement, the primary 
explanatory variables to be explored were paternal insulin resistance [using the 
Homeostasis model assessment (HOMA) with glucose (mmol/l) and insulin (pmol/l)]  
and paternal endothelial function by flow mediated dilation (% change in diameter of Chapter 2: Research Methods and Materials 
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brachial artery between before and after flow i.e. 100x(after-before)/before). Ten 
events (cases) are required for each coefficient estimated in a logistic regression.  In 
this analysis eight coefficients were estimated. Therefore, sample size was calculated 
at 80 cases and 80 controls. 
2.1.3 Sample size calculations 
Sample size calculations were undertaken using NQuery 6.0 to show the size of 
effect detectable in a case-control study with 160 participants.  A total of 151 
observations are required to detect an odds ratio (OR) of 0.5 (or 2.0) as significantly 
different from 1.0 with 80% power and 5% two-sided significance when one 
normally distributed covariate is added to the model after adjustment for prior 
covariates and it is assumed that the covariate’s multiple correlation with covariates 
already in the model is 0.4 and that the ratio of cases to controls at the mean is 1:1. 
 
In logistic regression an OR of 0.5 for a continuous variable implies that there is a 
50% decrease in the odds of being a case for every one unit increase in the 
continuous variable and an OR of 2.0 for a continuous variable implies that the odds 
of being a case is doubled for every one unit increase in the continuous variable. 
Thus if a log transformation is applied to the primary explanatory variable IR so that 
the variable is normally distributed and IR is input as 10 x log(IR) then the study is 
large enough to detect a doubling in the odds of being a case for every 0.1 increase in 
log(IR). Or if the primary explanatory variable FMD then the study is large enough 
to detect a 50% decrease in the odds of being a case for every 1% increase in FMD, 
after adjustment for other covariates under the above assumptions, after adjustment 
for other covariates under the above assumptions.  
2.1.4 Statistical analysis 
Cases and controls were assessed for comparability with simple descriptive statistics.  
Baseline characteristics of cases and controls are summarised with means and 
standard deviations (or medians and interquartile ranges, if appropriate).  95% 
confidence limits are given for continuous variables, e.g. age, and frequency counts 
and percentages for categorical variables, e.g. sex. Statistical analysis was carried out 
using STATA 10 (StataCorp LP, Texas USA) and GraphPad Prism version 5. Visual Chapter 2: Research Methods and Materials 
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assessment of normality curves for variables was undertaken to assess for normality. 
When comparing the means of two variables an unpaired t-test was used for 
continuous variables and a 2x2 table for categorical data. Two tailed P-values <0.05 
were considered statistically significant.  
 
Multivariable logistic regression was carried out on paternal phenotype data using 
STATA.  Results are reported as odds ratios with 95% confidence limits.  
Explanatory variables were assessed as significant at the 5% level. 
 
 
2.2 Feasibility of recruitment 
 An audit performed in 2007 showed almost 300 babies whose birth weight was <10
th 
centile were delivered at UCH (2007 delivery rate of 3,450). Delivery rates 
subsequently increased to nearly 5,000/ year with more cases of FGR being seen.  
At the start of the study a further audit was done. As customising of birth weights is 
not routine at UCH the audit investigated clinical information about babies born of 
low birth weight (defined as babies born at <2.5kg).  Between August 2010 and July 
2011, 120 babies were born weighing <2.5kg.Of these babies, 50% were delivered 
early due to maternal complications and were appropriately sized for their gestation; 
30% were born early but appropriately sized for their gestation (classified as 
spontaneous preterm deliveries); 10% of babies born <2.5kg had fetal anomalies and 
in 22.5% of cases FGR was identified. 1/3 of these cases of FGR were accompanied 
by maternal pre-eclampsia.  
Extrapolation of these figures suggested 24 babies <2.5kg would be eligible for 
recruitment to the study.  
Assuming half of all babies <10
th centile are likely to be constitutionally small and 
not be eligible for inclusion and of the remainder of these about a fifth (based on the 
audit figure) would meet the inclusion criteria, then in a unit delivering 5,000 
babies/year one would expect to identify 50 babies/ year. 
Hence, based on an 80% uptake for recruitment, a 2 year recruitment period for the 
study was felt to be justified. Chapter 2: Research Methods and Materials 
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2.3 Recruitment criteria 
In order to minimize differences in fetal growth caused by the maternal in utero 
environment, pregnant mothers were included as cases or controls only if: 
 
  Aged 18 to 45 years  
  Body mass index (BMI) 20 - 35kg/m2,  
  Non smokers  
  No significant maternal medical problems 
  No drug, alcohol or substance use in pregnancy 
 
 
And where the pregnancy was: 
 
  A natural conception 
  Singleton pregnancy 
 
Women whose partner smoked had an additional test for cotinine (ABS Laboratories 
Ltd., Birmingham, UK), a metabolite of nicotine as an indicator of passive smoking.  
 
Couples were recruited as cases with a pregnancy affected by fetal growth restriction 
(FGR), as defined by an antenatal <10
th customised birth weight centile where 
induction of labour or delivery by caesarean section was planned in view of fetal 
size.  
Pregnant women and their partners who were thought to be having a normally grown 
baby with an estimated fetal weight between 10
th and 95
th customised centile were 
recruited to the study as controls. Participants were offered an additional fetal 
ultrasound scan at 34 weeks, which I performed, to confirm predicted size.  
 
Women  and  their  partners  who  met  inclusion  criteria  were  approached  while 
attending antenatal clinics or fetal ultrasound  sessions.  Some eligible  participants 
responded to a research poster. 
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2.4 Diagnosis of FGR 
FGR is defined as a fetus who has failed to reach its growth potential (Pallotto E et 
al., 2006). The diagnosis of FGR in-utero remains a difficult subject. A small for 
gestational  age  (SGA)  baby  is  commonly  defined  as  one  who’s  estimated  fetal 
weight  and/or  abdominal  circumference  (AC)  on  ultrasound  is  less  than  the  10
th 
centile  for  its  gestational  age  (RCOG  Green  Top).  However,  this  cohort  is  a 
heterogeneous group and includes constitutionally small babies, pathologically small 
babies and babies small due to known causes such as chromosomal abnormalities. 
True  fetal  growth  restriction  reveals  an  inability  of  a  fetus  to  reach  its  (unique) 
growth potential not simply a predisposition to being small compared to a cohort of 
babies born at the same gestation. Babies born with true FGR have a much poorer 
prognosis than those who are SGA (Jones, 1986). In order to improve our prediction 
of  true  FGR,  customized  antenatal  fetal  growth  charts  (www.gestation.net)  were 
used. 
EFW and AC centile are customised depending on maternal height, weight, fetal sex 
and ethnicity, which have all been shown to have a bearing on expected growth 
potential.    Customising  has  been  shown  to  be  able  to  reclassify  27.5%  of  SGA 
fetuses (as defined by 10
th centile) back to being appropriately grown (Mongelli & 
Gardosi).  
 
2.5 Exclusion Criteria 
In order to exclude babies who are small due to known causes and, therefore, not 
likely to be secondary to placental insufficiency the following exclusion criteria were 
made;  
1.  Small babies in the presence of severe maternal medical problems such as 
cardiac, endocrine, renal or haematological disease 
2.  Known maternal drug or excess alcohol intake 
3.  Multiple pregnancies 
4.  Known fetal congenital infections such as CMV, toxoplasmosis 
5.  Known congenital chromosomal abnormalities 
6.  Known congenital structural malformations 
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2.6 Study Protocol   
All  study  assessments  were  carried  out  in  the  Clinical  Research  Facility,  UCLH 
(Figure  2.1).  This  facility  has  a  dedicated  temperature  controlled  (maintained  at 
24
oC) clinical study room. 
Men were studied within 4 weeks of offspring birth; women were asked to return for 
a study visit six months after the birth of their child. Participants were asked to fast 
overnight for at least 10h before the study. 
Each study visit required approximately 45 minutes to complete. All subjects were 
given an information leaflet and asked to sign consent forms prior to commencing 
the investigations.  
 
 
 
Figure 2.1   The study room in the Clinical Research Facility containing equipment 
necessary to perform studies 
 
Subjects completed a questionnaire enquiring about past medical, family and 
treatment history (Appendix 4 S9). Study participant’s own birth weight was 
recorded as remembered personally or from a parent. Weight, height and waist 
circumference (measured twice between the top of the iliac crests) were recorded. 
After resting, two measures of supine blood pressure (BP) were taken 15 minutes 
apart.  Chapter 2: Research Methods and Materials 
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Endothelial function was assessed by performing flow mediated dilatation (FMD) on 
the brachial artery and pulse wave velocity recordings were undertaken.  
 
Feedback to participants about results was available. Clinically significant results 
were conveyed to the subject as a priority along with relevant support literature and 
advice. Where appropriate, general practitioners (GPs) were contacted on behalf of 
the subject. 
 
Fasting venous insulin, glucose and lipid levels were measured. Insulin resistance 
was calculated using HOMA (Matthews DR et al., 1985). The blood was centrifuged 
within 1hr of venepuncture and plasma and serum were frozen at -80
oC. All blood 
samples were processed in the same laboratory within the Clinical Research Facility.  
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Figure 2.2 Flow diagram of recruitment pathway along with timeline for study visits and 
measurements being taken.  
1. Male Study: Fathers of pregnancy investigated for; 
2. Primary Outcomes of vascular function and insulin resistance by measuring; 
 
3. 1. Flow-mediated (endothelial) dilatation to assess endothelial function 
 
2. Fasting serum glucose and insulin for HOMA measurement 
Secondary outcomes 
1. Phenotype data (Weight, height, blood pressure, abdominal circumference) 
2. Other metabolic & vascular markers 
 
-  Delivery details including presence or absence of pre-eclampsia 
-  Record Neonatal details: birth weight, ponderal index, gestation, 
gender, delivery 
-  Obtain umbilical cord blood, placental section & placental weight 
4. Female Study: Women during postnatal period undergo 
same study as men 
 
Recruitment 
2 groups of pregnant women and their partners – (the fathers 
of the pregnancy) approached and consented 
Confirmation of inclusion criteria. 
Antenatal ultrasound scan for AGA babies. 
 
CASES     
FGR group EFW<10
th 
customised centile 
CONTROLS 
AGA group EFW 
>10
th to <95
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2.7 Homeostasis model assessment (HOMA) measurement 
HOMA was first described in 1985 (Matthews DR et al., 1985) and it uses fasting 
state glucose and insulin to predict beta cell function and insulin resistance. 
 
It has been published over 500 times and in more than half of these studies a non-
diabetic population was used. The model has been validated compared to both direct 
and indirect methods of assessing beta cell function and insulin resistance. It is 
described as one of a family of “paradigm models” which use theoretical solutions 
adjusted to population norms in order to predict outcomes (Wallace TM et al., 2004).  
 
The original model was improved with the understanding that there is variation in 
hepatic and peripheral glucose resistance.  A second updated model was published in 
1996. In contrast to the original model, this version allows assessment of 
hyperglycaemic subjects and an estimate of proinsulin secretion can be made. This is 
significant from a clinical laboratory perspective because it permits the use of either 
total radioimmunoassay or specific insulin assays.  
2.7.1 Sampling 
Taking three paired samples of glucose and insulin is theoretically better due to the 
pulsatile nature of insulin secretion. However, this has been shown to be unnecessary 
in practise.  It has been suggested that individual sampling is an acceptable practise 
(Wallace TM et al., 2004). This study, which included thirty subjects, demonstrated 
individual paired samples yielded near perfect correlations to the mean taken from 
three paired samples taken at five minute intervals. 
2.7.2 Validation 
HOMA has been validated compared to several other methods to measure IR and 
beta cell function. The “gold standard” test looking at these measurements is often 
quoted as the hyperinsulinemic euglycemic clamp which acts as a complex stress test 
and is time and labour intensive. HOMA correlates well to this test and furthermore 
is simpler to apply to large cohorts of subjects (Bonora E et al., 2000).  Chapter 2: Research Methods and Materials 
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The model has been used in more than 150 epidemiological studies looking at groups 
and their differing glucose tolerance. A study from Mexico looked at 1,449 
individuals with normal and impaired glucose tolerance and showed that those with 
higher baseline IR  were more likely to go onto develop diabetes during the 3.5 year 
follow up period (Haffner SM et al., 1996)  . 
A comparison of HOMA reproducibility and the OGTT suggested that the HOMA 
model reflects the most physiological reaction and differentiates well between groups 
with normal glucose tolerance, impaired glucose tolerance (IGT) and T2DM (Levy 
JC et al., 1998). 
2.7.3 Evidence for impaired glucose tolerance and T2DM risk 
There are numerous papers exploring impaired glucose tolerance in relation to the 
development of T2DM. In a meta-analysis of 28 studies that looked at the relative 
risk of developing diabetes in populations of subjects with and without impaired 
glucose tolerance there was a six fold increase in risk (95% confidence interval 4.66 
to 7.38). Furthermore there was a 1.67- 3.08 relative risk of suffering from a fatal 
cardiovascular event in association with IGT (McMaster University Evidence Based 
Practice Center).  
 
2.8 Endothelial function measurement 
I measured endothelial function using brachial artery flow-mediated dilatation 
(FMD) in the quiet, temperature-controlled CRF study room (in accordance with 
previously reported protocols in Okorie et al., 2011).  
 
The vascular endothelium responds to flow by releasing mediators that cause 
dilation. By measuring the diameter change of the brachial artery during flow 
situations it has been shown that endothelial function can be reliably assessed 
(Calermajer et al., 1997). 
FMD should be performed in a standard way in order to achieve a high degree of 
accuracy and reproducibility. Using an ultrasound probe in the longitudinal plane, a 
segment of brachial artery is identified and studied before and after a five minute Chapter 2: Research Methods and Materials 
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compressive arterial occlusion.   FMD is expressed as a percentage change from 
baseline brachial artery diameter (mm) to maximum dilation (mm) after hyperaemia. 
2.8. 1 Image Acquisition 
Participants were positioned on a bed and left to rest for at least ten minutes, having 
fasted overnight. The right arm was rested in an arm holder and the forearm was 
raised slightly using a foam pad (see figure 2.3). An 8.5cm wide pneumatic cuff was 
then placed 2cm distal to the medial epicondyle. Cuff pressure inflation was 
controlled by an automatic cuff inflator (Hokanson Cuff Inflator. PMS Instruments 
Ltd, Maidenhead, UK) 
 
The ultrasound machine used was an Aloka SSD 5000 and the probe a 13MHz linear 
array transducer (Aloka Holding Europe, AG Switzerland).The image was acquired 
in B-mode and the probe fixed so that a 5-10cm segment of the brachial artery 
proximal to the antecubital fossa was in view. 
Longitudinal end diastolic images, in conjunction with ECG tracing were acquired 
every three seconds during the 11minute recording (1minute baseline, 5minutes with 
cuff inflation at 300mmHg and 5minutes with cuff deflated). Blood flow velocity 
was continuously monitored during the scan by switching to a B/D (Doppler) mode 
for the test duration. 
 
Figure 2.3 The apparatus used in order to study the brachial artery by ultrasound. Ultrasound 
probe is held in position over the brachial artery with subject’s arm resting.  Chapter 2: Research Methods and Materials 
 
61 
   
2.8.2 Analysis  
Images were acquired and analysed (Figure 2.4) using automated software (Brachial 
Tools Medical Imaging Applications, Iowa, USA). With the initial segment recorded 
a smaller region of maximum clarity was selected for analysis. Internal 
reproducibility was performed by looking at different segments within each scan. 
 
Analysis exclusion criteria were poor image quality, if recording was deemed to be 
unrepresentative of the true vessel diameter or if the image did not return to near 
baseline after reperfusion.  Each image-recording was validated by a second operator 
blinded to the subject’s group. This led to 22 (18.5%) scans being excluded from the 
final analysis due to lack of agreement.  
 
 
   
Figure 2.4 The image on left is picture obtained on the screen of the brachial artery and the 
box is where the analysis of flow occurs. The image obtained by the software of the dilation 
recorded is shown on the right) 
 
 
2.9 Pulse Wave Velocity  
Pulse wave velocity was recorded using the Vicorder automatic device (Smart 
Medical, Moreton-in-March, Gloucester) 
Participants were placed in a semi-prone position with the head and shoulders raised 
approximately 30 degrees. The neck pad was placed around the participant’s neck 
with the pressure pad over the carotid artery and care taken not to over tighten. Chapter 2: Research Methods and Materials 
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An appropriately sized cuff was placed around the right upper thigh. Both neck and 
thigh cuffs were attached to the Vicorder.  A measurement was taken from the 
suprasternal notch to the middle of the thigh cuff using the umbilicus as a midpoint 
landmark. This was input along with the lying blood pressure reading. Cuff inflation 
then occurred, resulting in waveform generation. Once a steady pattern was 
established the image was frozen and data recorded (Figure 2.5). 
 
Figure 2.5 Carotid artery recording top and below is femoral. TT is transit time 
 
2.10 Sample collection, handling and storage 
2.10.1 Parental Blood Samples 
Blood was taken at the time of the study visit for fathers. Mothers had blood taken 
when recruited antenatally and postnatally as part of their study visit. 
 
Venepuncture was performed on each participant and 20mls of blood removed. All 
participants had fasted and been resting for 20minutes before sampling for study 
visits. All sampling occurred in the study room which was a temperature controlled 
area. 
 
Following the study visit whole blood was sent to the UCLH biochemical laboratory 
using routine validated biochemical assays for the following measurements: fasting 
glucose, insulin, triglycerides (TG), total cholesterol (TC), high density lipoprotein 
cholesterol (HDL) & low density lipoprotein cholesterol (LDL), urea, creatinine and Chapter 2: Research Methods and Materials 
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C-reactive protein (CRP). LDL cholesterol was calculated using the Friedewald 
formula.  
Homeostasis model assessment (HOMA) of insulin resistance (IR) was measured 
from fasting glucose and insulin values (HOMA-IR = fasting glucose x fasting 
insulin/ 22.5). These values were calculated using a freely available software 
package from the Diabetes Trial Unit, Oxford, UK 
(http://www.dtu.ox.ac.uk/homacalculator/download.php) 
 
Whole blood was also stored in two aliquots and frozen immediately at -80
oC.  Blood 
was centrifuged at 3000rpm for 10minutes. The resulting plasma and serum was 
stored in 2-4 aliquots at -80
oC within one hour of the sample being taken.  
 
All samples were colour coded, logged and stored according to being a case or 
control.  All participants were allocated unique anonymised identification number. 
These allowed family units to be linked (fathers, mothers and babies) and enabled 
one to identify if a participant was a case or control.  
 
2.10.2 Placental like growth factor (PLGF) measurements 
Aliquots of 250µl of plasma, extracted from paternal whole blood, were assayed for 
PLGF by Dr Anna Jeffery Smith using the Alere Triage PLGF test (Alere Inc., San 
Diego).  This assay employs antibodies specific for the PLGF-1 isoform and runs on 
the commercially available, point of care Alere Triage MeterPro (Alere, San Diego, 
USA). The MeterPro is a portable device which can be used in combination with the 
Triage test cartridges to analyse the concentration of a range of analytes in blood. 
The device has a laser that hits a test cartridge when inserted in the meter. This 
causes fluorescent dye in the test cartridge to emit energy. The amount of energy the 
fluorescent dye emits is proportional to the concentration of analyte in a sample. 
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2.11 Fetal samples 
Immediately following delivery of the placenta, umbilical cord blood was taken from 
the umbilical vein or artery, centrifuged and stored at -80
oC as plasma and serum for 
later measures of metabolites. Gestational length, offspring gender, weight and 
length were recorded.  
 
Plasma extracted from whole cord blood was used to assess insulin, c-peptide and 
glycated haemoglobin by TDL laboratories (London, UK) using standardized assays 
and methods.  
 
2.12 DNA extraction 
2.12.1 DNA extraction fetal cord blood and parental whole blood 
 
Cord blood was extracted from the umbilical cord immediately after delivery of the 
placenta. A portion of free flowing vein or artery was used to collect up to 20mls of 
blood. DNA extraction was performed as soon as possible after collection. If any 
delay was expected in extracting DNA it was refrigerated at +4
oC prior to extraction. 
 
DNA was extracted with the QIAamp DNA Mini Kit (QIAGEN Ltd, Manchester 
UK) using 200µl of blood. At least three aliquots were extracted for each subject.  
The optional step to remove RNA was used and additional steps recommended were 
carried out. Elution was performed using 200µl RNA/DNA free water. Water was 
used in preference to TE after discussion with Deborah Hughes from the Institute of 
Neurology due to concerns that the TE could interfere with processes required in 
DNA preparation for exome sequencing. DNA was stored at -20
oC once eluted.  
 
2.12.2 DNA extraction of placental and cord tissue 
Placental and umbilical cord tissue were stored at -80
 oC, removed at time of 
extraction and placed onto ice. For each sample, 480µl of buffer solution and 20µl Chapter 2: Research Methods and Materials 
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proteinase K solution (Qiagen Ltd, UK) was put into a 1.5ml eppendorf. The buffer 
solution contained 50mM Tris 8.0, 10mM EDTA and 0.5% SDS and was suggested 
by Dr Melissa Smart, Queen Mary University, London.  A 5mm slice of tissue 
(around 10g) was removed by scalpel and placed in the buffer. 
This was left in a dry heater at 55
oC overnight in order to digest the tissue. Once all 
tissue appeared digested the solution was vortexed for 15 seconds and 200µl of 
solution was removed and used to continue the extraction process.  
DNA was isolated from placental tissue (paired with cord blood samples) using the 
DNeasy Blood & Tissue Kit (Qiagen, UK) according to manufacturer’s protocols. 
DNA samples were then further processed to ensure DNA quality using the Genomic 
DNA Clean & Concentrator Kit (Zymo Research, Cambridge Biosciences, UK). 
 
2.12.3 Genomic DNA clean-up 
 
In order to improve the quality of genomic DNA (improved 260/230 ratio), a 
genomic DNA clean-up kit was used (Zymo Research, through Cambridge 
Bioscience, UK) according to manufacturer’s instructions.  All samples that were 
being run on the arrays were cleaned up, including DNA from placentas and cord 
blood.  
 
2.12.4 DNA quantification and quality   
DNA concentration and purity was assessed by a Thermo Scientific NanoDrop™ 
1000 spectrophotometer according to the manufacturer’s protocol. DNA 
concentration from all individuals sequenced was also assessed by fluorometric assay 
using a Qubit® 2.0 Fluorometer (Life Technologies) following manufacturer’s 
instructions. A 1% Agarose gel was run in order to assess DNA integrity. 
Agarose gels were prepared by weighing out the appropriate amount of agarose in a 
conical flask and adding the correct volume of 1  TBE.  The flask contents were 
mixed by gentle swirling and heated in a microwave to dissolve the agarose. The 
dissolved agarose was left to cool to approximately 60
oC before the addition of 5 l 
of 0.5g/ml ethidium bromide.  The melted agarose was then poured into a pre-Chapter 2: Research Methods and Materials 
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sealed gel cast containing a well comb.  Agarose gels were left to set for 20-30 
minutes at room temperature. 
 
The agarose gel was placed in an electrophoresis tank (BIO-RAD Laboratories, Inc) 
containing sufficient 1X TBE buffer. Electrophoresis was carried out at 80 volts for 1 
hour or until the required resolution was achieved. DNA fragments were visualised 
under UV light and the gel was photographed on a UV trans illuminator. 
 
Stock DNA was normalised to a concentration of 45ng/μl by dilution with Molecular 
Biology Grade water. 1µl of normalised DNA was employed to measure the 260/280 
and 260/230 ratios using a Nanodrop-1000. Samples with a 260/280 ratio >1.75 and 
a 260/230 ratio > 1.8 were discarded from analysis. 
 
 
2.13 Whole exome sequencing 
Next generation sequencing platforms are high-throughput DNA sequencing 
technologies based on the principle of running thousands or millions of clonally 
amplified or single DNA sequences in parallel (Mardis ER, 2008).  
Exome sequencing is one of the ways in which NGS has been successfully used to 
identify novel genetic mutations in rare diseases by the targeted sequencing of the 
subset of the human genome that is protein coding. 
Exomes are the subset of the genome that is protein coding. Whilst exomes 
constitutes <2% of the genome it has been shown that most alleles that underlie 
Mendelian disorders disrupt the protein coding region of the genome (Bamshed MJ 
et al., 2011). It is also known that a defect in the protein coding region is far more 
likely to have a functional/ deleterious defect. As such the exome is a highly enriched 
subset of the genome to search for variants with large effect sizes. 
In exome sequencing, a DNA library is constructed from total genomic DNA and 
enriched for sequences corresponding to exons by aqueous phase hybridization 
capture (in-solution capture). Genomic DNA is initially randomly fragmented and 
oligonucleotide adaptors are ligated to each end. The whole exome is then captured 
and enriched by in-solution hybridisation to 95-mer biotinylated DNA Chapter 2: Research Methods and Materials 
 
67 
   
oligonucleotide baits (Illumina TruSeq).  Illumina provide a kit for exome capture 
that is scalable to automation using DNA bait (Bamshed MJ et al., 2011). 
Amplification and parallel sequencing (described below) of the fragments can then 
occur. Samples are run on an Illumina next generation sequencing platform (in this 
study a HiSeq1000, Institute of Neurology), to generate 2x100bp read length DNA 
sequences.  
The first step is bridge amplification of single DNA molecules (generated during the 
library preparation) on the surface of a flow cell by an automated device called a 
Cluster station. A flow cell is an 8-channel sealed glass micro fabricated device 
allowing amplification of fragments on its surface and containing DNA polymerase 
to produce multiple copies (around one million) of the molecule that initiated the 
cluster reaction.  
The second step is the sequencing-by-synthesis approach during which DNA 
polymerase is added together with all four nucleotides each carrying a base-unique 
fluorescent label and with the 3’-OH group chemically blocked such that each 
incorporation becomes a unique event. After incorporation, an imaging step occurs 
prior to the 3’ blocking group being removed to prepare the strand for the next 
incorporation.  
By continuing for a set number of cycles discrete sequences reads of 76 or 100 bases 
in length can be obtained.  With a base-calling algorithm assigning sequence and 
quality values to each read. Illumina have also incorporated a quality checking 
pipeline into the data run. 
2.13.1 Exome Protocol 
2.13.1.1 Sample Preparation 
DNA samples being used for exome sequencing (n=10) were subject to the same 
DNA quality control checks as described previously (2.12.4). As per UCL Institute 
of Neurology requirements, 3.2ug of DNA at 100ng/µl according to Qubit reading 
were prepared in 32µl of H2O. Only samples with an A260/A280 ratio of 1.8-2.0 were 
sent.  To asses DNA integrity, 1µl  of diluted DNA (100ng/µl) was  run on a 1% 
agarose gel with 1Kb ladder alongside.  Chapter 2: Research Methods and Materials 
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2.13.1.2 Exome capture and sequencing 
A total of 3.2µg of high quality DNA was sent to UCL Institute of Neurology in 
London.  Samples were processed using Illumina TruSeq sample preparation and 
capture  (64Mb),  (Illumina).  Samples  were  processed  according  to  the  Illumina 
Paired-End  Sequencing  Library  Protocol  and  run  on  an  Illumina  HiSeq1000 
sequencer; paired end 2x100bp read length with an aimed median coverage of 30x. 
Samples were multiplexed 5 per lane of a flowcell.  
2.13.2 Exome analysis 
The sequencing reads resulting from the HiSeq1000 were aligned by the GOSgene 
Bioinformatics team to the human reference genome (GRCh37 release, downloaded 
from the ENSEMBL database, corresponding to Hg19 NCBI built 37.1) with BWA 
(Burrows-Wheeler Alignment Tool) software (Li H, 2009). The GATK tool suite 
was used to further process the alignments (base quality score recalibration, indels 
realignment,  duplicate  removal)  (McKenna  A,  2010).  Variant  calling  was  also 
performed using GATK Unified Genotyper multi-sample SNP caller. A summary of 
the  sequencing  coverage  produced  by  GATK  DepthOfCoverage  profiler  was 
generated. SNPs and small insertions/deletions (indels) annotation and interpretation 
analysis were generated through the use of Ingenuity Variant Analysis
TM software 
(www.ingenuity.com/variants) from Ingenuity Systems.  
A binary format of aligned sequencing data named BAM file was generated for each 
sample.  BAM  files  containing  SNP  and  indels  calls  were  visualised  using  the 
Integrative  Genomics  Viewer  IGV  (http://www.broadinstitute.org/igv/UserGuide). 
Relevant  known potential  target  genes were  checked for pathogenic variants  and 
coverage.  Variants  were  prioritised  by  predicted  frequency  starting  from  “novel” 
variants  (i.e.  not  annotated  in  databases  including  dbSNP,  NHLBI  Exome 
Sequencing  Project  (ESP)  and  1000genomes),  predicted  effect  (starting  from 
essential splice site, stop gained, stop lost, frameshift indels and non-synonymous 
variants). 
The dbSNP database serves as a central repository for both known single base 
nucleotide substitutions and short deletion and insertion polymorphisms. The NHLBI 
GO Exome Sequencing Project (ESP) provides an exome variant server. This Chapter 2: Research Methods and Materials 
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repository currently contains exome data representing over 200,000 diseased 
individuals. Exome data from 6,500 individuals is publicly available and is used as a 
means of identifying variants and their frequencies across individual genes.  
 
2.13.2.1 Downstream analysis 
 
Downstream variants (an example of output is shown in figure 2.6) analysis included 
the assessment of the quality of the reads  from the bam  files, assessment  of the 
mappability and existing structural variations in the chromosomal region, assessment 
of  the  novelty  against  internal  GOSgene  databases  (for  common  currently  not 
publically  available  variants),  details  of  gene  functions  (review  of  databases  and 
literature), affected domains and prediction of the biological impact (SIFT, Polyphen 
and Mutation Taster), amino acid conservation, expression pattern, existing animal 
models  and  any  other  relevant  information  (including  phenotype  indications  via 
OMIM and HGMD). 
2.13.2.2 Functional predictions of candidate mutations  
Evidence for pathogenicity for missense variants was assessed using Polymorphism 
Phenotyping v2.0.23 (PolyPhen-2) [http://www.genetics.bwh.harvard.edu/ pph)] and 
SIFT (http://sift.jcvi.org/). SIFT (Sorting Intolerant From Tolerant) is a program that 
predicts whether an amino acid substitution affects protein function so that users can 
prioritize substitutions for further study. SIFT can distinguish between functionally 
neutral and deleterious amino acid changes in mutagenesis studies and on human 
polymorphisms (Ng PC et al., 2003). The PolyPhen-2 software classifies the 
functional effect of a missense mutation into three categories using empirically 
derived rules to predict whether the mutation is damaging, i.e. is supposed to affect 
protein function, or benign, i.e. most likely lacking any phenotypic effect (Ramensky 
V, 2002).Chapter 2: Research Methods and Materials 
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Figure 2.6.An example of the output of exome data from a single sample which 
includes all annotated gene variants identified across all the exomes covered.  
2.13.2.3 Data filter pipeline 
A data filter pipeline was developed which consisted of several steps in order to 
reduce the number of variants assessed. First, variants were eliminated that were not 
present  in  the  actual  coding  sequence  and  synonymous  variants  other  than  those 
occurring at canonical splice sites. Initial analysis, therefore, concentrated on stop-
gain, stop-loss, frameshift, splice site and those mutations which were undefined.  
Stop gain mutation are defined as those where an amino acid is substituted for a stop 
instructions thus terminating the sequence early whereas a stop loss mutation has the 
opposite effect of not terminating a sequence as expected.  Frameshift mutations 
refer to those mutations that, through the insertion or deletion of nucleotides, lead to 
an altered amino acid sequence.  
A frameshift mutation (also called a framing error or a reading frame shift) is a 
genetic  mutation  caused  by  indels  (insertions  or  deletions)  of  a  number  of 
nucleotides in a DNA sequence that is not divisible by three. Due to the triplet nature 
of gene expression by codons, the insertion or deletion can change the reading frame 
(the grouping of the codons), resulting in a completely different translation from the 
original. The earlier in the sequence the deletion or insertion occurs, the more altered 
the protein (Losick R et al., 2008). Often the severity of the effect will be a result of a 
premature termination of the protein sequence.  
Then a second filter was applied in order to identify which of these mutations were 
potentially novel and remove common variants. Variants were filtered out that were 
present and referenced in dbSNP 130 or in the ESP (exome server project) with a Chapter 2: Research Methods and Materials 
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frequency of >0.3 % or the 1000 Genomes phase 1 project data with a mean allele 
frequency (MAF) > 0.3%. Finally, the remaining variants were filtered against an in-
house exome database of genetic variants from over 300 other individuals (all non-
diabetic) obtained from other GOSgene exome sequencing projects.  
The same variant pipeline filter was carried out for all ten samples and individual 
samples were then cross referenced to identify overlapping variants. Interesting rare 
variants related to MODY or those with known pathological associations were taken 
forward if found in isolated samples. For all other candidates, if the same variant was 
identified in three or more samples those variants were taken forward for subsequent 
assessment. 
A second form of data filtering was performed by inputting the annotated Variant 
Call Format (vcf) file into Ingenuity Variant Analysis (Ingenuity, San Diego, USA). 
The Ingenuity software uses an Interactive Filter Cascade which allows for 
elimination of common and non-deleterious variants with a basic set of filters, 
reducing the number of variants significantly. Then, using keywords, a search can be 
performed on the remaining variants. This keyword search within the Ingenuity 
ontology provides identification and prioritization of compelling variants based on 
knowledge of disease, phenotypes, processes, and pathways and the pathway 
information available in the Ingenuity Knowledge Base. Variants in genes within 1- 
or 2- network “hops” of upstream or downstream genes can also be identified. A hop 
refers to the number of genes between the gene of interest and the condition. 
2.13.3 Candidate gene and SNPs selected for a priori list 
Candidate genes were chosen based on their association with known or putative role 
in monogenic diabetes and transient neonatal diabetes (Bonneford A et al., 2010) in 
both published literature and OMIM database. 
MODY is not a single entity as at least twelve MODY subtypes with distinct genetic 
aetiologies have been reported in the literature: MODY1-HNF4A; MODY2-GCK,; 
MODY3-HNF1A; MODY4-PDX;  MODY5-HNF1B; MODY6-NEUROD1; 
MODY7-KLF11; MODY8-CEL; MODY9-PAX4;  MODY10-INS;  MODY11-BLK 
and more recently MODY12-ABCC8 (Bonneford A et al., 2010; Bowman P et al., 
2012 and Farjans SS et al., 2011). Chapter 2: Research Methods and Materials 
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SNPs implicated from whole-genome-significant associations with T2DM (Voight 
BF et al., 2010; Zeggini E et al., 2008; Dupuis J et al., 2010; Feero WG et al., 2010 
& Granup N et al., 2010), fasting glucose or birth weight (Hirokoshi et al. Nat Genet: 
2013, Freathy et al., 2010 and Andersson et al., 2009) were included.  
 
Candidate SNPs thought to have a role in beta cell function and glucose homeostasis 
were also included. In total 73 candidate genes were selected along with MODY 
candidates (Appendix 4 S3). 
 
 
2.14 Validation of exome data 
Exome data was validated in one of two ways; variants of interest that corresponded 
to a risk SNP were genotyped in the entire cohort (offspring, mothers and fathers in 
cases and controls). Variants thought to be novel were Sanger sequenced. In these 
instances parental DNA was also Sanger sequenced along with the case offspring in 
which the variant was identified.  
2.14.1 Genotyping  
Genotyping employs the use of real time polymerase chain reaction (PCR) which is 
able to amplify and simultaneously quantify targeted DNA molecules. A thermal 
cycler is used for PCR in order to rapidly heat and cool samples allowing the core 
processes (separation of the nucleic acids double chain, alignment of the primers 
with the DNA template and extension) to occur repeatedly.   
 
Real time PCR utilizes sequence specific DNA probes containing oligonucleotides, 
labelled with fluorescent reporters, which allow for detection only after hybridization 
of the probe with its complimentary DNA sequence.  
Thermal light cyclers have the ability to illuminate each sample with a beam of light 
of a specified wavelength and detect the amount of fluorescence emitted.  
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2.14.2 TaqMan Genotyping 
 
The TaqMan method relies on the 5’-3’ exonuclease activity of Taq polymerase.  
Taqman probes consist  of a flourophore covalently attached to the 5’ end of the 
oligonucleotide probe and a quencher at the 3’ end. A quencher molecule quenches 
the  fluorescence  emitted  by  flourophore  excited  by  a  cycler’s  light  source.  The 
inhibiting action of the quencher is dependent on its proximity to the flourophore. 
 
Taqman  probes  are  allele  specific  annealing  with  a  DNA  region  amplified  by  a 
specific  set  of  primers.  During  the  PCR  cycle,  the  forward/reverse  primer  pair 
anneals to the template DNA, along with the respective allelic probe. When the probe 
is entirely complementary to the target sequence, Taq polymerase extends the primer 
and synthesises the complimentary strand from 3’ to 5’. The 5' to 3' exonuclease 
activity of the polymerase degrades the probe that has annealed to the template.  
 
Probe degradation releases the fluorophore which breaks and moves away from the 
quencher, allowing fluorescence of the fluorophore. A 7900HT Sequence Detection 
machine (Applied Biosystems, California, US) which is a real-time PCR thermal 
cycler,  is  able  to  detect  the  fluorescence  which  is  directly  proportional  to  the 
fluorophore released and the amount of DNA template present in the PCR. As the 
number of PCR cycles increases the level of fluorescence increases. The magnitude 
of the increase is dependent on the sample genotype; this property enables genotype 
identification. 
2.14.2.1 TaqMan genotyping protocol 
DNA concentration was standardised to 5ng/μl and a total of 10ng of DNA was used 
in  each reaction.  I was guided through the  genotyping protocol  with  Dr Melissa 
Smart  and reactions  were performed  at  QMUL Genome Centre,  London, UK. A 
Biomek 2000 robot (Beckman Coulter, High Wycombe, UK) transferred DNA from 
four  96-well  plates  into  one  MicroAmp®  Optical 384-Well  Reaction Plate with 
Barcode (ABI, Life Technologies, UK).  The plate was left to dry out overnight at 
room temperature in a sterile paper bag.  Chapter 2: Research Methods and Materials 
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A  master  mix  comprising  2.5μl  TaqMan  Absolute  quantitative  PCR  Rox  Mix 
(ABgene, UK), 0.125μl 40x Assay(TaqMan forward and reverse oligonucleotides 
and their respective labelled probe pairs (Appendix 4 S5), 2.375μl Sigma ddH2O per 
well was prepared and a 5μl aliquot was added to each well using an 8-channel 
pipette. Plates were sealed with a clear plastic lid (ABgene, UK) to prevent excess 
evaporation and then centrifuged at 1,000 rpm for 1 minute. Each plate underwent 
the following PCR program on a Tetrad 2 Thermal Cycler PCR System (Bio-Rad, 
USA) 384- well heated block: 
 
95°C for 10 minutes 
95°C for 15 seconds         x 40 cycles 
60°C/62°C for 1 minute    
2.14.2.2 Sample analysis 
The 7900HT Sequence Detection machine read all plates and different genotypes 
were  identified  by  SDS  v2.3  (Applied  Biosystems).  Output  was  both  an  allelic 
discrimination plot (Figure 2.2) and in a text output file. The file was then converted 
from 384-well to four 96-well plates in Microsoft Excel, and merged with the study 
database.  
 
 
Figure  2.7:  Screen  capture  from  SDS  v2.3.  A  typical  allelic  discrimination  plot,  with 
successful separation of the three genotype groups – homozygotes (• & •) and heterozygotes 
(•). Unassigned genotypes were those that did not cluster with other samples, this included 
NTCs-negative controls (×). Chapter 2: Research Methods and Materials 
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2.14.2.3 Statistical methods 
Statistical analyses were performed using Intercooled Stata 10 for Windows 
(StataCorp LP, Texas, USA). Cohort characteristics are presented as means and 
standard deviation unless otherwise stated.  
Hardy-Weinberg equilibrium (HWE) was examined using the Pearson’s Chi-square 
test which tests goodness of fit. A p value of <0.05 was taken as deviation from 
HWE. Blood pressure and all anthropometric measures were natural log-transformed. 
For association studies a p value of <0.05 was taken as statistically significant. 
Setting a threshold of significance was the chosen method above Bonferroni 
corrections, since the candidate genes studied had been selected for based on an a 
priori hypothesis and biological plausibility. Haplotype association
 analysis was 
carried out using Thesias (www.ecgene.net). 
2.14.3 Sanger Sequencing 
Sanger’s method is based on the use of dideoxynucleotides (ddNTP’s) in addition to 
the normal nucleotides (NTP’s) found in DNA. ddNTPs are essentially the same as 
nucleotides except they contain a hydrogen group on the 3’ carbon instead of a 
hydroxyl group (OH).  
DNA is denatured by heating and specifically designed primers (3’ end is located 
next to the sequence of interest) anneal to the template strand. Fluorescently labelled 
nucleotides allow the final product to be detected on a gel (Russell, 2002)Different 
ddNTPs are added to the primer/DNA template solution in an automated process. 
This is done in a single tube containing all 4 ddNTPs each labelled with a different 
fluorescent dye. DNA is synthesised and nucleotides are incorporated into the chain. 
ddNTPs will be randomly incorporated. This causes a chain terminating event by 
preventing the addition of further nucleotides.  Chapter 2: Research Methods and Materials 
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The key to the Sanger method is that all reactions start at the same nucleotide and 
end with a specific base. When the same chain is synthesized many times different 
length DNA fragments will result with the same starting and end nucleotide. The 
chains are then denatured again, and run on a gel to separate out the different size 
bands. By combining all 4 reactions on one gel the DNA sequence can be 
determined. In automated procedures, this reading is done by a laser which is able to 
identify the different wavelengths that the ddNTPs fluoresce at.  
2.14.3.1 Sanger Protocol 
Dr  Louse  Ocaka  at  UCL  GOSgene  performed  sample  preparation  for  Sanger 
sequencing and showed me the technique. I provided purified DNA of which 1µl 
underwent a polymerase chain reaction (PCR). This was performed on a PTC-100 
Peltier Thermal Cycler (MJ Research) equipped with a heated lid thus eliminating 
the necessity to overlay PCR reactions with mineral oil to prevent evaporation.    
Amplification was carried out under the following general conditions: 
 
 
     Initial denaturation:   95°C       for 5 minutes 
                  95°C       for 30 seconds 
35  cycles  of:                     50 - 65°C   for 30 seconds 
               72°C       for 30 seconds 
             Final extension:           72°C       for 5 minutes  
                    Hold:     10°C  
 
 
PCR products were visualised by loading 5µl of the reaction on an agarose gel of the 
appropriate concentration depending on the size of PCR product. A negative control 
(no DNA) was always included in the experiment. 
2.14.3.2 Primer Design 
PCR primers are oligonucleotides usually in the region of 18-25 bp in length. These 
oligonucleotides bind to a target sequence allowing a polymerase to initiate synthesis 
of a complementary strand. To ensure optimal results, random base distribution for 
each primer was designed with a similar GC content for both primer pairs, with 
levels of GC content between 40% and 60%. Primers were designed with an A or T 
nucleotide at the 5’ end and a C or G at the 3’ end to act as an anchor. Each primer Chapter 2: Research Methods and Materials 
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was more than 20bp in length to increase complexity and binding specificity. Primers 
were  designed  at  least  40  bp  away  from  the  intron/exon  boundary  to  ensure 
successful  amplification  and  sequencing  of  the  splice  site.  Primer  pairs  were 
designed to have similar annealing temperatures. All primers were synthesized by 
Sigma-Aldrich  Ltd  (Appendix  4  S4).  Primers  were  diluted  according  to 
manufacturer’s instructions in order to obtain a final stock concentration of 100µM 
diluted with dH2O and working stock concentration of 10mM.  
 
2.14.3.3 PCR Product Purification 
The ExoSAP-IT enzyme (Amersham Life Science, Buckinghamshire, UK), which 
removes unwanted dNTPs and primers, was used to purify PCR products. Generally, 
30µL reactions were prepared consisting of 1µL (1 unit) ExoSAP-IT enzyme, added 
to 100-200ng (generally 2-3µL) of PCR product and made up to 30 µL with dH2O. 
The reaction was mixed thoroughly and incubated at 37°C for 15 minutes.  Enzymes 
were inactivated by heating to 80°C for 15 minutes. 
 
2.14.3.4 QIAquick Gel Extraction 
PCR  products  were  electrophoresed  on  a  0.5  %  agarose  gel,  gel  extracted,  and 
purified.  DNA in the range of 70 bp to 10 Kb was extracted and purified using the 
QIAquick gel extraction kit according to the manufacturer’s guidelines (QIAGEN
®). 
Upon resolving DNA on an agarose gel, the band of interest was excised from the gel 
and the gel slice weighed.  Buffer was added to the gel and incubated at 50
oC for ten 
minutes  A  QIAquick  spin  column  and  centrifugation  was  then  used  to  elute  the 
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2.14.3.5 Automate d DNA Sequencing 
DNA  was  sequenced  using  ABI  BigDye  terminator  cycle  sequencing  chemistry 
version 3.1 on an ABI 3100 automated sequencer (Applied Biosystems) according to 
manufacturer’s instructions. A 13l aliquot of purified PCR product was then used 
for cycle sequencing. The 20µl Cycle sequencing reaction contained 13µl of purified 
PCR product,  1µl  of BigDye, 1µl  of  a 0.8µM  concentration primer, 5µl  of ABI 
sequencing buffer.  Cycle sequencing of sequencing reactions was conducted on a 
PTC-100  Peltier  Thermal  Cycler  (MJ  Reseach)  using  the  following 
thermocycling conditions for 30 cycles of 96°C for 30 second, 50° C for 15 minutes 
and 60° C for 4 minutes.  
  
2.15 DNA methylation 
Epigenetic modifications are modifiable structural changes to DNA, such as histone 
modification and DNA methylation that result in changes to gene expression and 
phenotype without altering the nucleotide sequence (Bird A, 2007). DNA 
methylation is widely studied and occurs as a result of covalent binding of a methyl 
group to cytosine residues in cytosine/guanine rich regions of DNA (CpG islands). It 
is maintained during cell division in mammals only at the dinucleotide C-G by the 
enzyme DNA methyltransferase 1 
There are several ways to assess methylation ranging from locus specific to genome 
wide. The Infinium 450 Human Methylation (450 HM) Bead chip (Illumina Inc, San 
Diego, CA) is one of the latest platforms able to assess methylation at a genome wide 
level and was the platform used for this work. 
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2.15.1 The Infinium HumanMethylation450 (HM450) BeadChip 
The HM450 BeadChip allows epigenome wide scanning of > 485,000 CpG 
methylation sites per sample at a single-nucleotide resolution. The HM450 Beadchip 
incorporates the chemistry of two different chemical assays (Infinium I and Infinium 
II) carrying information about the methylation state via the number of probes. 
Infinium I contains two beads per CpG locus. Each of the two bead types are 
attached to single stranded DNA oligonucleotide probes that differ in sequence only 
at the 3’ free end. The 3’ end of each probe is designed to match either a protected 
“methylated” cytosine or a thymine, bisulphite converted, “unmethylated” base. The 
probes are designed on the assumption that within a 50 base pair (bp) span of the 
genome, methylation of any CpG loci are likely to have the same methylation status.  
The Infinium II assay is designed with one probe. The 3’ end of the probe 
complements the base directly upstream of the query site. A single base extension 
results in the addition of a labelled G or A base complementary to either the 
methylated C or unmethylated T. This design has the advantage of allowing up to 
three CpG sites within a 50bp span, removing the assumption of concurring 
methylation status within the query site.  
The  array  is  run  using  high  quality  DNA  that  has  been  bisulphite  converted. 
Bisulphite conversion converts unmethylated cytosine bases into uracil. The resulting 
product contains unconverted cytosine where they were previously methylated, and 
uracil, where cytosine was previously present but unmethylated. Chapter 2: Research Methods and Materials 
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Bisulphite treated DNA is subjected to whole genome amplification (WGA) 
amplifying uracil as complementary thymine. The products are then enzymatically 
fragmented, purified and applied to the chip. The bisulphite converted amplified 
DNA products are denatured into single strands and hybridized to the chip via allele 
specific annealing to either the methylation specific probe or the non-methylation 
probe Allele-specific single base extension of the primer incorporates a biotin 
nucleotide or a dinitrophenyl (DNP) labelled nucleotide. (C and G nucleotides are 
biotin labelled; A and T nucleotides are DNP labelled.) Signal amplification of the 
incorporated label further improves the overall signal-to-noise ratio of the assay. 
Immuno-histochemical assays are performed by repeated rounds of staining with a 
combination of antibodies to differentiate the two types (www.illumina.com). After 
staining, the chip is scanned using the Illumina HiScan SQ two-colour laser scanner, 
to show the intensities of unmethylated and methylated bead types.  
2.15.2 Internal Quality Control Checks 
Data generated is subject to internal quality control checks incorporated into the 
genome studio package. In order to assess the quality of specific steps in the array, 
sample independent checks are performed using control probes which include: 
  bead-staining controls  with biotin (green) and DNP (red) of DNA;  
  extension controls  
  hybridisation controls and subsequent target removal 
 
Staining controls assess the efficiency of the intensity of the red and green channel. 
Background fluorescence failure leads to difficulty discriminating red and green 
channels and requires removal from further analysis. Signal intensity can also be 
affected by the C-G content and leads to sample removal. 
Extension controls measure the efficiency of extension of the nucleotide sequences to 
the probes. A and T are assessed in the red channel and C and G in the green 
channel.  
Hybridisation probes test the overall performance of the entire assay using synthetic 
targets (which complement the sequence on the array) not DNA. The synthetic 
targets are present at low, medium and high concentrations in the hybridization Chapter 2: Research Methods and Materials 
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buffer so should be represented as specific low, medium and high intensities, 
representing the concentration present. Target removal tests the efficiency of 
stripping after extension. The control probes are extended using the probe sequence 
as template (which generates labelled targets) and should result in low signal 
compared to hybridized controls as probe sequences are designed so that extension 
from the probe does not happen. Both hybridisation and target removal should be 
read in the green channel. 
Sample dependent QCs allow for evaluation of performance across samples. The 
controls are designed against bisulphite converted human DNA sequence. These 
probes do not contain CpG dinucleotides so performance does not rely on 
methylation status of template DNA and include;  
  a test of the bisulphite conversion efficiency,  
  comparison of  specificity of probe binding and primer extension, 
  non-polymorphic (NP) controls  
  negative controls 
 
Bisulphite conversion (BS) controls query a C/T polymorphism created by 
conversion of non CpG cytosines (C) in the genome. BS I conversion use Infinium I 
probe design. If conversion is successful, converted C probes will match converted 
sequence and be extended. C1, C2 and C3 probes should be read in the green channel 
and C4, C5 and C6 in the red channel. BS failure results in unconverted U probes 
where extension fails   
BS II controls use Infinium II probe design. Successful BS conversion incorporates 
an A nucleotide and the probe will have intensity in the red channel. If cytosine 
unconverted the G base will be incorporated and the probe will have intensity in the 
green channel.  
Specificity controls monitor non-specific primer extension for Infinium I and II 
probes and are designed against non polymorphic T sites. Specific I probes are 
designed to monitor allele specific extension for Infinium I probes. Methylation of a 
specific cytosine is assessed using query probes for methylated and unmethylated 
state of each CpG locus. A PM control queries an A/T match which corresponds to 
an unmethylated C state; a G/C match corresponds to a methylated C so G/T and is Chapter 2: Research Methods and Materials 
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interrogated through an MM control probe. A G/T mismatch corresponds to non-
specific detection of methylation signal over unmethylated background so should 
give a low signal. 
Cross hybridisation can occur on all bead arrays due to regions of sequence 
homology. Specific probes susceptible to this cross hybridisation have been 
identified and are easily filtered out of downstream analysis. 
 
The mean signal of negative control probes will define background signal. Negative 
controls are randomly permutated sequences that should not hybridize to the DNA 
template. The average background signal establishes methylation limits for the 
probes. 
Finally, non-polymorphic regions of the bisulphite-converted genome are used as a 
control to test overall assay performance by designing A, C, T and G probes within 
these non-polymorphic regions that can be compared across different samples.  
2.15.3 Sample Dependent QCs and expected intensities 
Genome studio incorporates and assesses the sample dependent QC’s. The package 
generates visual maps of signal intensities that are read within the specified channel 
(red, green or both). For BS conversion I (C1-C3) in the green channel and C4-C6 in 
the red channel, signal intensity should be high compared with probes U1-U3 in 
green channel and U4-U6 in red channel. Specificity probes I and II are read in the 
green and should have a high signal intensity for GT mismatch 1, 2, 3 (PM) but low 
for mismatch 1, 2, 3 (MM). Specificity II probes should be read in the red channel 
and have a high intensity. Non polymorphic probes for bases A and T should have 
high intensity in red channel and C and G should have high intensity in green 
channel. Negative controls can be read in either channel and should yield low signal 
intensity (Table 2.1 reports Genome studio expected intensities in QC probes as 
described). 
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QC  Name  Channel  Intensity 
BS conversion I  C1, C2, C3  green  High 
BS conversion I  U1, U2, U3  green  Background 
BS conversion I  C4, C5, C6  red  High 
BS conversion I  U4, U5, U6  red  Background 
BS conversion II  1,2,3,4  red  High 
Specificity I  GT mismatch 1,2,3 (PM)  red/green  High 
Specificity I  GT mismatch 1,2,3 (MM)  red/green  Background 
Specificity II  Specificity 1,2,3   red  High 
Non polymorphic  NP (A), (T)  red  High 
Non polymorphic  NP (C) (G)  green  High 
Negative  Average  both  Background 
Negative  StdDev  both  Background 
Table 2.1 Expected intensities of sample dependent QC probes. Adapted from Illumina 
Infinium HD assay methylation protocol guide 2013 
2.15.4 Probe Filtering  
The following probes were filtered out of the final analysis: 
1.  X and Y chromosome probes were removed in all studies to prevent 
differential methylation being called from different numbers of X and Y 
chromosomes in mixed sex experimental groups 
2.  Cross-hybridising probes were removed (see section above)  
3.  P values are generated for each probe on the beadarray, describing the 
variance in intensity generated from the beads per probe.  A high level of 
intensity variation implies that there is signal noise and  only probes with a p 
value of <0.01 are included in analysis 
2.15.5 Assessment of Methylation data 
Illumina’s custom software Genome Studio is able to generate an .idat file from raw 
data and methylation values (beta values) are generated as a fluorescence intensity 
ratio between the two bead types are calculated. A ratio value of 0 equals to non-
methylation of the locus; a ratio of 1 equals to total methylation; a value of 0.5 means 
that one copy is methylated and the other is not, in the diploid human genome. Chapter 2: Research Methods and Materials 
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Classically, beta values of samples can be plotted using unsupervised cluster plots or 
multi-dimensional scaling (MDS).  The dimensions on these plots (shown on the X 
and Y axes) represent a calculation based on the number of probes examined and the 
number of samples. To quantitatively estimate differences of MDS plots, both of 
these variables need to be constant. However, all being constant, clustering of 
samples can help to visually identify differences that may be technical i.e. due to 
batch effect or biological i.e. disease compared to control.   
Beta values are variable or ‘ heteroscedastic’ and prevent use of statistical tests that 
rely on Gaussian distribution i.e. t tests. Beta values are often transformed to M 
values to improve normality and more accurately take into account the bimodal 
distribution of methylation across the genome (Du et al, BMC Bioinformatics 
2010).  The M value equates to the log2 ratio of the intensities of the methylated 
versus unmethylated probes.  Once transformed, M- values do conform to statistical 
tests that rely on Gaussian distribution and allow for more direct analysis comparison 
of methylation values within cohorts. 
2.15.6 Methylation data analysis 
Once the processing steps described previously have been undertaken, t-test statistics 
can be used to generate p values, to determine the degree of significance between the 
means of  two groups.  As these array experiments incorporate multiple testing (i.e. 
interrogation of each array probe is one test), a standard p value is not sufficient to 
control for the likelihood of false positives.  A correction for multiple testing should 
be performed, as a False Discovery Rate (FDR)-adjusted p value. 
Through the use of t tests, an FDR adjusted p values can be generated between two 
groups (for these experiments this was the mean difference between case and 
controls) for each position. Those that reached an adjusted p value <0.05 were 
classified as differentially methylated positions (DMPs).  Chapter 2: Research Methods and Materials 
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2.15.7 Assessment of single nucleotide polymorphism (SNP) influenced 
methylation 
Single nucleotide polymorphisms (SNPs) can influence methylation values. In order 
to assess their potential influence a histogram of beta values at each probe position 
can be generated to visualize methylation values. DMPs that exhibit methylation 
(beta) values of 0%, 50% or 100% methylation are consistent with the presence of 0, 
1 or 2 copies of a SNP that can create or abolish a CpG site.  Illumina software that 
lists known interacting SNP-CpG sites (now over 150,000 positions) and in 
conjunction with methylation value evidence can support discovery of those DMPs 
that are influenced by the presence of a SNP. 
2.15.8 Gene Ontology (GO) pathway analysis 
The GO (The GO Consortium, 2000) database assigns biological descriptors (GO 
terms) to genes on the basis of the properties of their encoded products. These terms 
fall into three types: cellular component, biological process, and molecular function. 
Genes assigned the same GO term can thus be regarded as members of a category 
(‘‘GO category’’) of genes that are more closely related in terms of some aspect of 
their biology than are random sets of genes (Holmans P, 2009). 
 
Gene Ontology (GO) analysis was performed using software that directly interacts 
with the Limma R package. GO terms were generated from DMPs identified in the 
analysis. Only those terms that reached a threshold of significance are reported and 
were taken forward. A cut-off p-value of <0.0001 and a fold change of 2 rounded up 
(expected versus actual gene count) was taken to be significant.  
2.15.9 Marmal-aid analysis 
‘Marmal-aid’, is the first meta-analytical tool for DNA methylation (freely available 
at http://marmal-aid.org). In Marmal-aid, all publicly available Illumina450K data 
(8,531 different arrays as of April 15, 2013) is incorporated into a single repository 
allowing for re-processing of data including normalisation and imputation of missing 
values. This database can be easily queried to gain insight into the functionality of Chapter 2: Research Methods and Materials 
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certain CpG sites of interest without having to rely on gene centric approaches such 
as Gene Ontology. 
 
2.16 Illumina 450HM array protocol 
2.16.1 Bisulphite conversion and QC 
With direct guidance from Dr Melissa Smart at the Blizard Institute QMUL, London; 
500ng of high-quality genomic DNA was bisulphite converted using the EZ-96 DNA 
Methylation Deep-well Kit (Zymo Research, Cambridge Biosciences, UK) according 
to manufacturer’s protocols for the Illumina Infinium Assay.  
In order to check bisulphite conversion success a qPCR was performed (Appendix 4; 
S7 and S8). This experiment uses two qPCR reactions designed against parts of the 
MLH and GAPDH gene. The MLH primer (Sigma Aldrich, UK) is designed against 
the expected sequence after bisulphite conversion and the GAPDH (Sigma Aldrich, 
UK) for the non-converted sequence. If conversion has been successful the MLH 
primer pair product will be seen. If unsuccessful, then GAPDH primer sequence will 
match template and produce product. The ratio of each of these products in a given 
sample can then be used to determine the conversion efficiency.  
 
MLH1           F(5’>3’)  GGAGTGAAGGAGGTTACGGGTAAGT 
                     R(5’>3’)  AAAAACGATAAAACCCTATACCTAATCTATC 
GAPDH        F(5’>3’)  CGCCCCCGGTTTCTATAAAT 
                     R(5’>3’)  CAAAAGAAGATGCGGCTGAC 
 
Table 2.2 MLH1 and GAPDH forward and reverse primers as supplied by Sigma Aldrich 
(UK).  
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2.16.2 Allocation to array  
4ul of bisulphite-converted samples were randomly assigned to the Illumina 
HumanMethylation 450Beadchip (Sandoval et al. 2011). Samples were randomized 
at the point of bisulphiting and before being plated out. Samples that initially failed 
the bisulphite QC (did not meet threshold of  >97% conversion) were removed and 
replaced with further aliquots of the sample that did pass a subsequent QC.  
2.16.3 Data generation 
 An .idat file was generated and using Limma (Smyth 2004), an R-based package 
available via Bioconductor 2.11 and beta methylation values were generated from 
raw array data. Data quality checks were performed using in-built control probes to 
examine bisulphite conversion and array performance as described. 
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Chapter 3: Parental Phenotype of FGR Offspring 
 
3.1 Introduction 
Fetal growth is influenced by maternal in utero environment and genetic factors 
inherited from both parents.   
Studies of monogenic disease, in particular MODY and GCK gene variants, support 
a paternal genetic influence in reduced fetal growth. The correlation between father 
and offspring of phenotypic measures (such as similarly low birth weight) support a 
paternal genetic influence (Godfrey KM et al., 1997)  
Men who fathered small for gestational age infants were also more likely to be obese 
and have larger waist circumferences (McCowan LM et al., 2011). Epidemiological 
studies have identified that men who develop diabetes in later life were more likely 
to have fathered low birth weight offspring (Davey Smith G et al., 2004; 
Wannamethee SG et al., 2004, and Hypponen E et al., 2003). Furthermore, that poor 
fetal growth and low birth weight are risk factors for the future development of 
impaired glucose tolerance metabolic syndrome and T2DM (Hales CN et al., 1991& 
Barker DJP et al., 1993). These findings strongly support a paternal effect on both 
fetal growth and birth weight and transmission of metabolic risk.  
In this first experiment I aimed to identify if a paternal phenotype could be 
recognised amongst men who fathered pregnancies affected by fetal growth 
restriction. I recruited and studied a cohort of otherwise healthy couples thought to 
be having a growth restricted offspring and compared them with couples having an 
appropriately grown baby.  In order to categorize if a specific metabolic and vascular 
phenotype could be identified, parental anthropomorphic measurements were taken 
along with fasting glucose and insulin. A surrogate marker of insulin resistance 
(HOMA-IR) was calculated and compared between men who fathered a growth 
restricted offspring and those who fathered an appropriately sized offspring. 
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Although poor growth results from several different mechanisms, placental 
dysfunction is thought to be the underlying reason behind most unexplained or 
idiopathic growth restriction. As the placenta is half paternal in origin, it seemed 
likely that a paternal influence would be most apparent in cases of growth restriction 
thought to secondary to placental dysfunction (as opposed to maternal disease or 
poor nutritional status). Therefore, only such cases of growth restriction were 
recruited. In order to enhance any underlying paternal effect, extensive maternal 
exclusion criteria were employed with the aim of recruiting non-smoking mothers of 
similar age, weight, parity and ethnicity in both groups.  
 
3.2 Hypothesis 
Insulin resistance, identifiable in fathers at the time of the pregnancy and inherited by 
a fetus from its father, will result in a growth restricted phenotype in-utero and 
predispose both offspring and father to later life development of diabetes. 
 
3.3 Specific aims 
1.  To identify if there is a paternal phenotype associated with fathering a growth 
restricted offspring at the time of the index pregnancy. 
2.  To specifically identify whether men who fathered a growth restricted 
pregnancy had an insulin resistant phenotype as assessed by the HOMA-IR 
model. This would support the hypothesis that insulin resistance has a dual 
effect to cause growth restriction and diabetes.  
3.  To assess vascular function of men who father growth restricted pregnancies 
and compare them to men who father appropriately grown babies through the 
use of flow mediated dilation of the brachial artery. 
4.  To study female partners in the same way as fathers in order to assess the 
extent of maternal influence in these cases. 
5.  To characterise the phenotype of FGR offspring and perform measures of 
insulin and c-peptide hormones on both FGR and AGA babies in order to 
support the hypothesis of insulin resistance being present in FGR offspring.  
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3.4 Methods 
3.4.1 Study Design and Population 
A case control study was undertaken at University College London Hospital (UCLH) 
between September 2009 and May 2011. Ethical approval for the study was granted 
by the Joint UCLH/UCL (alpha) Ethical Committee (09/H0715/28). All participants 
gave informed consent. 
 
Couples were recruited who were thought to be having a growth restricted or 
appropriately grown baby as described in the detailed methods section 2.3 to 2.5.  
Briefly to recap, growth restriction was defined as an antenatal <10
th customised 
birth weight centile as assessed by ultrasound where induction of labour or delivery 
by caesarean section was planned in view of fetal size.  
Pregnant women and their partners were recruited as controls that were thought to be 
having a normally grown baby with an estimated fetal weight between 10
th and 95
th 
customised centile as assessed by an antenatal ultrasound. 
Study design methods are described in detail in methods section 2.6 to 2.11. Briefly, 
key measurements for each participant were: 
3.4.2 Father Studies 
Each father completed a questionnaire enquiring about past medical, family and 
treatment history. Own birth weight was recorded as remembered personally or from 
a parent. All study assessments were carried out in the Clinical Research Facility, 
UCLH. Men were studied within 4 weeks of offspring birth. The study room was 
temperature controlled at 24
oC. Participants were asked to fast overnight for at least 
10h before study. Weight, height and abdominal circumference were recorded. After 
resting, two measures of supine blood pressure (BP) were taken 15 minutes apart.  
Fasting venous insulin, glucose and lipid levels were measured. Insulin resistance 
was calculated using the HOMA model (as described in section 2.7). The blood was 
spun within 1hr of venepuncture and plasma and serum were frozen at -80
oC. All 
blood samples were processed in the same laboratory.  Chapter 3: Parental phenotype of FGR offspring 
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I measured endothelial function using brachial artery flow-mediated dilatation in a 
quiet, temperature-controlled room in accordance with protocol described in section 
2.8.  
3.4.3 Fetal sample collection and measurements 
At the time of childbirth, umbilical cord blood was taken from the umbilical vein or 
artery, centrifuged and stored at -80
oC as plasma and serum for later measures of 
fetal insulin and c-peptide levels. Gestational length, offspring gender, weight and 
length were recorded.  
 
3.4.4 Statistical Analysis 
An initial calculation (using STATA) determined that 151 observations would be 
sufficient to detect a doubling in the odds ratio of being a case for every unit increase 
in log HOMA insulin resistance after adjusting for other co-variables, at 0.80 power 
and 0.05 significance.  
Further statistical analysis of the data was performed using the STATA 10 package 
with guidance from a UCL statistician (Mrs Pauline Rogers). HOMA insulin 
resistance was log
e transformed to improve normality. All results are recorded as 
mean (standard deviation) unless otherwise stated. Paternal data was initially 
analysed by univariable logistic regression. The four coefficients with the lowest p 
value were used to generate a multivariable model (further information provided in 
methods section 2.1.2 to 2.1.4).  
3.4.5 Statistical revision of numbers 
In all, after recruitment, 119 paternal observations were made. Using the actual 
HOMA IR results, we were able to re- calculate using our sample size of 119 
observations which showed we were powered at 0.96 to detect a doubling in the odds 
of being a case for every unit increase in log HOMA IR. Hence we were able to stop 
recruited at the intended time end-point despite failure to recruitment the initial 
sample size. 
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3.5 Results  
3.5.1 Recruitment numbers to study groups 
Recruitment occurred over a 15month time period (September 2009- May 2011).  Of 
couples approached, 38 families declined to participate, 10 potential cases and 28 
controls. Of the 10 cases, women experienced stillbirths in two instances, thought to 
be as a consequence of growth restriction. Families where in-utero demise was a 
possibility were approached in this study as it would have been useful to be able to 
include this population. However, of three families that were approached in the 
antenatal monitoring period, in two cases the family declined to take part in the 
study. In the third case, the family wanted to be involved in the study, but delivered 
unexpectedly at another hospital and could not be included.  
Forty four couples were included as cases with a pregnancy affected by fetal growth 
restriction (FGR), <10
th customised centile where induction of labour or delivery by 
caesarean section was planned in view of fetal size. Of these cases, 2 women went 
into spontaneous labour before their planned induction date but were still included in 
the study.  
Eighty five pregnant women and their partners who were thought to be having a 
normally grown baby with an estimated fetal weight between 10
th and 95
th 
customised centile as were included as ‘controls’. All participants had an additional 
fetal ultrasound scan at 34 weeks to confirm predicted size (unless a third trimester 
scan had already been done n=10). After delivery, neonatal measures that did not 
match predicted fetal growth led to the exclusion of 8 families (6 controls and 2 
cases) and two further families withdrew consent to study participation after 
delivery. Final study analysis was between 42 cases and 77 controls (Figure 3.1). 
In terms of recruitment the vast majority of participants were recruited from within 
the maternal fetal assessment unit at University College Hospital. A minority were 
approached directly in the fetal medicine unit (where complex fetal growth 
restriction cases are managed) or through antenatal classes or in antenatal clinic.  
Fourteen couples expressed interest through email correspondence after seeing 
posters about the study.  Four of these were classified as cases and 10 as controls. All 
couples who instigated email contact agreed to participate in the study when further 
information was provided to them.   Chapter 3: Parental phenotype of FGR offspring 
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Seven couples, thought to be having a growth restricted offspring, agreed to donate 
fetal samples but did not want to undergo any studies themselves.  
3.5.2 Baseline characteristics 
Baseline characteristics of offspring confirmed that case and control subjects met the 
study criteria (Table 3.1). Data was available for all 77 control offspring and 42 case 
offspring that were being studied as part of a family. 
   CASES           CONTROLS          
BABY                       
   Mean (n)  SD  25th  75th  Mean (n)  SD  25th  75th 
Customised birth 
centile (%) 
 
1.8 
 
2.2 
 
0.1 
3.2   
49.6 
 
27.5 
 
26 
 
73.9 
Gestation (days)  256  29  236  279  283  9.3  274  291 
Birth weight (g)*  2019  752  1378  2650  3517  367  3290  3800 
 
Table 3.1 Birth characteristics of offspring cases (<10
th customised birth weight centile: 
n=42) and controls (10
th - 95
th customised birth weight centiles; n=77). Customised birth 
centiles are gestation specific and detect fetal growth restriction despite reduced gestation 
3.5.3 Offspring Data 
There were significant differences between case and control birth weight and 
gestational age at delivery which was to be expected by the study design. The mean 
customised birth centile in controls was 49.6
th ﾱ27.5 centile and in cases was 1.8
th ﾱ 
2.2 centile.  
 
Of the seven cases in which permission was given for collection of just fetal samples 
the average birth weight was 2.29ﾱ0.29 kg and gestation 273ﾱ12 days (equivalent to 
39 weeks gestation). 
 
3.6 Maternal phenotype data 
Female pre-pregnancy age, weight (kg), heights (cm) and parity were recorded 
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significant results. Antenatal data was available on 76 controls and all 42 cases. 
Smoking status was assessed through antenatal records and confirmed that no women 
recruited smoked.  
 
MOTHERS  CASES           CONTROLS          
   Mean  SD  Min  Max  Mean  SD  Min  Max 
Age (years)  33.8  4.52  25  44  32.3  3.57  20  39 
Weight (kg)  62.7  9.2  48.4  84.1  64.4  10.5  44  94 
Height (cm)  163  5.7  152  175  166  5.8  155  185 
Birthweight (g)  3007 (20)  576  1000  3800  3322 (45)  425  2300  4300 
BMI (kg/m
2)  23.3  3.5  19  32  23.4  3.4  18  32 
Nulliparous  31 (73.8%)         57 (74.0%)        
Multiparous  11 (26.2%)         20 (26.0%)        
 
Table 3.2 Maternal baseline characteristics. Antenatal statistics gathered from antenatal notes 
and interview (for own birthweight). Confirmed all women met inclusion criteria.  
3.6.1 Routine Antenatal Maternal Glucose Data 
As part of routine antenatal care at University College Hospital, London all pregnant 
women are offered a random glucose at booking and 28 weeks of pregnancy and 
these results were extracted and compared between control and case subjects.  
 
Maternal random glucose levels at the booking antenatal visit (usually between 8 and 
12 weeks of pregnancy) were similar [case subjects 4.45 ﾱ0.52 mmol/L and control 
subjects 4.54ﾱ 0.54 mmol/L, P = 0.44].  
 
3.6.2 Antenatal vitamin and micronutrient data  
A protocol amendment meant that at the time of recruitment to the study (34 weeks 
of pregnancy) an extra sample of blood could be taken from female participants at 
the same time as their routine antenatal blood test. Whole blood was stored for DNA 
extraction but samples were also centrifuged and serum stored. Aliquots of female 
antenatal serum were processed by The Doctors Laboratory Ltd, London, UK for 
vitamin D, vitamin B12, folate and homocysteine levels using routine validated 
clinical biochemical assays.  Chapter 3: Parental phenotype of FGR offspring 
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As these micronutrients have been shown to influence fetal outcomes and  
deficiencies are associated with poor fetal growth it was important to investigate 
maternal nutritional levels during pregnancy in order to identify their potential role in 
this cohort. Due to the later addition of this sampling time point, 45 samples (29 
control and 18 cases) were processed.  
 
Women with FGR had lower antenatal folate, vitamin D and homocysteine levels but 
this did not reach statistical significance (Table 3.3). 
  CASES   
(mean) 
SD  CONTROLS 
(mean) 
SD  P value     (95% CI) 
No samples  18    29     
B12       
(pmol/L) 
384.5  188.2  332.2  137.5  0.29                         
(-44.8 to 149.3) 
Folate 
(nmol/L) 
10.1  4.33  11.3  4.6  0.37                         
(-1.5 to 4.01) 
Vitamin D 
(ng/mL) 
44.2  29.5  50.6  31.4  0.49                         
(-25.4 to 12.4) 
Homocysteine 
(umol/L) 
6.9  2  17.1  26.4  0.12                         
(-2.75 to 22.6) 
 
Table 3.3 Measurement of female participants’ antenatal (34weeks gestation) micronutrient 
and vitamin levels for B12, folate, vitamin D and homocysteine.  
 
3.6.3 Antenatal maternal plasma cotinine levels 
Women who smoked were excluded from the study due to the known association of 
smoking with fetal growth restriction. However, we not exclude fathers who smoked. 
In order to investigate the potential in-utero environmental effect of smoking within 
a household (i.e. by a father) cotinine (a metabolite of nicotine) levels were measured 
in women whose partners smoked.  Only 3 women (2 cases and 1 control) out of a 
sample of 17 women who had a partner, who smoked, had detectable serum cotinine 
levels. These levels were compatible with passive smoking (15.7, 45.9, 59.3ng/mL). Chapter 3: Parental phenotype of FGR offspring 
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3.6.4 Postnatal maternal phenotype study  
All women were recruited antenatally, but studied postnatally due to the confounding 
effect of pregnancy. Visits took place 6 months after delivery +/- 1 month, except if 
women were exclusively breastfeeding (n=9), in which case they were seen between 
6months and 1 year (when infant weaning commenced). 
 
Women were invited for follow up, by letter, email and telephone and in total 60 
(51.2%) female participants (37 controls and 23 cases) returned to be studied. 
Several of the initial cohort could not be contacted due to out-of-date contact details 
(n=10). 8 women were pregnant again at the time of call-back and hence not eligible 
to be studied and due to the time lapsed were not called back after the subsequent 
pregnancy. 10 women declined to come back having moved area and 15 women 
declined due to work or family commitments. Due to time constraints 9 women 
recruited at the end of the study were not invited back. All women were asked about 
their on-going consent to the study when contact was established and all were happy 
for data to be used in situations where they were unable to attend postnatal follow-
up. 
Women who returned underwent exactly the same study as their partners in the same 
room within the Clinical Research Facility. Physical measurements revealed very 
little difference in weight (kg), abdominal circumference (cm), blood pressure 
(mmHg) between control and case women (Table 3.4) 
  CASES  CONTROLS     
  Mean (SD)  Mean (SD)  p-
value 
95% CI 
 
Number (n) 
Weight (kg) 
 
23 
63.2 (10.6) 
 
37 
62.9 (8.4) 
 
 
0.9 
 
 
(-6.6 to 5.87) 
Abdo Circumference (cm)  82.3 (8.6)  81.8 (6.4)  0.84  (-4.63 to 5.68) 
Systolic BP (mmHg)  103.6 (15.2)  109.9 (7.8)  0.08  (-0.72 to 13.2) 
Diastolic BP (mmHg)  64.1 (7.9)  65.2 (8.0)  0.64  (-3.53 to 5.65) 
   
Post pregnancy 
 
Pre pregnancy 
   
Case weight (kg)  63.2 (10.6)  63.2 (9.6)  0.98  (-6.75 to 6.62) 
         
Control weight (kg)  62.9 (8.4)  64.1 (10.4)  0.55  (-2.82 to 5.21) 
Table 3.4 Female postnatal study. Physical measurements of the 37 control women originally 
recruited and 23 case women including weight (kg), height (cm), abdominal circumference 
(cm) and blood pressure (mmHg) which revealed no statistical differences.  Chapter 3: Parental phenotype of FGR offspring 
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It is striking to note that pre and post-pregnancy weights were similar in the female 
cohort. Assuming that weight is one surrogate marker, it suggests that this post-
pregnancy study was a reasonable surrogate marker of pre-pregnancy female status 
(which is the time point I was interested in trying to recreate). 
3.6.5 Postnatal maternal blood results (glucose homeostasis) 
As shown in table 3.5, blood glucose results remained similar postpartum (control 
subjects 4.57ﾱ 0.46 mmol/L and case subjects 4.53ﾱ 0.37 mmol/L, P = 0.78). 
Postpartum, maternal insulin levels were also similar between control (3.92 ﾱ2.15 
mIU/L) and case (4.38 ﾱ2.41 mIU/ L) subjects; P = 0.57. Postnatal maternal HOMA 
index was similar between control (0.56ﾱ0.24) and case (0.58 ﾱ0.29) subjects; P = 
0.57. 
 
  CASES 
Mean 
 
SD 
CONTROLS 
Mean 
 
SD 
P-value        
(95% CI) 
Fasting glucose 
(mmol/L) 
4.53  0.37  4.57  0.46  0.78                    
(-0.21 to 0.26) 
Fasting insulin  
(mIu/L) 
4.38  2.41  3.92  2.15  0.57                      
( -2.27 to 0.46) 
IR (HOMA)  0.58  0.29  0.56  0.24  0.57                     
( -0.19 to 0.34) 
 
Table 3.5 Postnatal maternal glucose homeostasis including glucose (mmol/L), insulin 
(mIu/L) and HOMA IR in control (n=37) and in case women (n= 23). 
3.6.6 Postnatal maternal blood results (metabolic status) 
Blood from participants was processed at University College Hospital biochemistry 
laboratory, using standard validated biochemical assays for; urea, creatinine, c-
reactive protein and lipid profiles along with glucose, insulin and glycated 
haemoglobin (HbA1C).  
As shown in table 3.6, results revealed no significant differences between controls 
and cases particularly in the lipid profile of triglycerides (control 0.60 ﾱ0.23 mmol/L 
and case 0.61ﾱ0.26 mmol/L) and HDL cholesterol (control 1.81ﾱ0.38mmol/L and 
case 1.80ﾱ0.33 mmol).  Chapter 3: Parental phenotype of FGR offspring 
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  Cases mean (SD)  Controls mean 
(SD) 
  p-value  95% CI 
Number samples  23  37       
Urea   4.55 (1.15)  4.77 (1.02)    0.56  (-0.44 to 0.8) 
Creatinine  61.5 (9.6)  61.7(13)    0.95  (-6.56 to 7.05) 
Triglycerides (mmol/L)  0.61 (0.26)  0.6 (0.23)    0.98  (-0.14 to 0.14) 
Cholesterol (mmol/L)  4.79 (1.1)  4.49 (0.69)    0.26  (-0.78 to 0.22)  
HDL (mmol/L)  1.8 (0.33)  1.81 (0.38)    0.98  (-0.21 to 0.21)  
LDL (mmol/L)  2.55 (0.80)  2.41 (0.67)    0.53  (-0.57 to0.3) 
 
Table 3.6 Female postnatal biochemical results. Urea, creatinine and lipid profile all reveal 
no statistically significant differences between controls and cases. 
3.6.7 Postnatal serum vitamin and micronutrient levels 
Postnatal serum vitamin B12, folate and vitamin D were assessed in 18 control and 
11 case women. In both cases and controls levels were higher than seen during 
pregnancy. However, no statistical difference was seen between cases and controls 
for serum B12, folate or vitamin D levels postnatally (Table 3.7). 
 
  CASES   
(mean) 
SD  CONTROLS 
(mean) 
SD 
No samples  11    18   
B12       
(pmol/L) 
462.9  198.1  469.1  157.9 
Folate 
(nmol/L) 
11.6  5.1  12.3  4.5 
Vitamin D 
(ng/mL) 
51.1  28.2  45  16.7 
 
Table 3.7 Measurement of female participants’ postnatal micronutrient and vitamin levels for 
B12, folate, and vitamin D in 18 controls and 11 cases which revealed no statistically 
significant results.  
3.6.8 Postnatal maternal vascular results 
Women were also studied using both flow mediated dilatation (FMD) and pulse 
wave velocity (PWV).  
Flow mediated dilatation in women postnatally revealed some interesting differences 
between case and control women. Of the 33 postnatal controls where FMD was 
performed (4 women returned on a day where FMD was not possible), 29 of the Chapter 3: Parental phenotype of FGR offspring 
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scans were eligible for inclusion after quality control checks and 18 of 21 scans 
performed on case women were eligible for comparison. 
Control women postnatally had higher FMD 10.26 ﾱ2.44% than case women FMD 
6.98ﾱ0.97% which was statistically significant p=0.0003 (95% CI 1.61-5.06). In this 
analysis smoking did not need to be adjusted for as no women included in the study 
smoked.  Of case women studied, 4 had experienced early onset pre-eclampsia in 
conjunction with growth restriction. Postnatal FMD in these women revealed a mean 
FMD of 6.68ﾱ1.5% versus 7ﾱ0.68%) in case women with growth restriction only. 
 
Pulse wave velocity revealed that despite no statistical difference there was a trend 
for case women to have higher PWV [controls 6.54ﾱ0.57 m/s and cases 6.95ﾱ 0.10 
m/s] with a p-value= 0.1 (95% Confidence Interval -0.86 to 0.77).   
 
 
3.7 Paternal phenotype data 
Phenotype data was available on all male participants (n=119). In contrast to 
mothers, fathers of growth-restricted offspring (case subjects) had greater waist 
circumference and blood pressure and were more likely to smoke than fathers of 
normal grown offspring (Table 3.8). 
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Table 3.8 Baseline paternal phenotype including; physical, vascular, metabolic and smoking status
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
   CASES           CONTROLS             
   Mean (n)  SD  Min  Max  Mean (n)  SD  Min  Max  p value 
Age (years)  34.8  5.71  23  47  33.3  4.69  22  50  0.158 
Weight (kg)  83.4  11.8  57  106.9  80.2  10.2  55.2  112  0.13 
Height (cm)  177  7.0  166  193  179  6  161  195  0.28 
Birthweight (g)  3127 (20)  597  1000  3970  3506 (37)  380  2780  4540  0.005 
Waist circumference (cm)  94.1  8.23  71  114  89.6  8  60.5  113  0.005 
BMI (kg/m
2)  26.2  3.25  18.7  31.5  25.2  2.93  16.8  32.2  0.08 
Systolic BP (mmHg)  121.5  8.73  102  137  117.7  5.86  105  130  0.006 
Diastolic BP (mmHg)  70.5  7.16  57  85  66.9  6.31  55  83  0.005 
Fasting glucose (mmol/L)  4.87  0.41  4.2  6.4  4.72  0.32  3.9  5.4  0.037 
Fasting insulin (mIU/L)   7.1  4.29  2  17.5  4.81  2.61  1.5  11  0.001 
Insulin Resistance (HOMA)  0.93  0.51  0.4  2.2  0.63  0.31  0.4  2  <0.001 
Cholesterol (mmol/L)  4.85  0.89  2.8  7.2  4.65  0.86  3.1  7.8  0.27 
Triglycerides (mmol/L)  1.06  0.48  0.5  2.5  0.9  0.38  0.4  2.2  0.06 
HDLCholesterol (mmol/L)  1.29  0.32  0.7  2.3  1.41  0.34  0.9  2.7  0.09 
LDL Cholesterol (mmol/L)  3.01  0.92  1.2  5.7  2.82  0.83  1.2  6.1  0.28 
FMD (%)  6.45  3.5  1.15  15.6  8.12  3.08  3.65  17.17  0.017 
Smokers  17 (40.5%) 
     
15 (19.5%) 
     
0.008 Chapter 3: Parental phenotype of FGR offspring 
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3.7.1 Paternal blood results- glucose homeostasis 
Blood was available to analyse and a result was available in all cases (in three 
situations the test was repeated due to failure of the initial sample). Fasting glucose 
and insulin levels were both higher in case subjects, which resulted in an elevated 
HOMA-IR (Figure 3.1).               
                                                     *  
 
 
Figure 3.1Box Plot of IR values which were statistically significantly different between case 
(42) and control (77) men (* p<0.0001) 
 
3.7.2 HOMA beta cell function 
In contrast to HOMA-IR beta cell function (as measured through HOMA-β%) was 
seen to be increased in cases versus controls. Male controls had a HOMA- β  of 
73.4ﾱ21.6 with cases mean 94.7ﾱ 40 and a significant p-value of 0.0007 (-33.28 to -
9.14).  
 
Mid- way through the trial we also began to assess glycated haemoglobin (HbA1C) 
in some of the study men but the difference between cases and controls did not reach 
statistical significance (p=0.6   95%  CI -0.361 to 0.220)  in part due to the limited Chapter 3: Parental phenotype of FGR offspring 
 
103 
   
numbers (cases n=11 and controls n=14) . Case men had an HbA1C of 5.31 ﾱ 0.34% 
versus control men who had a slightly lower value of 5.24ﾱ 0.34% 
 
3.8 Paternal vascular status  
3.8.1 Flow mediated dilation 
In analysis, exclusion criteria of recordings included: poor image quality; if 
recordings were deemed to be unrepresentative of the true vessel diameter or if 
images did not return to near baseline after reperfusion (Figure 3.3a).  Each image-
recording was validated by a second operator unaware of the subjects’ group. Of 119 
scans assessed in this fashion 22 (18.5%) were excluded from the final analysis due 
to above criteria. The remainder were included in analysis (example in Figure 3.3b)  
 
 
 
 
Figure 3.2a. FMD scan (above) excluded from analysis due to failure of image to return to 
baseline Chapter 3: Parental phenotype of FGR offspring 
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Figure3.2b. Suitable FMD scan for analysis : flat baseline, clean peak and  return to baseline 
 
As an independent variable, FMD in case men was significantly lower [6.45ﾱ3.45%] 
than control men [8.12ﾱ3.08%], suggesting more endothelial dysfunction. However, 
once adjustment had been made for smoking status then this difference was removed. 
Smoking is known to affect endothelial function (Hirofumi T, 2008) and as such 
should be included in any analysis; however, it does not negate the increased 
cardiovascular risk identified in these men. 
3.8.2 Pulse Wave Velocity  
Pulse wave velocity was only performed on 50 controls and 30 cases and 4 of these 
recordings were excluded due to technical issues after analysis. The results (Table 
3.9) showed that case men had slightly higher PWV than control men but this was 
not significant (p=0.6 95 CI% -0.56 to 0.37). I believe that this technique would have 
yielded information consistent with FMD given larger numbers of participants.  
  CASES  CONTROLS 
Mean (m/s)  7.21  7.12 
SD  0.98  0.99 
SEM  0.18  0.14 
N  29  47 
 
Table 3.9 PWV data for control (n=50) and case (n=30) men. Case men had a higher mean 
PWV (m/s) but this did not reach statistical significance Chapter 3: Parental phenotype of FGR offspring 
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3.9 Phenotype statistical analysis 
Initial univariable logistical regression analysis confirmed that paternal insulin 
resistance, blood pressure, and waist circumference were higher in case compared 
with control subjects, while flow mediated dilatation was reduced and case fathers 
were more likely to smoke cigarettes (Table 3.9). The four most statistically 
significant paternal coefficients were log HOMA-IR, smoking, waist circumference, 
and diastolic blood pressure, which were analysed in the multivariable analysis. 
Paternal insulin resistance and smoking remained different after multivariable 
analysis, and therefore the final model was run with these two variables (Table 3.10). 
Compared with fathers of normal grown offspring, men who fathered pregnancies 
affected by fetal growth restriction had an OR 7.68 (95% CI 2.63–22.4, P , 0.0001) 
of having a 1-unit higher log HOMA-IR value and 3.39 (1.26–9.16, P = 0.016) of 
being a smoker (Table 3.10).  
Coefficients  Univariable analysis     Multivariable analysis  
                 
   Odds 
ratio 
95% 
Confidence 
Interval 
(CI) 
p  Odds 
ratio  CI  p 
     
 
  
   
  
logIR (HOMA)  5.99  2.25-15.91  <0.0001  7.68  2.63-22.4   <0.0001 
Smoker  3.09  1.10-8.22  0.01  3.39  1.26-9.13  0.016 
Diastolic Blood 
Pressure (mmHg)  1.09  1.02-1.16  0.006 
   
  
Systolic Blood 
Pressure (mmHg)  1.08  1.02-1.14  0.007   
 
  
Waist circumference 
(cm)  1.08  1.02-1.14  0.007   
 
  
FMD (%)  0.84  0.73-0.97  0.021        
BMI (kg/m
2)  1.12  0.99-1.28  0.081 
   
  
Weight (kg)  1.03  0.99-1.07  0.133   
 
  
Age (years)  1.06  0.98-1.14  0.158          
Table 3.10 Logistical regression of paternal variables. Compared with fathers of normal 
grown offspring, men who fathered pregnancies affected by fetal growth restriction had an 
OR 7.68 (2.63-22.40; p<0.0001) of having a 1 unit higher log HOMA IR value and an OR 
3.39 (1.26-9.16; p=0.016) of being a smoker. (OR, odds ratio: HOMA, homeostasis model 
assessment; FMD, flow-mediated dilatation; BMI, body mass index).  Chapter 3: Parental phenotype of FGR offspring 
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In order to assess maternal confounding sensitivity analyses was performed using 
forward stepwise regression, first including all paternal explanatory variables 
followed by addition of maternal explanatory variables (maternal age and BMI) to 
the model, With this use of step-wise regression, no maternal variable affected the 
differences identified in paternal insulin resistance or smoking. 
HOMA beta cell function was assessed in a similar fashion. Significance was lost in 
a model including adjustment for logIR (data not shown). However, it did retain 
significance when adjusted for age, smoking status and abdominal circumference. 
Men who fathered a growth restricted offspring had an OR 1.03 (p=0.03) of having a 
one unit increase in beta cell function compared to men who fathered appropriately 
sized babies. 
        cas_con | Odds Ratio   Std. Err.      z    P>|z|       [95% CI]   
Homa β|   1.015724   .0073583     2.15   0.031     1.001403    1.030249 
age      |   1.037631   .0510038     0.75   0.452     .9423298     1.14257 
smoker |   3.516152   1.793553     2.46   0.014     1.293834    9.555575 
Abdo    |   1.033914   .0339851     1.01   0.310     .9694048    1.102716 
 
Table 3.11- Logistical regression of HOMA-β with age, smoking status and abdominal 
circumference (cm) including odds ratio, standard error (Std Err), p-value and 95% 
confidence interval 
3.9.1 Secondary Analysis 
Secondary analysis was performed assessing the data in a more clinical context. 
Using the criteria for the insulin resistance syndrome defined by the European Group 
for the study of insulin resistance in non-diabetic individuals
 the majority of men in 
the highest quartile for insulin resistance (n=30) were cases (19/42 cases (45%) 
compared with 11/77 controls (14%) (Figure 9a). 
Further risk factors as defined The European Group for the Study of Insulin 
Resistance are: 
(1) Central obesity: waist circumference 94 cm or more 
(2) Dyslipidaemia: triglycerides (TG) 2.0 mmol/l or more and/or HDL-C less than 
1.0 mmol/l or treated for dyslipidaemia 
(3) Hypertension: blood pressure 140/90mmHg or more 
(4) Fasting plasma glucose at least 6.1 mmol/l. Chapter 3: Parental phenotype of FGR offspring 
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With use of these criteria for the insulin resistance syndrome, the majority of men in 
the highest quartile for insulin resistance (n = 30 of 119) were case subjects (19 of 42 
case subjects (45%) compared with 11 of 77 control subjects [14%] (Table 3.12). 
Most of these case subjects (10 of 19 [53%]) also had an increased abdominal 
circumference >94 cm (Figure 3.3b), which was only noted in 2 of 11 (18%) control 
subjects (Figure3.3a). This information was then used to generate a second model 
limited to fathers in the top quartile for insulin resistance and their related insulin 
resistance traits (Figure 3.3b).  
 
 
 
n=  n= 
Abdominal circumference (cm)  10  2 
Triglycerides (mmol/L)  2  1 
HDL-Cholesterol (mmol/L)  4  2 
Blood Pressure (mmHg)  0  0 
Fasting glucose (mmol/L)  1  0 
Top 25% (n=30) fasting insulin value of our 
population(n=119)  19 (45.2%)  11 (14.3%) 
Of these: no further risk factors  n(% of 19)  5 (26.3%)  8 (72.3%) 
1 further risk factor  10 (52.6%)       1 (9%) 
2 further risk factors or IR syndrome  4 (21%)       1 (9%) 
 
Table 3.12 Fathers with insulin levels in the highest quartile were selected (n=30). This 
included 19/42 (45%) of cases and 11/77 (14%) controls.  These men were assessed for the 
presence of other risk factors for the insulin resistance syndrome as a % of the number of 
men identified in each group.  The majority of men in this top quartile for insulin resistance 
who fathered growth restricted offspring had 1 or 2 further risk factors for the insulin 
resistance syndrome (14/19; 74%) versus only 18% (2 of 11)  of the controls identified.  
 Chapter 3: Parental phenotype of FGR offspring 
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Figure 3.3a. Of individuals who were within top 25% insulin, the number of subjects who 
met other criteria for insulin resistant syndrome including waist circumference >94cm, TG ≥ 
2mmol/l, HDL-C≤ 1mmol/l, BP >140/90 mmHg or blood glucose≥ 6.1mmol/l. Case men are 
in blue and controls in red.  
 
Figure 3.3b - Association between paternal insulin resistance syndrome (with individual 
criteria represented) and fathering a pregnancy affected by fetal growth restriction. Case 
fathers are in blue and controls in red.  
Graph shows % of men in top quartile of insulin and of those, who had further risk factors 
for IR syndrome.  Men who fathered growth restricted offspring were more than three times 
more likely to fall into the highest insulin resistance quartile, with more than half of them 
having a waist circumference >94cm. 
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This information could be used to generate a second model looking specifically at the 
risks for those in the highest quartile of insulin levels.  
 After multivariable analysis, men in the top quartile for insulin resistance who 
fathered a growth-restricted fetus had an OR 6.72 (95% CI 2.43–18.58; P ,0.0001) of 
having further risk factors for the insulin resistance syndrome and OR 3.36 (1.28–
8.28; P-value 0.013) of being a smoker compared with fathers of normal grown 
offspring. 
  Univariable    Multivariable 
  OR  P value  95% CI  OR  p value  95% CI 
IR syndrome 
risk factor 
5.86  <0.000
1 
2.25-15.27  6.72  <0.000
1 
2.43-
18.58 
Smoking  3.09  0.01  1.10-8.22  3.26  0.013  1.28-8.28 
 
Table 3.13 Secondary multivariable analysis of men in top quartile of insulin levels in 
cohort, including smoking status then men who fathered growth restricted baby nearly seven 
times more likely to have other risk factors for insulin resistance syndrome.  
 
3.10 Paternal Placental like growth factor (Plgf) 
63 male control and 32 case serum samples were suitable for analysis.  In 8 of the 32 
cases mothers had PET. No controls had PET. As shown in Figure 3.4, PlGF levels 
in male controls; 11.80ﾱ 0.51 ng/L (meanﾱSEM) and PlGF levels in cases; 
10.86ﾱ0.67 ng/L (no difference in cases with PET 10.8ng/L) A student t-test was 
performed on the data which revealed the difference did not reach significance [p 
value 0.3 (CI -0.8- 2.6)]  
 
 
           
 
 
 
 
 
 
Figure 3.4 Bar chart of PLGF levels (ng/L) in case and control fathers 
P= 0.3 Chapter 3: Parental phenotype of FGR offspring 
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3.11 Fetal phenotype measurements 
Weight and gestation was recorded for all babies and this data is presented already in 
section 3.5.2. It proved to be far more difficult recording length due to many of the 
FGR babies requiring admission to the Special Care unit where this measurement 
was not an immediate priority. It was, therefore, decided not to continue to record 
ponderal index due to the variability of data collection.  
Overall baby gender was well matched in the study with 39 boys and 38 girls being 
born in the control group versus 20 boys and 22 girls in case offspring. In the control 
group boys were 228g heavier on average than girls. There was no difference in 
weights seen between boys and girls born in the case group (Table 3.1).  
3.11.1 Fetal sample collection 
As babies were being born throughout the study, it was not possible to achieve 100% 
collection of cord blood and placental samples. Of 119 deliveries, samples were 
retrieved in 58 controls (75% of trios) and 30 cases (3 where consent just for samples 
had been given) so 64% of trios) which resulted in an overall collection rate of above 
70% for offspring where parental data was also available). The slightly lower number 
of cases also reflected situations where it was not possible to collect umbilical cord 
blood or where placentas needed to be sent before any sampling (total n=5). In two 
control cases where sampling was missed at the time of delivery, buccal swabs were 
used on offspring during postnatal visits at the request of parents.  
3.11.2 Glucose homeostasis in offspring 
Due to the nature of collections and prioritisation of use, it was not always possible 
to collect enough cord blood in order to obtain plasma and serum. Only samples 
where there was enough cord blood and the collection had been taken within one 
hour of delivery were centrifuged to achieve plasma or serum from cord blood.  
 
This meant that 12 plasma samples were available from fetal growth–restricted 
offspring and 21 from normal grown offspring in order to assess for insulin and c-
peptide level (Table 3.14). In 2 controls and 2 cases a c-peptide result was 
unavailable. Both control and case offspring had similar insulin levels (5.41ﾱ3.52 Chapter 3: Parental phenotype of FGR offspring 
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and 7.12ﾱ8.66 mIU/L, P = 0.43) respectively, and similar c-peptide levels (1.04ﾱ0.42 
and 1.21ﾱ0.63 ug/L, P = 0.38).  
 
  CASES   
(mean) 
SD  CONTROLS 
(mean) 
SD  P value  
No samples  11    18     
Insulin (mIu/l)  7.12  8.66  5.41  3.52  0.43  
No samples  10    19     
C-peptide (ug/l)  1.21  0.63  1.04  0.42  0.38 
 
Table 3.14 Offspring plasma levels of c-peptide (ug/l) and insulin (mIU/l) in growth 
restricted offspring (cases) and appropriately grown offspring (controls). 
 
3.11.3 Family Glucose Homeostasis Comparison  
Individual analysis was undertaken to assess correlation between fetal cord blood 
insulin and paternal insulin levels (Table 3.15). 
Firstly, for cord blood plasma insulin levels available, paternal log IR was 
interrogated to assess whether the small sample size could reflect the larger dataset. 
This initial analysis seemed promising and revealed the mean paternal IR (with 
offspring data available) was significantly different (p=0.008 95% CI 4.13-7.3) with 
control mean serum insulin 4.36ﾱ2.8 mIU/L and cases 8.69ﾱ5.8 mIU/L.  
In concordance with the above data paternal logIR between controls (-0.27ﾱ0.04) and 
cases (-0.03ﾱ0.09) remained significantly different (p=0.006 95% CI -0.28 to -0.1) 
However, comparison of all samples revealed no correlation seen between paternal 
logIR and offspring cord blood serum c-peptide or insulin levels in our cohort 
(p=0.57) (Figure 3.5)  
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Figure 3.5. Graphical representation of correlation between paternal log HOMA-IR and 
offspring serum cord insulin (mIU/l) 
 
 
 
Table 3.15 Family glucose homeostasis in controls and cases. In babies only glucose and c-
peptide recorded. In mothers, antenatal random glucose (mmol/l) along with postnatal study 
recorded. Fathers fasting values recorded.  
 
 
Family 
member  Group 
Random 
glucose  
Fasting 
glucose 
Fasting 
insulin*  IR (HOMA) 
C-peptide* 
(ug/L) 
     
(mmol/L) 
AN 
(mmol/L)  
 (mIU/L)        
BABIES 
Cases 
Controls     
  
7.12 (8.66 )  
5.41 (3.52)    
1.21 (0.63) 
1.04 (0.42) 
   p value        0.43     0.38  
MOTHERS 
Cases 
Controls 
4.45 (0.52) 
4.54 (0.54) 
4.53 (0.37) 
4.57 (0.46) 
4.38 (2.41) 
3.97 (2.15) 
0.58 (0.29) 
0.56 (0.24)    
   p value  0.44  0.78  0.57   0.57    
FATHERS 
Cases 
Controls     
4.87 (0.41) 
4.72 (0.32) 
7.1 (4.29) 
4.81 (2.61) 
0.93 (0.52) 
0.63 (0.31)    
   p value     0.037   0.001  0.0003     Chapter 3: Parental phenotype of FGR offspring 
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3.12 Remembered parental birth weight 
As part of the questionnaire, both parents were asked if they knew of their own birth 
weights. This information was self -reported often through another family member. 
Parental birth weight was known in 57 (48%) fathers and 65 (55%) mothers. Case 
fathers, were lighter than control fathers (birth-weight 3127ﾱ597g, versus 
3506ﾱ380g, respectively (p=0.0045). Case mothers, were lighter than control 
mothers (birth-weight 3007ﾱ576g versus 3322ﾱ425g, respectively (p=0.012).  
 
 
 
 
Table 3.16 Family birth weights in grams (as remembered) in relation to offspring birth 
weight.  
 
 
 
 
 
 
 
 
CONTROLS              CASES          
p 
value 
   n 
Mean 
(grams)  SD  Range  N 
Mean 
(grams)  SD  Range    
Baby (total)  77 
 
3517 
 
367 
 
2760-4400 
 
42  2019 
 
752 
 
560-3280  <0.001 
Male baby  39  3629 
 
   20  2019  903       
Female baby  38  3401 
 
   22  2019  627       
Father*  37  3506  380  2780-4540  20  3127  597  1000-3970  0.0045 
Mother*  45  3322  425  2300-4300  20  3007  576  1000-3800  0.012 Chapter 3: Parental phenotype of FGR offspring 
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3.13 Discussion 
This case-control study identified women with pregnancies affected by fetal growth 
restriction and showed that their partners were more insulin resistant and more likely 
to smoke compared with fathers of normal grown offspring. Fathers of growth-
restricted offspring also had other elements of the insulin resistant syndrome 
including; high blood pressure, endothelial dysfunction, upper body fat redistribution 
and a more atherogenic lipid profile. These observations support epidemiological 
studies that have consistently observed an increased incidence of type 2-diabetes and 
cardiovascular disease amongst men who previously fathered low-birth weight 
offspring (Davey Smith G et al., 2004; Wannamethee SG et al., 2004, and Hypponen 
E et al., 2003).  
Although the study provides objective evidence of sub-clinical insulin resistance at 
the time of fathering a growth-restricted offspring, the Exeter Family Study of 
Childhood Health (EFSOCH), which studied almost 1000 normal grown offspring 
and their fathers, did not find an association between offspring birth weight and 
paternal insulin resistance (Knight et al., 2006). Unlike the cohort I recruited, 
however, the EFSOCH study only investigated offspring with a normal birth weight 
(2.95kg - 3.98kg). Under these circumstances paternally inherited insulin resistance 
may be compensated by increases in fetal insulin production. This suggestion was 
supported by their observation that paternal insulin resistance was inversely 
correlated with fetal insulin concentrations (Shields et al., 2007). In a sub-set of our 
study population, I was unable to detect such a relationship between paternal insulin 
resistance and fetal cord blood insulin or c-peptide levels although fetal insulin levels 
were higher in FGR offspring but this did not reach statistical significance. It is 
possible that the secondary analysis did not have statistical power to detect such a 
correlation. Another explanation is that,  in this study, cases may have included a 
mixture of growth restricted offspring, some with insulin resistance and high fetal 
insulin levels and others with reduced beta cell function and low fetal insulin 
secretion, so that a clear difference could not be detected  in overall insulin levels 
between cases and controls. It is possible that other heritable factors that are passed 
from father to offspring influence both paternal phenotype and fetal growth. Chapter 3: Parental phenotype of FGR offspring 
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Men who fathered growth restricted offspring were themselves smaller at birth. This 
observation could be explained by either the inheritance of genes that limit fetal 
growth, such as described in the fetal insulin hypothesis or fetal adaptations in 
response to relative malnutrition in utero, the thrifty phenotype (Hales CN et al., 
1991). Fetal growth restriction is associated with an increased risk of perinatal death 
(Cruz-Lemini M et al., 2012). It is also possible that survivors of fetal growth 
restriction, like all the cases in this study, have inherited paternal characteristics that 
predispose to weight gain and cardiovascular risk factors. During the study, cases of 
fetal growth restriction resulted in intrauterine death, but the families were unwilling 
to participate in the study. Whether families of fetal growth restricted offspring that 
result in perinatal death are different from families of survivors remains a 
challenging question to answer. 
In the study the effect of maternal environment was minimised by only including 
healthy pregnant women within pre-specified phenotypic limits and excluding fetal 
growth restriction due to recognized maternal or fetal diseases. This allowed study 
pregnancies predominantly affected by placental disease. These predetermined 
maternal inclusion criteria are likely to have strengthened the effects of paternally 
inherited factors. Others have found that men who father small for gestational age 
(SGA) offspring are more likely to be overweight and to have a greater waist 
circumference than fathers of normal grown offspring (McCowan et al., 2011). This 
study adds objective measures of paternal insulin resistance, endothelial function and 
lipid profile to these phenotypic characteristics.  
Differences in paternal blood pressure and endothelial function between the groups 
were no longer evident following adjustment for paternal smoking. Cigarette 
smoking is known to independently raise BP and impair flow-mediated dilatation 
(Hirofumi T et al., 2008). Maternal smoking is a recognized risk factor for fetal 
growth restriction (Reeves S et al., 2008). Women who smoked were therefore 
excluded from the study. However, the partners of some women smoked during 
pregnancy. Paternal smoking has previously been associated with fetal growth 
restriction and correlates with levels of maternal cotinine (Suter M et al., 2010). In 
this study, maternal cotinine was only detectable in serum of 3/17 women whose 
partner smoked, compatible with low-level passive smoking. Although fetal cotinine 
levels from umbilical cord blood were not checked, it is unlikely that maternal Chapter 3: Parental phenotype of FGR offspring 
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passive smoking contributed to fetal growth restriction. Maternal smoking can cause 
epigenetic change to human placental genes (Suter M et al., 2010). It is currently 
unknown whether paternal smoking can cause epigenetic change that is inherited by 
the fetus and placenta.  
For pragmatic reasons, insulin resistance was measured using the HOMA model 
derived from fasting insulin and glucose. A more robust, but invasive technique is 
the euglycemic insulin clamp (Matthews et al., 1985). HOMA correlates well with 
clamp-derived methods (Matthews et al., 1985) and, in this cohort, is supported by 
other parameters associated with the insulin resistant syndrome. 
The metabolic pattern in case men was of insulin resistance but accompanying beta 
cell dysfunction was not evident. Whilst T2DM classically presents with both 
features, studies have shown that in isolation insulin resistance can represent one of 
the earliest phases of progression towards disease development several years later 
(Skarfors ET et al., 2010). This early pre-diabetic stage can be accompanied by other 
signs of diabetes risk including hypertension and obesity which is consistent with the 
findings in this study.  
It has been suggested that T2DM disease is triggered by different genetic defects; 
one defect affects beta cell function and is expressed later in life and another, present 
from early life, is responsible for the  insulin resistant phenotype particularly through 
the impaired stimulation of glycogen formation in skeletal muscle (Beck-Nielsen H 
et al., 1994). This sequence of events would be consistent with the paternal 
phenotype identified by this study.  
GCK mutations are thought to be responsible for a significant proportion of 
diagnosed MODY cases but classically present from a young age with impaired 
glucose stimulated insulin secretion and mild beta cell impairment (Hattersley A et 
al., 1999). This presentation gives rise to the possibility that the metabolic pattern 
seen in these men who fathered growth restricted offspring may share limited 
aetiology with current known genetic causes of MODY where the primary defect is 
beta cell impairment rather than insulin resistance. 
Only 4 fathers of growth-restricted pregnancies (9.5% of cases) fulfilled a European 
definition
 of the insulin resistant syndrome (Balkau B et al., 1999) but this does not 
negate the early pre-diabetic state I identified. The majority of cases in the top 25% 
for insulin resistance also had central obesity as defined by a waist circumference > Chapter 3: Parental phenotype of FGR offspring 
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94cm. Insulin resistance is closely linked with central obesity, which in turn precedes 
other elements of the metabolic syndrome (Cameron AJ et al., 2008). Sub-clinical 
insulin resistance at the time of fathering a growth restricted offspring not only 
explains the association with future paternal T2DM and cardiovascular disease, but 
identifies a group of men with a reversible risk factor for future metabolic and 
vascular disease (Reddy KJ et al., 2010), just as gestational diabetes identifies 
women at risk of future diabetes (Bellamy L et al., 2009).  
In men with established T2DM, a similar log unit increase in HOMA insulin 
resistance to that found in fathers of growth restricted offspring, has been associated 
with a 31% increased risk of cardiovascular disease (Bonora E et al., 2002). Insulin 
resistance in men without diabetes is an independent risk factor for future 
cardiovascular disease (Nakamura K et al., 2010 and Hanley AJ et al., 2002). Dietary 
and lifestyle measures can reverse insulin resistance and reduce future cardiovascular 
risk (Eriksson J et al., 1999 and Caterson ID et al., 2012). The observations from this 
study suggest at the time of fathering a growth restricted offspring that these men 
may benefit from advice on a healthy life-style as part of primary prevention of 
diabetes and cardiovascular disease.  
Inheritance of common insulin control genes (Freathy et al., 2010), rarer monogenic 
disorders of glucose metabolism whose primary defect is not beta cell defects 
(Hattersley A et al., 1999), or other as yet unidentified heritable factors, may explain 
this observed link between paternal insulin resistance and fathering a growth 
restricted offspring. It is possible that paternal life-style leading to obesity and 
smoking, may influence change that leads to insulin resistance, which is inherited by 
offspring and manifest as fetal growth restriction (Ng SF et al., 2010).  
Despite other anthropomorphic parameters revealing no significant differences 
between case and control women antenatally or postnatally, endothelial dysfunction 
appeared to differ between the two groups. Postnatal FMD in women, whose 
pregnancy had been affected by growth restriction, suggested significantly more 
endothelial dysfunction (6.98 ﾱ0.97%) than women who had an appropriately grown 
baby (10.26 ±2.4%). This pattern of endothelial function has been reported before in 
relation to postnatal FMD studies on women whose pregnancies have been affected 
by pre-eclampsia (Noori M et al., 2010 and Hamad RR et al., 2007). Chapter 3: Parental phenotype of FGR offspring 
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In fact postnatal FMD measurements by Noori et al. on pre-eclamptic subjects 
yielded very similar results (FMD controls 9.64ﾱ0.6% versus cases 7.3ﾱ2.4 %) to the 
ones seen in this cohort. When women who had experienced pre-eclampsia were 
removed from the growth restriction analysis then results remained significantly 
different between FGR case women and controls.  
 
A previous study (Paradisi G et al., 2011) has reported similar differences in reduced 
FMD in women who had experienced a small for gestational age baby but in this 
small cohort, these women had higher blood pressure and a strong family history of 
heart disease, making it difficult to interpret whether pre-existing risk factors or a 
pregnancy affected by FGR was the cause of the endothelial dysfunction.  
Given  that  antenatally  these  women  exhibit  no  other  signs  of  increased 
cardiovascular risk then the possibility arises that the pregnancy itself causes some 
underlying  damage  to  the  mother.  A  large  retrospective  study  has  shown  that 
maternal risk of ischaemic heart disease (IHD) admission or death is associated with 
delivering a baby in  the lowest  birthweight  quintile for  gestational  age (adjusted 
hazard ratio 1·9 [95% CI 1·5–2·4]) as well as preterm delivery (1·8 [1·3–2·5]) and 
pre-eclampsia (2·0 [1·5–2·5] but that these associations are additive (Smith GC et 
al., 2001). In this study maternal smoking was not factored in and the presence of 
underlying maternal disease (although screened for) was not known.  
Recently, risk of maternal IHD was evaluated in a population based cross-sectional 
study of 6,608 women with a prior live term SGA birth. Delivery of a SGA infant 
was strongly associated with greater maternal risk for IHD (age adjusted OR; 95% 
CI:  1.8;  1.2,  2.9;  p = 0.012),  independent  of  the  family  history  of  IHD,  stroke, 
hypertension  and  diabetes  (family  history-adjusted  OR;  95%  CI:  1.9;  1.2,  3.0; 
p = 0.011) as well as other risk factors for IHD (risk factor-adjusted OR; 95% CI: 1.7; 
1.1, 2.7; p = 0.025). (Bukowski R et al., 2012). However, despite decreased FMD, it 
remains to be seen if cardiovascular disease will develop in the current cohort of 
women who had a growth restricted pregnancy complicated specifically by placental 
dysfunction.  
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3.14 Summary 
This case-control study identified that men who fathered growth restricted offspring 
(mean 1.8ﾱ2.2
th customised birth centile) were more insulin resistant and more likely 
to smoke compared with fathers of normal grown offspring (49.6ﾱ27.5
th) customised 
birth centile. In the study all offspring met the inclusion criteria.  
Fathers of growth-restricted offspring also had other elements of the insulin resistant 
syndrome, including high blood pressure, endothelial dysfunction, and upper body 
fat redistribution and tended to a more atherogenic lipid profile. 
 
Of those fathers who smoked, plasma cotinine levels in their partners during the 
pregnancy revealed no evidence that women were actively smoking or exposed to 
high levels of passive smoke.  
 
In contrast to fathers, mothers recruited and shown to similar in weight, age, height 
and parity at the time of their pregnancy. Postnatally they again were phenotypically 
similar with no differences identified between blood pressure, abdominal 
circumference or weight.  Metabolically; postnatal lipid profiles and glucose 
homeostasis were similar between mothers. Endothelial function was, however, 
found to be impaired in case women.  
 
Although insulin and c-peptide levels were found to be higher in FGR offspring there 
was no statistically significant difference between case and control offspring plasma 
cord blood values but sample size was small.    
 
This study identified that men who fathered a growth restricted pregnancy had a pre-
diabetic phenotype at the time of the pregnancy that could have contributed to fetal 
phenotype. Furthermore, that their metabolic dysfunction was one primarily of 
insulin resistance in conjunction with higher abdominal circumferences.  
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Chapter 4: The Genetics of Fetal Growth Restriction 
 
4.1 Introduction 
The fetal insulin hypothesis states that low birth weight and susceptibility to T2DM 
could both be two phenotypes of the same genotype. Fetal insulin mediated growth 
can reflect maternal glycaemia and fetal genetic factors which regulate the ability of 
the fetus to secrete insulin and the degree of insulin resistance in fetal tissues. A 
genetic defect in the sensing of maternal glucose by the fetal pancreas, fetal 
pancreatic insulin secretion, or the action of the insulin on the insulin-dependent 
tissues, would all result in reduced fetal growth (Hattersley and Tooke, 1999).  
T2DM is characterized by insulin resistance and/or beta-cell dysfunction. Therefore, 
genetic variants impacting on insulin secretion and action could alter both fetal 
growth and susceptibility to T2DM. 
 
Studies of rare monogenic diabetes support this idea. Mutations in a single gene, 
such as GCK or KCNJ11, are associated with diabetes and reduced birth weight 
(Hattersley A et al., 1998).  Furthermore, studies of the GCK gene, has shown that a 
mutation present in a father and inherited by his offspring, results in a lower weight 
baby, than if the offspring is born without the mutation or if the mutation was present 
in mother and offspring (Hattersley A et al., 1998).  
Genome wide association studies of birth weight have identified variants in genes 
known to predispose to diabetes, which if present in the fetus are associated with 
reduced birth weight (Freathy et al., 2010).  
  
Together these data provide evidence for a genetic contribution to T2DM and low 
birth weight which is most evident when inherited from father to offspring.  
 
In this chapter I investigated family genotypes in order to identify whether there was 
any evidence of a specific, paternally inherited, fetal genotype in FGR offspring. As 
genes associated with monogenic diabetes have been implicated in low birth weight 
with evidence of inheritance from the father, these genes were of particular interest.  Chapter 4: The Genetics of FGR 
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Whole exome sequencing (WES) of FGR offspring was the platform selected as it 
provided  the  opportunity  to  capture  genes  of  interest,  but  also  investigate  FGR 
offspring for novel genetic variants.  
Validation of exome sequencing was undertaken with Sanger sequencing when novel 
and very rare variants were identified. Taqman genotyping was used to validate other 
MODY variants of interest in FGR offspring. Parental DNA was also genotyped in 
order to assess patterns of inheritance.  
A  panel  of  risk  SNPs  associated  with  T2DM,  insulin  resistance  syndromes  and 
elevated fasting glucose were genotyped if they were present in 3 or more of the 
exome samples. The cohort was underpowered, but associations identified with FGR 
may provide support for a larger study to detect differences. Parental DNA, allowed 
for assessment of inheritance of risk SNPs and their possible role in FGR in support 
of the fetal insulin hypothesis.   
 
4.2 Hypothesis 
Genetic inheritance of insulin resistance by a fetus from its father will result in a 
growth  restricted  phenotype  in-utero  and  predispose  both  offspring  and  father  to 
T2DM in later life. 
 
4.3 Specific Aims 
 
1.  To discover novel genetic variants in growth restricted offspring through the 
use of whole exome sequencing. 
2.  To identify whether variants in MODY candidate genes are associated with 
growth restriction and identify whether there is evidence of transmission from 
father to offspring. 
3.  To identify the presence of T2DM SNPs in the cohort of growth restricted 
and appropriately grown offspring and parents.  
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4.4 Methods 
4.4.1 Study population and design 
Ten Caucasian FGR offspring were selected from the original cohort of trios 
collected that were felt to best represent a growth restricted phenotype. Cases were 
selected with different gestational ages at delivery. WES required 3.3ug of DNA 
from DNA extracted from FGR offspring cord blood (as described in methods 
section 2.12) which was used as it had yielded the highest DNA concentrations 
between cord blood, cord and placenta. After preparation and enrichment (as 
described in methods section 2.13) samples were run on the HiSeq1000 genome 
analyzer.  
Data was aligned and annotated as described previously in section 2.13.1.  Filtering 
of the data was performed manually and with the use of Ingenuity Variant Analysis 
software as detailed in methods section 2.13.2.  
Candidate genes for MODY, T2DM, insulin resistance (IR) and elevated fasting 
glucose were identified through WES and genotyped using TaqMan technology 
(Applied Biosciences, ABI, Warrington UK) as described in detailed methods 
section 2.14.1. Reactions were performed on 384-well microplates and analysed 
using ABI TaqMan 7900HT software. Sanger sequencing was performed with 
novel/rare variants from FGR offspring, identified through WES (along with parental 
DNA). Primer design and PCR conditions were followed as described in methods 
section 2.14.2.  
 
4.4.2 Statistical Analysis 
Statistical  analyses  of  genotyping  were  performed  using  Intercooled  Stata  10  for 
Windows (StataCorp LP) according to detailed methods in section 2.14.1.3. Data is 
presented as meansﾱ SD unless otherwise stated.  
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4.5 Results 
4.5.1 FGR offspring birth phenotype characteristics 
Ten cases were selected from the original FGR offspring cohort as being most 
representative of a cross-section of pre-term and term growth restricted offspring 
secondary to placental dysfunction (Table 4.1). Four of the 10 cases were delivered 
at 34 weeks or less. In 2 of these cases the primary indication for delivery was 
maternal pre-eclampsia in association with growth restriction. In the other two cases, 
delivery was indicated purely for the fetal condition of severe in-utero growth 
restriction.  
Of the remaining 6 cases all were delivered after 34 weeks and none of these 
pregnancies were complicated by pre-eclamspsia. All women were induced or 
delivered by elective caesarean section because of the presence of fetal growth 
restriction as evidenced by ultrasound. 
All babies were born alive with an average birth weight of 1854g (range 779-2730g) 
but separating babies born ≤34 weeks, the average birth weight for those 4 infants 
was 965g versus 2446g (range 1900-2730) for the 6 babies born after 34 weeks. 
Customising birth centiles which is calculated from birth weight, gestation, maternal 
ethnicity, parity, weight and height has the advantage of adjusting birth weight for 
gestation.. The average birth centile for these 10 offspring was the 1.1th centile 
(range 0-3.8%). Four of the offspring were boys and 6 were girls (Table 4.1).  
ID 
Baby 
gender 
Gest 
(weeks) 
Birth 
Weight 
(g) 
Birth 
centile 
% 
≤34 
weeks 
331MBV  M  37+2  1900  0.1    
337ECb  F  29+4  850  0  y 
386SSa  F  39+3  2650  3.8    
39NK  F  38+1  2410  0.7    
413BTa  M  38+4  2480  1.1    
53ALa  M  38+2  2510  3    
328LB  M  28+4  855  0.1  y 
227FBa  F  30+1  779  0  y 
156BTc  F  40+4  2730  2.1    
334MVb  F  34  1378  0.1  y 
 
Table 4.1 The phenotypic characteristics of the FGR offspring samples including baby 
gender, gestation born at (weeks), birth weight (grams), and customised % birth centile   Chapter 4: The Genetics of FGR 
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4.5.3 Parental Phenotype 
Maternal and paternal phenotype data was also available for these offspring and is 
described in table 4.2. Mean maternal age was 34.2ﾱ5.5 years versus average 
paternal age of 35.4ﾱ4.8 years. For most couples this was their first child but in two 
instances they had one child already. For case mothers the mean BMI was normal at 
22.3ﾱ3.1 kg/m
2 but for fathers it was raised at 27.62ﾱ.9 kg/m
2, as was their HOMA 
IR (mean 1.1). No mothers smoked, but two fathers did.  
 
 
Mother 
   
 
 
Father   
           
ID 
Mat 
Age  BMI  Parity  PET 
  Pat 
Age  BP  BMI  IR  Abdo  Smoker 
331MBV  33  27.8  0       34  117/68  30.7  1.4  113.5   
337ECb  27  20  0       34  129/75  30.6  0.8  92.5   
386SSa  40  20.4  0       34  131/85  31.5  1.9  90  y 
39NK  34  22.9  1       33  127/74  27  0.4  96  y 
413BTa  33  20.4  1       35  119/69  24  0.6  92   
53ALa  26  26  0       27  114/61  25.1  1.2  90.5   
328LB  44  25.9  0  y    44  123/76  30.1  1.5  95.5   
227FBa  37  20  0  y    40  120/73  27.3  0.9  107   
156BTc  32  20  0       37  11/737  23.5  0.8      
334MVb  36  20  0       36  132/76  26.6  1.6  98.5   
 
Table 4.2 Phenotypic characteristics of parents of FGR offspring used including; maternal 
age, BMI in kg/m
2 (calculated weight/height
2), parity and presence of pre-eclampsia (PET) 
and paternal age (years), blood pressure (mmHg), BMI, HOMA insulin resistance (IR), 
abdominal circumference and smoking status  
4.5.2 DNA Quality Control (QC) 
The 10 FGR offspring DNA samples that were prepared for analysis and all passed 
initial QC and concentration checks as described previously (Table 4.3). Samples 
were run on 1% Agarose gel according to methods as described previously in section 
2.12.4 and the DNA was found not to be degraded (Figure 4.1). 
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Sample ID  Concentration (ng/ul) Volume (ul)  Total ng  260/280   260/230  
331MBV  100  32  3200  1.79  2.27 
337ECb  100  32  3200  1.9  2.39 
386SSa  100  32  3200  1.84  2.27 
39NK  100  32  3200  1.86  2.35 
413BTa  100  32  3200  1.84  2.39 
53ALa  100  32  3200  1.84  2.29 
328LB  70.60  43  3035.8  1.84  2.21 
227FBa  100  32  3200  1.84  2.36 
156BTc  74.50  42  3129  1.87  2.27 
334MVb  81.40  38  3093.2  1.82  2.26 
Table 4.3 Offspring cord blood DNA samples used in exome sequencing. Sample ID, 
concentration (ng/ul), volume and total amount present (ng) along with Nanodrop 260/280 
and 260/230 purity readings.  
 
 
Figure 4.1 Agarose gel (1%) of genomic DNA (331,337, 385, 39, 413, 53, 328, 227, 156 and 
334) with 1kb ladder at ends of gel Chapter 4: The Genetics of FGR 
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4.6 Analysis of variants by manual filtering 
4.6.1 Loss/gain of function variant call 
Using the following filters; stop gain, stop loss, frameshift insertion/deletion, splice 
site and not defined then 75 variants were identified that were present in 3 or more of 
the 10 samples. 
4.6.2 Non synonymous & non frameshift insertion/deletions variant call 
Non-synonymous (NS) variants result in the substitution of a nucleotide and 
subsequent introduction of a different amino acid in a sequence and can have 
functional significance. Non frameshift mutations were annotated separately, but in 
effect are similar to NS variants. These variants result in insertions or deletions of 
nucleotides in a number divisible by three which means the amino acid sequence is 
altered by an insertion or deletion but does not give rise to a shift in the triplet 
reading frame of the gene. 
Assessment of non-synonymous variants yielded a further 158 variants with a 
frequency in ESP database of <0.05 or blank (meaning no frequency in ESP 
database).  The same filter was applied for non frameshift variants which revealed a 
further 82 variants in three or more samples.  
 
Overall 75 novel loss/gain of function mutations and 240 non synonymous or non-
frameshift variants were identified in three or more FGR offspring samples. A 
second approach using Ingenuity was employed to try and identify which of the 
novel candidates were most likely to have a biologically significant effect. 
4.6.3 Ingenuity variant analysis call incorporating a biological filter 
The 10 FGR ‘vcf’ files were input into Ingenuity Variant Analysis along with 5 
control samples from the GOSgene database.   
From all samples uploaded to Ingenuity (including the 5 control samples) there were 
414304 variants identified on 20496 genes. Ingenuity filters were then set using 
similar terms as employed in the manual assessment approach. For common variants, 
Ingenuity was set to exclude all referenced dbSNP variants. However, as Ingenuity Chapter 4: The Genetics of FGR 
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used the latest version of dbSNP (137 at the time of analysis) this resulted in a 
reduced set of variants than the manual filtering process. Other filters were set to 
exclude all referenced variants that had a frequency <3% according to the 1000 
genomes project and <1% of the NHLBI ESP database. Those variants not thought to 
be pathogenic (according to Polyphen and SIFT) were excluded and finally a 
biological significance filter was applied to the remaining variants (Figure 4.2).  
 
Figure 4.2 Filter cascade applied to genetic variants identified in 10 FGR samples 
 
The following biological terms were applied as a filter: fetal growth restriction; 
maturity onset diabetes of the young; type 2 diabetes and pre-diabetes. Lists of 
variants were then generated for genes directly associated or 1 or 2 hops away to 
compare sensitivity. When only those genes directly associated with the terms were 
used this resulted in only 2 potential variants being identified.  
 
When two hops were applied this resulted in 174 variants of interest and when one 
hop was applied this resulted in 71 variants (Appendix 4 S6) being identified and on 
further assessment interesting candidate genes were present so the final analysis was 
therefore carried forward on these variants. 
None of the 71 variants were seen in the 5 controls (which were set as a separate 
filter) and the next step in the analysis was again to assess whether they could be 
identified in any of the current exome data held by GOSgene.  
This was done through the use of a software package PLINK/SEQ (a library for the 
analysis of genetic variation data) and the assistance of Dr Chiara Bacchelli who had 
access to the data. Chapter 4: The Genetics of FGR 
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Of the 71 variants, 10 could not be identified in any other GOSgene samples and a 
TBP variant was included as it was a tri-nucleotide repeat insertion which showed 
similarities to another pathological condition (spino-cerebellar ataxia) and needed 
further sequencing for clarity. 
 
Of the 10 variants identified (Table 4.4), I then sought to stratify those with greatest 
biological plausibility in order to take them forward to validate. Of these 10, KRT8, 
TBP, TDG and KDM4B were connected in Ingenuity to fetal growth restriction with 
KRT8 also connected to T2DM and MODY. SAFB2 was connected to T2DM and 
MODY. 
KRT8 and SAFB2 are predicted by SIFT and Polyphen to be pathogenic which 
supports the concept that these genetic variants could have a functional role. 
However, when BAM files were checked, poor coverage was found in KRT8 and 
SAFB2 raising the possibility of a false positive.     
 
Sanger sequencing was, therefore, performed in order to validate the exome finding. 
In total, 6 variants (highlighted in bold in table 4.4) were taken forward to validate by 
Sanger sequencing in each of the FGR offspring DNA in which they were present as 
well as parental DNA. 
These variants in KRT8, SAFB2, TDG, TBP, RPL14 and KDM4B and the two 
variants identified in HNF1a and HNF4a were Sanger sequenced.  
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  19    5144411                           KDM4B        **             p.963_964ins ESITVSCGVGQGAGGGWEHSDNLYP 
** KDM4B Transcript variant c2889_2890ins 
 GAGAGCATCACGGTGAGCTGTGGGGTGGGGCAGGGGGCGGGGGGAGGCTGGGAGCACAGCGACAACCTGTACCCC                                                                                              
KDM4B Protein variant p.963_964insESITVSCGVGQGAGGGWEHSDNLYP *** RPL14 Transcript variant c.445_446insCTGCTGCTGCTGCTG 
 
Table 4.4 The 2 MODY variants and 10 novel variants identified in Ingenuity according to filter settings previously described and also not recognised as being 
present in in-house database of exomes.  Number of offspring present in, chromosome and position, reference and observed allele (where applicable), 
transcript variant and gene name, impact and protein transcript along with SIFT function prediction reported. Highlighted in bold are variants identified to be 
taken forward for validation  
No 
samples            Ch  Position 
Ref 
Allele 
Sample 
 Allele 
Variation 
Type 
Gene 
Symbol  Transcript Variant  Protein Variant 
Translation 
Impact 
SIFT Function 
Prediction 
2  12  1.21E+08  C  A  SNV  HNF1A 
 
p.P291Q  missense 
  1  20  43043289  C  T  SNV  HNF4A  c.C569T:p.P190L  p.P212L  missense 
                       
3  2  1.32E+08  G  T  SNV  TUBA3C  c.1040G>T  p.C347F  missense  Damaging 
4  11  47857258  G  A  SNV  NUP160  c.1046C>T  p.S349F  missense  Damaging 
7  12  53343231  G  C  SNV  KRT8  c.274G>C; c.-44734+268C>G  p.A92P  missense  Damaging 
7  19  5587270  A  G  SNV  SAFB2  c.2846T>C  p.F949S  missense  Damaging 
3  12  1.04E+08  G  C  SNV  TDG  c.23+1G>C          
3  6  1.71E+08     CAGCAGCAG  Insertion  TBP*  c.189_190insCAGCAGCAG  p.43_44insQQQ  in-frame    
9  6  1.71E+08     GCA  Insertion  TBP*  c.155_156insGCA  p.52_53insQ  in-frame    
3  19  50308921  C  A  SNV  AP2A1  c.2472C>A  p.Y824*  stop gain    
5  2  1.79E+08  A  C  SNV  TTN  c.61653T>G  p.I20676M  missense    
8  3  40503520     ***  Insertion  RPL14    p.149_150insAAAAA  in-frame    
* TBP transcript suggested varying length of insertions in samples (treated as one variant) 
*** RPL14 Transcript variant  c.445_446insCTGCTGCTGCTGCTG 
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4.7 Novel/ rare variant in MODY genes 
I screened for currently known MODY genes in the exome data and included the 
following genes; HNF1α; HNF1β, HNF4α, GCK, KCNJ11, CEL, NEUROD1, PDX1, 
WFS1, PPARG, NOTCH2, MADD and GLIS3. Ingenuity was used for this process 
and a gene candidate text file was uploaded and used as a separate filter. 
Displayed in table 4.5, are the 6 rare genetic variants, according to ESP (underlined) 
within MODY genes identified or not recorded in dbSNP130 and predicted to be 
pathogenic in SIFT and Polyphen. In total, 8 variants in 7 genes across the 10 
samples were identified, all of which were non synonymous mutations (see next 
section for remaining two variants).  
Ch  Position  Obs  Ref  Gene  Si  ESP 
dbSNP 
(130) 
  17  36059141  T  C  HNF1β  D  0.00028 
 
het 
1  120478125  A  C  NOTCH2  D  0.00223 
 
het 
4  6302816  C  G  WFS1  D  0.00437  rs35031397  het 
12  12143527  G  A  HNF1α  D  0.24642  rs2464196  het 
20  43034783  C  T  HNF4α  D  0.04211  rs736823  het 
11  17408831  G  C  KCNJ11  D  0.03365  rs1800467  hom 
 
Table 4.5 MODY variants of interest identified, gene name, predicted dangerous by SIFT, 
ESP frequency as recorded in Ingenuity and  rs number where available as taken from 
Ingenuity and  location on chromosome, variant observed and whether heterozygous or 
homozygous.  
 
It was possible using custom assays (designed by Sigma Aldrich) to perform Taqman 
genotyping in order to validate findings in the variants.  
A manual search was also undertaken through the data, which revealed two very rare 
variants in HNF1αand HNF4α (in the same fetal sample-227FB) not predicted to be 
dangerous by Sift (therefore not identified by Ingenuity). 
      Gene                                    Ch   Position     Obs      Ref 
   HNF1α       -                            12   12143125    T           C         het 
     HNF4α       -                   20   43043289    T           C         het 
 
These two rare MODY variants were Sanger sequenced in the one FGR offspring in 
which they were identified. Corresponding maternal and paternal DNA in this Chapter 4: The Genetics of FGR 
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offspring were also Sanger sequenced in order to identify the inheritance pattern for 
the variants. Sanger sequencing was performed as these variants had only been 
reported once previously in ESP.  
 
4.8 Assessment of exome coverage in relation to MODY genes 
As part of the assessment of WES capture, overall read depths were calculated for all 
exome coverage (Table 4.6). The actual coverage of the exomes within each of the 
individual candidate genes of interest was also investigated in order to assess 
whether coverage was adequate to capture the entire region of interest (Table 4.7).  
 
Read 
depth   1X  5X  10X  15X  30X 
HNF1α  99.63  95.74  90.65  86.05  64.24 
HNF1β  100.00  98.88  97.22  92.19  71.35 
HNF4α  97.93  95.00  93.16  86.11  64.46 
GCK  90.97  85.83  83.68  82.23  69.29 
KCNJ11  96.69  87.90  83.32  81.37  71.22 
PDX  79.74  62.08  48.61  40.03  25.76 
NOTCH2  99.32  95.74  92.50  86.18  54.40 
WFS1  94.60  86.13  79.03  73.27  52.23 
 
Table 4.6 represents the mean coverage of all individual exomes together within each of the 
MODY genes of interest where variants were identified. Values are a % of coverage at 1, 5, 
10, 15 or 30 read depth. For HNF1α, HNF1β, HNF4 α and NOTCH2 coverage is above 90% 
at 10X. GCK and KCNJ11 are coverage is above 80% at 10X but PDX is not well covered 
above 5X. 
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Table 4.7 Coverage of all exomes across samples. Total coverage of DNA bases and mean coverage depth of read (X). Along with % of bases above 1,5,10,15 
and 30 covering areas
Sample 
id 
total 
coverage 
Mean     
(X) 
%_bases_ 
above_1 
%_bases 
above_5 
%_bases_ 
above_10 
%_bases_
above_15 
%_bases  
_above_30 
Median 
(X) 
Internal 
 
 
     
     
     
328LB  1840720090  29.65  94.7  89.2  82.4  73.4  40.5  26.11 
 
39NK  2101494548  33.85  91.3  75.2  65.2  58.2  42.3  25.2 
 
53AL  2073917523  33.4  94.6  89.6  83.9  76.7  48.6  31.26 
 
156BT  1905955206  30.7  94.2  89.1  82.6  73.9  43  27.07 
 
227FB  1746333617  28.13  93.3  83.4  73.6  64.4  38.5  24.1 
 
331MVB  2959079719  47.66  90.1  69.2  59.8  54.9  45.4  30.19 
334MV  3135911493  50.51  92.9  84  77.7  72.7  59.1  43.88 
337EC  1920511772  30.93  94.8  89.8  83.9  76.1  44.8  29.2 
 
385SS  4982261824  80.25  94.6  82.5  75.3  70.9  62.2  69.4 
 
413BT  1801203846  29.0  94.3  83.3  71.5  62.3  40.4  27.74 Chapter 4: The Genetics of FGR 
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4.9 Sanger sequencing validation of novel variants 
4.9.1 Investigation of exome predicted novel KDM4B variant 
In order to confirm that the insertion c.2889_2890ins in KDM4B was present, Sanger 
sequencing was attempted on the samples. However, it was not possible to perform 
Sanger sequencing to validate this variant due to the length (75 bases) of the 
insertion. Instead PCR amplification and visualization of the PCR products on a 1% 
agarose gel was performed on all family members (Table 4.8). The two PCR 
products resulting from the different size alleles can be clearly distinguished on the 
gel (Figure 4.3) confirming an insertion was present. 
Lane  Family  Member 
  1  53  Baby  Homozygous 
2 
 
Father  Heterozygous 
3 
 
Mother  Heterozygous 
4  156  Baby  Heterozygous 
5 
 
Father  Wild type 
6 
 
Mother  Heterozygous 
7  227  Baby  Homozygous 
8 
 
Father  Heterozygous 
9 
 
Mother  Homozygous 
10  334  Baby  Homozygous 
11 
 
Father  Homozygous 
12 
 
Mother  Heterozygous 
13  337  Baby  Homozygous 
14 
 
Father  Homozygous 
15 
 
Mother  Heterozygous 
16  385  Baby  ? Homozygous 
17 
 
Father  Fail 
18 
 
Mother  ?Wild type 
19  413  Baby  Heterozygous 
20 
 
Father  Heterozygous 
21 
 
Mother  Homozygous 
22 
 
control  negative 
 
Table 4.8 Family members and presence of KDM4B insertion  
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Variant Validated: 
Sequence: GAGAGCATCACGGTGAGCTGTGGGGTGGGGCAGGGGGCGGGGGGAGGCTGGGAGCACAGCGACAACCTGTACCCC;
Figure 4.3 Agarose gel of KDM4B insertion fragment (mutant allele 622bp) as visualised on gel in families with insertion 
B baby, F father, M mother on gel 
 
Family             53                  156                   227                 331                   337                   385                   413                   neg    
Member         B       F     M      B     F       M      B     F      M    B     F       M      B      F      M     B     F        M    B      F       M 
Lane      
                         1       2      3      4      5       6       7      8      9    10    11     12   13    14    15   16    17       18   19    20     21    22   
622 bp 
547bp 
Mutant allele = 622 bp 
Wild type allele = 547 bp 
1
 
k
b
 
l
a
d
d
e
r
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4.9.2 Validation of location of KDM4B insertion 
Whilst Sanger sequencing had proved difficult, it was possible from the gel to 
amplify the DNA fragments present and therefore confirm the location and sequence 
of the insertion. The sequence predicted from the exome data was validated but not 
the location of the insertion. Instead the sequence was found and confirmed to be an 
intronic insertion observed between c.2901+63 and c.2901+64 with c.2901 being the 
last coding nucleotide of exon 20 of the KDM4B transcript. The change was actually 
observed in intron 20-21.The correct description of the insertion is as follows: 
c.2901+63_2901+64insGAGAGCATCACGGTGAGCTGTGGGGTGGGGCAGGG
GGCGGGGGGAGGCTGGGAGCACAGCGACAACCTGTACCCC 
 
 
 
 
Figure 4.4 Confirms the insertion c.2889_2890ins 
p.963_964insESITVSCGVGQGAGGGWEHSDNLYP  IS NOT PRESENT IN EXON in 
Child (337EC)  in the homozygous state, NOT PRESENT IN EXON in the father 
(335ECb) in the heterozygous state (excised fragment of 622 bp) 
 
Sample 15 622 bp - KDM4B F 
Sample 16  excised  
Top fragment 
 622 bp  
Sample 16 excised               
Bottom fragment  
 547 bp  
Affected child 
 337EC 
Father 335ECb 
Father 335ECb 
Father 335ECb 
Intron 20-21 
End of exon 20 Chapter 4: The Genetics of FGR 
 
137 
   
4.9.3 Presence of KDM4B insertion in control populations 
This intronic insertion was still not found to be present in the 1000 genome database, 
however, further validation was sought and the control population recruited for the 
study were then assessed for the presence or absence of the insertion. 
 
 
 
 
 
 
 
 
 
 
 
 
        Mutant 622bp fragment                              WT (wildtype) 547 fragment 
Figure 4.5 shows WT (547bp) and mutant fragments run on 1% agarose gel from 30 control 
samples from cohort as well as 18 GOSgene controls.1kb ladder used in lane 1 and lane 27  
Figure 4.5 shows that, despite its absence in the 1000 genome database, the insertion 
identified was also present in control samples from the same cohort. In total 48 
samples were run of which 3 failed. Of the remaining 45, 9 did not have the insertion 
but 22 were heterozygous and 14 were homozygous for the insertion. As the 
insertion was present in cases and controls I concluded that what appeared to be a 
novel finding in FGR families was also common in appropriately grown offspring. 
1000 bp 
700 bp 
500 bp 
400 bp 
300 bp 
200 bp 
75 bp 
1500 bp 
1000 bp 
700 bp 
500 bp 
400 bp 
300 bp 
200 bp 
1500 bp 
 A2   A3  A4   A5  A6  A7   A8  A10 A11A12 B2   B3   B4  B5  B6   B7   B8  B9  B11 B12  A3  A6  A7   A8 A11  
A12 B2   B4  B5   B8   B9    1    2      3     4     5     6      7     8     9    10   11   12   13   14   15   16   17   
Plate 4 Baby Controls  Plate 3 Baby Controls 
Plate 3 Baby 
Controls 
1       2     3      4      5     6      7      8    9    10   11    12    13  14    15    16   17   18    19   20   21    22   23   24    25   26   
27   28   29    30  31    32    33    34   35  36    37   38    39  40    41   42   43    44    45  46    47   48    49  50    51     
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4.9.4 Investigation of other potentially novel variants identified 
The TBP insertion was found to be a variant of a recognised single triplet base CAG 
repeat (coding for glutamine). A single triplet base insertion had been reported in the 
in-house exomes analysed. An increased number of repeat CAG sequences have 
been noted before in relation to neurodegenerative diseases, specifically 
spinocerebellar ataxia (Nolte D et al., 2010).  
In the FGR individuals, where a variant in TBP was identified by exome sequencing, 
insertion and deletion of the CAG repeat sequences was variable in number. In two 
cases there were 8 and 9 deleted glutamines identified. The remainder of samples had 
just a one insertion increase or were neutral in relation to the total number of CAG 
repeats within the stretch (Table 4.8).  
The variant in RPL14 validated but was found to be a polymorphic insertion that 
varied between individuals. Controls were also found to be a polymorphic in this 
region. ESP recognises a similar polymorphism close to our interrogated site and it, 
was therefore felt that we had identified a region already reported. 
 
4.10 Sanger sequencing of rare variants in MODY genes 
The two rare variants in one FGR offspring validated with Sanger sequencing. 
Inheritance was found to be maternal in HNF4α (Figure 4.6) and paternal in HNF1α 
(Figure 4.7).  
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Table 4.9 TBP insertion/deletion variant of triplet CAG/GCA repeat leading to variable polyglutamine repeat sequence  
Hom- homozygous for allele   Het- heterozygous for allele
Sample ID 
c.189_190ins   
CAGCAGCAG; 
p.63_64ins   
QQQ 
c.215_216insGCA; 
p.72_73ins           
Q 
c.223_225del 
CAG; 
p.72_73del  Q 
c.223_228del 
CAGCAG;p.75_
76del       QQ 
c.223_231del 
CAGCAGCAG;p
.75_76del 
QQQ 
c.223_259delCAGCAG
CAGCAGCAGCAGCAGC
AGCAG;p.75_83del 
QQQQQQQQQ 
c.223_237delCAG 
CAGCAGCAGCAGCAGCA
GCAGCAG;p.75_79del 
QQQQQQQQQ 
39NK  Hom  Clear  Clear  Clear  Hom  Clear  Clear 
53AL  Clear  Hom  Clear  Clear  Clear  Clear  Clear 
156BT  Clear  Hom  Clear  Clear  Clear  Clear  Clear 
227FB  Clear  Hom  Hom  Clear  Clear  Clear  Clear 
328LB_p3  Clear  Hom  Clear  Clear  Clear  Hom  Clear 
331MVB  Clear  Clear  Hom  clear  Clear  Clear  Clear 
334MVa  Clear  Hom  Hom  clear  Clear  Clear  Clear 
385SS  Clear  Hom  Clear  Clear  Clear  Clear  Hom 
413BT  Hom  Clear  Clear  Clear  Hom  Clear  Clear Chapter 4: The Genetics of FGR 
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HNF4A – Family 227 
 
 
Figure 4.6 Sanger sequencing of HNF4α variant in offspring, mother and father confirming 
segregation with mother. Red arrow is position of change 
     Baby 
   Affected 
   227FB 
   Father 
  M227FB 
 Mother  
 F227FB 
Het c.635C>T; p.P212L 
Het c.635C>T; p.P212L 
Clear 
c.635C>T; p.P212L Chapter 4: The Genetics of FGR 
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HNF1α – Family 227 
 
 
Figure  4.7  Sanger  sequencing  of  HNF1α  variant  in  offspring,  mother  and  father 
confirming segregation with father. Red arrow is position of change 
 
  Baby 
 Affected 
 227FB 
Mother  
F227FB 
   Father 
  M227FB 
c.1098C>A; p.P291Q 
Het. c.1098C>A; p.P291Q 
Het. c.1098C>A; p.P291Q 
Clear Chapter 4: The Genetics of FGR 
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4.11 Genotyping of risk SNPs identified from exome data 
From the a priori SNP list (Appendix 4 S3) those candidates present in three or more 
of the FGR offspring exome data were taken forward for genotyping.  Of the original 
list, 16 SNPs (Table 4.10)  present in three or more cases and this panel, along with 
the 2 variants in MODY associated genes (discussed in section 4.7), were taken 
forward to examine in the entire cohort of offspring, mothers and fathers in both 
cases and controls.  
Assay  Gene  rs 
1  ABCC8  757110 
2  ALDHIL1  1127717 
3  BMP2  235768 
4  CEL  62576769 
5  GCKR  1260326 
6  KCNJ11  5215 
7  KCNJ11  5218 
8  KCNJ11  5219 
9  NEUROD1  1801262 
10  PPARG  1801282 
11  SLC2A2  5400 
12  SLC30A8  1326663 
13  THADA  7578597 
14  WFS1  734312 
15  WFS1  1801214 
16  INSR   1799817 
Table 4.10 Panel of 16 T2 risk SNPs identified through exome sequencing of FGR offspring 
4.11.1 Sample numbers 
All available DNA passed QC checks as described in methods section 2.12.4. All 
assays worked and all SNPs provided genotypic data for analysis. Each SNP had a 
call rate above 97% and all were within HWE (except rs5400 on SLC2A2 where 
HWE  was  affected  by  the  calls  in  the  fathers).  Due  to  failures  and  original 
availability of DNA samples, sample numbers varied between offspring, mothers and 
fathers.  Forty-three  control  offspring  and  42  case  offspring  were  genotyped;  47 
control mothers and 29 case mothers were genotyped and 62 control fathers and 41 
case fathers were assessed.  
Baseline  characteristics  of the cohorts were similar to  previously reported values 
(results chapter 3) but due to sample variation, exact values are different. Gestation, Chapter 4: The Genetics of FGR 
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birth  weight  and  birth  centiles  were  significantly  different  between  FGR  case 
offspring (1.7ﾱ2.2%) and controls (53.2ﾱ28.4%) when all offspring- all genders and 
ethnicities  are  compared.  Offspring  gender  ratios  were  significantly  different 
between case and controls and there was a difference in male/female birthweight 
within groups. However, offspring birthweight remained significantly different when 
adjusted for ethnicity and gender.  There was no significant difference in maternal 
age or parity and all women in the study were nonsmokers.  Although, pregnancies 
were  identified  on  the  presence  or  not  of  FGR,  case  fathers  were  significantly 
different  than  control  fathers  in  several  phenotypic  respects  including;  insulin 
resistance, abdominal circumference and smoking when t-test statistics were applied 
(Table 4.11). When paternal data was adjusted for ethnicity, age and smoking status 
and run in a logistical regression model, phenotypic anthropomorphic measurements 
(blood  pressure,  BMI,  abdominal  circumference  and  insulin  resistance)  remained 
significantly different between male cases and controls.  
 
 
CASE  CONTROL 
  Offspring   Mean (SD)  Mean (SD)  p value 
No. samples  42  43 
   
Birth weight (g)  2192 (174)  3658 (125)  <0.0001 
Birth centile (%)  1.7 (2.2)  53.2 (28.3)  <0.0001 
Gender  17 male  28 male  0.002 
   25 female  15 female 
  Mothers          
No. samples  29  47    
Age (years)  35.8 (4.3)  35.6 (8.8)  0.4 
Parity  0.26  0.2  0.53 
Smoker (y)  0  0    
Fathers          
No.  samples  41  62    
Age (years)  34.7 (5.2)  33.5 (5)  0.06 
Smoker (y)  14/41  13/62  0.04 
SBP (mmHg)  121  117  0.008 
DBP (mmHg)  71  67  0.019 
BMI (kg/m
2)  26.4  25.1  0.05 
Abdo (cm)  94  89.4  0.01 
HOMA IR  0.78  0.58  0.003 
 
Table 4.11 Phenotypic characteristics of offspring, mothers and fathers in genotyping cohort 
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4.11.2 Allele Frequencies 
No significant differences were identified in allele frequencies when the SNPs were 
assessed in all individuals with a chi
2 case versus control test (Fisher’s exact in 
relevant samples). Frequencies were then assessed in separate case versus control 
mothers, fathers and offspring. In the majority of cases we were underpowered but in 
2 instances a significant result was seen. With rs757110 rarer homozygote (C/C) 
mothers were identified as being mothers of growth restricted babies and for 
rs62576769 less rare homozygotes (T/T) were identified as being growth restricted 
offspring.  
The SNP rs757110 on ABCC8 and rs62576769 on CEL are both implicated in 
MODY, however, frequencies in case and control parents (in rs757110) and in 
case/control offspring frequencies for rs62576769 did not did not show any 
differences.  
4.11.3 Regression of offspring birth weight in relation to fetal genotype 
Using offspring birth weight as a continuous variable and adjusting for baby gender, 
SNPs identified through the candidate panel were then assessed in a regression 
model. No significant p values were identified (primarily as the study was 
underpowered) but non-significant trends with birth weight could be seen and are 
reported. Only individuals of Caucasian ethnicity were used for this analysis. 
 
For the rare allele of SNPs rs62576769, rs5218, rs5400, rs734312 and rs1801214 the 
trend was increased birth weight.  
 
For the rare allele of SNPs rs757110, rs1127717, rs235768, rs1260326, rs5215, 
rs5219, rs1801282, and rs7578597 the trend was decreased birth weight.  
4.11.4 Regression of paternal logIR and BMI in relation to paternal genotype 
Regression analysis was also performed for paternal phenotype in relation to HOMA 
insulin resistance (logIR) when adjusted for BMI, smoking status and age. One 
significant result was identified with carriers of the rare allele of rs5400 having a 
lower IR value (p=0.04). This argues against this SNP having an effect on an insulin 
resistant mechanism in FGR fathers.  Chapter 4: The Genetics of FGR 
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Trends could be seen between paternal insulin resistance and genotype:- 
 
 
  Higher IR values were observed in carriers of the rare allele of; rs1127717, 
rs235768, rs1260326, rs1801282, rs734312 and rs1801214.   
  Lower IR value were observed in carriers of the rare allele of; rs 62576769, 
rs5215, rs5218, rs5219, rs1801262, rs5400 and rs7578597. 
 
BMI was assessed in a similar fashion to insulin resistance using logistical regression 
and adjusted for age and smoking status. Carriers of the rare alleles of rs757110, 
rs5215 and rs5219 were found to be significantly associated (p=0.05) with an 
increased BMI. Non significant trends are also reported:- 
 
  Increased BMI (kg/m
2) was observed in carriers of the rare allele of:  
rs1127717 and rs5218.       
  Decreased BMI (kg/m
2) was observed in carriers of the rare allele of: 
rs1801262; rs7578597; rs734312 and rs1801214. 
 
 
Abdominal circumference was also assessed but there were no significant 
associations. However, increased abdominal circumference trends were found to 
correlate well with increased BMI results and conversely the same allele trends were 
identified with decreased BMI and lower abdominal circumference.  
 
  Higher abdominal circumference (cm): rs757110, rs62576769, rs5215, 
rs5219, rs5400 and rs1799817 
  Lower abdominal circumference (cm): rs1801262, rs7578597, rs734312 and 
rs1801214 
4.11.5 Evidence of a paternal-fetal genetic effect through T2DM 
The same SNP on ALDH1L1 (rs1127717) was associated with a decreasing offspring 
birth  weight  trend  along  with  an  increased  BMI  and  IR  trend  in  fathers.  
Furthermore, decreased offspring birthweight and paternal BMI was raised with SNP 
rs5215 and rs5219 on KCNJ11. Chapter 4: The Genetics of FGR 
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4.12 Genetic variants in MODY genes replicated in Taqman 
genotyping 
4.12.1 Novel variants in FGR offspring in relation to rest of cohort  
The  two  rare  variants  in  separate  offspring  were  identified  through  exome 
sequencing  on  HNF1β  and  NOTCH  2  and  were  replicated  through  Taqman 
genotyping. Both offspring were heterozygotes. The parents of these offspring were 
the only other carriers of the same variant.  No other carriers of these variants were 
identified in the remaining cohort.  
 
The NOTCH2 variant (rare “A” allele) seen in one FGR offspring (156BT). The 
father of this offspring was homozygous for the common “T” allele and the mother 
was  the  heterozygous  carrier  of  the  “A”  allele.  However,  in  the  instance  of  the 
HNF1β mutation in a FGR offspring (53AL carrying the rare “T” allele), this variant 
had been inherited from the father (who was also heterozygous the “T” allele) with 
the mother being homozygous for the common “C” allele. 
4.12.2 Variants present in controls as well as cases 
The  heterozygous  variant  on  HNF4α  (rs736823)  was  found  in  only  one  case 
offspring in the cohort compared with 5 control offspring. In the FGR offspring the 
variant was inherited from the mother, versus in the controls 4 of the 5 offspring 
inherited the allele from their father. This argues against this allele being influential 
in a father to offspring genetic risk predisposing to FGR 
 
The variant on KCNJ11 (rs1800467) found through exome sequencing was validated 
with genotyping and again found to be homozygous in one FGR offspring (39NK). 
Both parents were found to carry one copy of the rare “C” allele. In three further 
cases,  this  “C”  allele  was  identified  in  FGR  offspring  who  were  found  to  be 
heterozygotes for this variant. In 2 of the 3 cases the variant was present in the father 
and not the mother. In one FGR case the parental data was not available. Two control 
offspring were heterozygotes for the variant, in one control this variant was present 
in the father and the second control father failed to genotype.  Chapter 4: The Genetics of FGR 
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The  variant  on  WFS1  also  validated  with  Taqman  genotyping.  The  SNP 
(rs35031397) was present in 2 case offspring who were both heterozygotes. In one 
case this variant was also present in the father and in the other case parental DNA 
was  not  available.  In the controls,  one offspring  was  a heterozygote for the rare 
variant and in this instance transmission was through the mother.  
The variant identified in HNF1α (rs2464196) from exome sequencing was identified 
in several case and control individuals in the genotyping with no discernible 
significant difference in allele frequency in offspring or fathers.Chapter 4: The Genetics of FGR 
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4.13 Discussion 
4.13.1 Novel variants/ polymorphisms discovered 
The nature of the variation in the variants called in TBP and RPL14, in themselves, 
do not represent a likely novel or known pathological change, rather are found to be 
polymorphisms of insertion sequences. However, the variability of the CAG repeat 
sequence in TBP requires further work to elicit whether any conformational or 
functional change is occurring depending on the number of consecutive glutamines 
present.  
 
These variants are discussed in more detail in chapter 7 in relation to potential role in 
the methylation differences identified in the FGR cohort.   
4.13.2 The novel insertion variant on KDM4B did not validate 
The insertion identified on KDM4B was initially an interesting finding. KDM4B is a 
Jumonj domain containing lysine K specific demethylase involved in the histone 
code, specifically able to demethylate trimethylated lysine 9 on H3.  
Along with other members of the Jumonji family it has been identified as a histone 
demethylase involved in transcriptional repression or activation, thereby able to have 
an impact on important cellular processes. However, its presence in control samples 
within our cohort of well grown fetuses does not support a unique functional role for 
this particular variant on KDM4B despite the fact that it has not been reported before 
in the 1000 genome project. It is unclear why this KDM4B variant was not previously 
reported. 
4.13.3 Discovery of rare MODY variants  
This work has identified rare non synonymous genetic variants in FGR offspring in 
genes associated with MODY. Of these variants, 2 (one in HNF1β and one in 
NOTCH2) are predicted to be pathogenic by Sift and Polyphen. In the case of the 
HNF1β variant, transmission was from father to offspring. Two other variants found 
in the same FGR offspring, (in HNF1α and HNF4α) whilst not predicted to be 
pathogenic have only been reported once in ESP as documented below (Table 4.12). Chapter 4: The Genetics of FGR 
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ch  Position  Gene  Obs 
allele 
Geno 
type 
other  SIFT  ESP (all) 
minor allele 
frequency 
Genotype 
frequency 
Inh 
12  121432125  HNF1α*  T  TC  het    T=1, 
C=13000 
TT=0,  
TC= 1, 
CC=6500 
pat 
17  36059141  HNF1β  C  CT  het  D  C=4, 
T=13002 
CC=0, 
CT=4, 
TT=6499 
pat 
20  43043289  HNF4α*  T  TC  het    T=1, 
C=13005 
TT=0, 
 TC= 1, 
CC=6502 
mat 
11  17408831  KCNJ11  C  CC  hom  D  C=434, 
G=12552 
CC=5, 
CG=424, 
GG=6064 
both 
1  120478125  NOTCH2  C  CA  het  D  C=27, 
A=12979 
CC=0, 
CA=27, 
AA=6476 
mat 
4  6302816  WFS1  G  GC  het  D  G=49, 
C=12957 
GG=1, 
GC= 424, 
GG=6064 
pat 
* inherited in same offspring 
 
Table 4.12 Frequency of genetic variants reported as according to Exome Server Project  
including; chromosome, position, observed and referenced allele and MAF along with 
parent-of-origin (pat or mat) 
 
Whilst WES has been used to identify novel variants in subjects with clinical 
symptoms of MODY before, this study is one of the first to use WES on subjects 
with the phenotype of FGR. This work offers novel insights into potential genetic 
mutations that could be influencing the development of growth restriction in a fetus. 
Paternal inheritance was shown to be present in one case, in HNF1β, a gene 
recognised in MODY and supports the fetal insulin hypothesis 
With the evolution of whole exome sequencing, it has become possible to widen the 
search for candidates implicated in disease causation in relation to MODY. Recent 
studies have yielded the identification of the 13
th MODY gene variant in KCNJ11 
through the use of WES (Bonnefond A, 2012), along with the identification of rare 
variants on genes (in MADD,NOTCH2, WFS1 and PPARG) that have been highly 
implicated in MODY (Johansson S et al., 2012). 
In this study, 2 FGR offspring were heterozygotes for the two rare variants identified 
(HNF1β and NOTCH2) consistent with the autosomal dominant pattern of Chapter 4: The Genetics of FGR 
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inheritance seen in MODY. According to recent diagnostic criteria for MODY (in 
relation to variants in GCK, HNF1α and HNF4α genes) novel variants must be 
reported as novel in the context of a relevant population and include the evidence in 
support of pathogenicity. This might include the absence from a large series of 
ethnically matched controls or MODY patients (testing of 210 normal chromosomes 
is necessary to achieve at least 80% power to detect a polymorphism present in 1% 
of the population (Ellard S et al, 2008).  
Based on both predictive modelling programmes SIFT and Polyphen the variants 
present in HNF1β and NOTCH2 have been classified as likely to have a pathogenic 
function. Furthermore, in the remaining genotyped cohort of DNA from 101 fathers, 
83 offspring and 76 mothers (along with 21 DNA samples from families with a 
pregnancy affected by gestational diabetes- data not shown) these two variants were 
absent. These variants were also found to be absent from over 300 subjects in the 
UCL GOSgene exome database and in positions captured by exome sequencing of 
these individuals reported in ESP (Table 4.12).  
Whilst HNF1β mutations are well established in MODY presentations, they are more 
commonly identified in association with renal cysts. It remains to be seen whether or 
not offspring go on to develop the clinical features of MODY later in life or if 
growth restriction might be the clinical phenotype of this variant. MODY is known 
to present as a heterogeneous condition with varying degrees of clinical 
manifestations and it may be that FGR should be considered within the classifying 
spectrum of physical presentations of MODY.  
NOTCH2 is more controversial as a MODY gene, having previously been linked to 
T2DM risk (Zeggini E et al., 2008). It has recently been put forward as a MODY 
candidate with a rare variant having been identified through WES performed on a 
subject with a clinical diagnosis of MODY (Johansson S et al., 2012).  
Interestingly, the same variant identified in the MODY patient is the one identified in 
our FGR offspring. Together these two studies provide evidence that links a genetic 
variant directly to both FGR and MODY.   
The maternal inheritance raises the question about the mechanism through which this 
NOTCH2 mutation may be acting. Other presentations of maternally inherited 
MODY mutations normally result in bigger babies due to the maternal Chapter 4: The Genetics of FGR 
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hyperglycaemic environment. Antenatal maternal glucose measurements in the FGR 
case revealed no such evidence of hyperglycaemia. Functional work is warranted in 
order to provide further evidence of the influence that this variant has on gestational 
glucose levels or another mechanism through which is might be acting.  However, 
this variant in NOTCH2 does fit the criteria to be considered a potential MODY 
candidate being both rare and predicted to be pathogenic 
In offspring 227FB, two very rare genetic variants (one inherited from the mother 
and the other from the father) were identified and validated with Sanger sequencing. 
In isolation, they are not predicted to be pathogenic, however, it has been established 
that HNF4α regulates the expression of HNF1α (Fajans SS et al., 2001) and variants 
in both these genes could be acting synergistically to negatively affect fetal growth. 
Maternal antenatal and postnatal glucose levels were normal with little other 
evidence of glucose intolerance. The clinical presentation in this offspring was of 
severe growth restriction in the presence of increased paternal IR and increased 
abdominal circumference. This FGR phenotype contrasted with the other cases of 
FGR where a potential MODY variant was identified which less severe presentations 
than 227FB as shown previously in table 4.2.  
When investigated in the entire cohort, the remaining two variants in KCNJ11 and 
WFS1 identified by WES were not isolated to FGR offspring and parents; however, 
this does not exclude an influence on fetal growth from these variants.  
In the current study I identified a rare variant in KCNJ11 (rs1800467), predicted to 
be dangerous by SIFT. One FGR offspring was found to be homozygous for this 
variant, confirmed through genotyping. Three further FGR cases were heterozygous 
for the mutation but two controls were also found to be heterozygotes. The 
homozygous genotype for this variant is very rare and supports a potential role in an 
FGR phenotype.  
KCNJ11 encodes the Kir6.2 subunit of the potassium ATP channel within the 
pancreatic beta cell. This channel is essential in glucose-stimulated insulin secretion 
and is the target of sulfonylurea drugs, which enhances insulin secretion.  
This gene has been suggested as a candidate potentially involved in both monogenic 
and T2DM diabetes pathogenesis. Activating mutations are known to cause neonatal Chapter 4: The Genetics of FGR 
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diabetes and a recent WES study identified a rare heterozygous mutation in KCNJ11 
(known to cause neonatal diabetes) as being causative in a clinical case of MODY 
(Bonnefond A et al., 2012). This finding supports the notion that KCNJ11 mutations 
can be associated with a large spectrum of diabetes phenotypes. KCNJ11 SNPs have 
also been one of the most robustly associated alleles with increased T2DM risk. The 
E23K variant of KCNJ11 (rs5219) has been shown to be associated with T2DM with 
an odds ratio of 1.23 (Zeggini et al., 2008).  
Heterozygous mutations in KCNJ11 cause neonatal diabetes which is different to the 
finding in the FGR subject. In contrast, mutations in ABCC8 (next to KCNJ11) 
which is also known to cause neonatal diabetes (Edghill EL et al., 2010) presents 
with both recessive and dominant mutations with subsequent varying phenotype. It is 
possible that different inheritance patterns of a mutation in KCNJ11 could lead to 
different phenotypic presentations which may include growth restriction. 
4.13.4 Birth Weight Associations with T2DM SNPs 
Trends were identified for both increased and decreased birth weight in relation to 
the panel of T2DM risk SNPs. The dual association with increased and decreased 
birth weight is not surprising as T2DM risk alleles in mothers could also be 
influencing birth weight. There is strong evidence that gestational diabetes in 
mothers is associated with increased birth weight of offspring, along with an 
increased maternal risk of T2DM later in life (Bellamy L et al., 2009). The 
association of mothers having an increased risk of the rare allele of SNP rs757110 on 
ABCC8 in association with bigger babies (although not pathologically big) would be 
consistent with this theory.  
4.13.5 Limited evidence for T2DM risk SNPs influencing FGR pathology 
My investigations have provided very limited support for T2DM risk SNPs having a 
pluripotent role in FGR and T2DM development, particularly in relation to a paternal 
inheritance pattern. The absence of substantive findings in FGR offspring in relation 
to these SNPs may be an issue of power but could also suggest that the influence of 
these SNPs may be less direct and part of a complex pathway eventuating in altered Chapter 4: The Genetics of FGR 
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fetal growth. Interpretations made using the birth weight regression analysis do 
warrant further discussion in three of the genotyped SNPs. 
When the more common “T” T2DM risk allele on KCNJ11 (rs5219) was assessed in 
the cohort, a trend towards lower birth weight and higher paternal BMI was 
observed. This would be consistent with the hypothesis that variants in KCNJ11 
could have a role to play in fetal growth and potentially in conjunction with obesity 
mechanisms, increase the risk of T2DM.  
The T allele of KCNJ11 SNP rs5219 has been found to be associated with an SGA 
cohort in New Zealand (Morgan AR et al., 2010), however, two previous studies 
which evaluated this variant in relation to birth weight found no association (Weedon 
MN et al., 2003 & Bennett AJ et al., 2008). 
 
The findings that both a rare variant and more common T2DM risk SNP on KCNJ11 
are present in this current FGR cohort means that this gene remains of interest as a 
candidate in FGR. However, the small sample number genotyped for the SNP means 
any results need to be interpreted with caution and repeated in a bigger cohort. 
The common proline (Pro) allele at position 12 on the PPARG gene is associated 
with T2DM risk (Altshuler D et al., 2000).  In this study I demonstrated that the 
presence of the protective alanine (Ala) allele was associated with a trend of lower 
birth weight in offspring with 21.4% of FGR offspring having a Pro-Ala/ Ala-Ala 
genotype versus 11.6% of appropriately grown offspring (Table 4.13). Despite the 
Ala allele being associated with decreased risk of diabetes it is associated with 
increased BMI in overweight individuals (Masud S et al., 2003). Furthermore, this 
allele has previously been associated with lower birth weight (Eriksson JG et al., 
2002) and with higher fasting insulin levels and insulin-to-glucose ratios in a group 
of young adults born SGA (Jaquet D et al., 2002). 
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Table 4.13 Allele frequency for SNP rs 1801282 Pro12Ala polymorphism on PPARG for 
offspring, mothers and fathers in the cohort   
 
Subjects who carried the Ala allele who were born SGA were found to have 
significantly increased insulin excursion under OGTT and fasting insulin-to-glucose 
ratio which was surprising, given the known increase in insulin sensitivity with this 
allele (Ek J et al., 2001). Furthermore, in this group of adults, increased BMI strongly 
potentiated IR in the presence of the polymorphism. This study supports the idea that 
genetic polymorphisms in PPARG can modulate insulin resistance parameters in 
adult subjects born SGA and provides a biological pathway to disease development. 
The question arises about its role in the fetus and whether environmental cues may 
be modulating fetal metabolic responses and influencing growth.   
 
Common variants in the gene WFS1 including the SNP rs734312 have been shown to 
confer risk of T2DM (Sandhu MS et al., 2007). The minor rare “G” allele in this 
cohort associated with a lower offspring birth weight trend and higher paternal 
insulin resistance. However, this is in contrast to the reduced risk of T2DM diabetes 
reported in association with the minor “G” allele. A study by Florez et al. did find 
that baseline minor allele homozygotes at SNP rs734312 had a higher insulinogenic 
index (p =0.02), but interpreted this as an appropriate compensatory response to their 
nominally lower insulin sensitivity (Florez JC et al., 2008).  
 
 It has been shown that this allele can confer differing risk depending on the glucose 
tolerance status of the individual. This may go some way to explain why no clear 
effect was shown in the case fathers – those with abnormal glucose regulation 
responding differently than glucose-tolerant individuals (Sparsø T, 2008). 
 
 
   Pro-Pro  Pro-Ala  Ala-Ala 
   genotype (n,%) 
 
  
Baby case  33 (78.6%)  8 (19%)  1 (2.4%) 
Baby control  38 (88.4%)    5 (11.6%)    
Male case  32 (80%)  7 (17.5%)  1 (2.5%) 
Male control  50(82%)  11 (18%)    
Female case  23 (79.3%)  6 (21.7%)    
Female control   38 82.6%)  8 (17.4%)    Chapter 4: The Genetics of FGR 
 
155 
   
4.14 Summary  
Rare genetic variants in genes associated with Maturity onset diabetes of the young 
(MODY) were discovered in fetal growth restricted offspring. Different variants, 
identified through WES, were present in 4 separate offspring affected by fetal growth 
restriction. Whilst proof of cause is still required they are highly implicated in the 
pathogenesis of growth restriction through their predicted pathogenicity, rareness and 
known biological mechanisms affecting insulin secretion and beta cell function.   
The panel of risk SNPs implicated in T2DM and insulin resistance risk were not 
shown to have a strong influence in this analysis, but interpretations of this data is 
limited by the small sample numbers. Lower birth weight trends were implicated in 
SNPs on KCNJ11, PPARG and WFS1 but alone are unlikely to be causal or have a 
strong direct effect on FGR pathogenesis. It is more likely these variants modulate 
fetal growth within normal parameters. 
Support for the fetal insulin hypothesis is derived from the findings of rare variants 
in MODY genes. The genes described affect insulin sensitivity and beta cell function 
and inheritance of this trait in a fetus may lead to growth restriction. A paternal role 
was identified with respect to some of these cases but the overall pattern of 
transmission of genetic risk factors also included mothers.  
Whilst genes seem to play a significant role in FGR pathogenesis this does not 
exclude other influences, such as DNA methylation, being involved.  Chapter 5: DNA methylation in FGR offspring 
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Chapter 5: DNA Methylation in Growth Restricted 
Offspring 
 
5.1 Introduction  
Fetal growth restriction (FGR) and low birth weight are a major cause of neonatal 
morbidity and mortality, associated with metabolic and cardiovascular disease in 
later life (Barker DJP et al., 1993 and Hales CN et al., 1991).  
It has been proposed that epigenetic reprogramming of fetal genes could cause both 
growth restriction and T2DM if they persist into later life (Simmons RA et al., 2007 
& Cutfield WS et al., 2007).  Direct evidence that epigenetic processes operating in 
human pre-natal life might influence postpartum phenotype, have come from studies 
of altered methylation status of selected candidate genes (Godfrey et al., 2007 and 
Heijmans BT et al., 2006). However these findings have not been reproducible in 
prospectively collected umbilical cord blood samples of babies born with growth 
restriction or across a range of birth weights (Tobi EW et al., 2011 and Adkins RM et 
al., 2012).  
 
To fulfil its growth potential, a fetus must assimilate an adequate nutritional and 
oxygen supply from its mother across the placenta. This process is therefore 
governed by a complex interplay between the feto-placental genome and its maternal 
environment (Brodsky D et al., 2004). In low-income nations, environmental 
influences on fetal growth are predominantly related to poor maternal nutrition, 
chronic disease or infections (Black RE et al., 2013). In high-income nations, fetal 
growth is more commonly compromised by poor placental development.  
Inadequate invasion of the placenta with increased resistance within utero-placental 
arteries can be identified at the end of the first trimester and therefore, pre-dates the 
growth decline in the fetus.  This sequence of events would suggest that poor 
placental development must precede the manifestations of growth-restriction in a 
fetus and hence investigation of the epigenome of both the placenta and fetus is 
warranted.  
 Chapter 5: DNA methylation in FGR offspring 
 
158 
   
Most human studies that have investigated the role of epigenetic events in FGR 
pregnancies have been limited to a small subset of the thousands of genes expressed 
in the FGR placentae (Piedrahita et al., 2011). New technologies, such as the 
Infinium Human Methylation 450 Beadchip®, provide an epigenome-wide 
assessment of methylation on more than 450,000 CpG sites on 99% of known genes. 
Placentas from pre-eclamptic pregnancies have been investigated using this 
technology and found to have a distinct methylation profile compared with 
normotensive pregnancies (Blair JD et al., 2013) but within this PET cohort, 
pregnancies also affected by FGR could not be differentiated. A genome wide 
approach has shown methylation differences throughout the genome on 
haematopoietic CD34+ cells from umbilical cord blood of FGR (Einstein F et al., 
2010). However, this study was limited to comparison of only 5 FGR cases and 
observed low levels (6%) of methylation difference. 
 
Therefore, in this chapter I investigated whether genome-wide DNA methylation 
might be altered in umbilical cord blood and placental tissue of growth-restricted 
offspring. In order to discover novel epigenetic events associated with placental 
insufficiency; a case-control study was conducted that identified otherwise healthy 
women with a pregnancy affected by FGR or appropriately grown offspring (AGA). 
An unbiased approach was taken by investigating the whole methylome of umbilical 
cord blood and placentae using the Infinium Human Methylation 450 Beadchip®. 
Findings were validated with a previously published placenta dataset and objective 
bioinformatic tools were used to identify functional pathways likely to be affected by 
the most differentially methylated positions. 
 
5.2 Hypothesis 
Aberrant DNA methylation may predispose a fetus to growth restriction in utero and 
lead to T2DM in adulthood. Chapter 5: DNA methylation in FGR offspring 
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5.3 Specific Aims 
1.  The interrogation of DNA methylation in both placenta and cord blood in 
order to identify differentially methylated positions (DMPs) between growth 
restricted and appropriately grown offspring. 
2.  To assess the similarities and differences between cord blood and placenta in 
FGR offspring. 
3.  To use bioinformatics tools (GO and Marmal-aid) to provide functional 
evidence for DMPs identified 
 
5.4 Methods  
5.4.1 Study population 
Offspring placental and cord blood samples from the case/control study undertaken 
at  University  College  London  Hospital  (UCLH)  were  used.  All  parents  gave 
informed consent.   
At child-birth, umbilical cord blood was taken from the umbilical vein, and stored at 
-80
oC. Placental samples were taken from the surface closest to the fetus in 1cm 
blocks of tissue from four quadrants around the umbilical cord insertion and stored at 
-80°C. Gestational age, offspring gender, weight, length and delivery details were 
recorded to confirm antenatal diagnosis of growth restriction. 
This experiment was designed to investigate DNA methylation in FGR offspring 
thought to be secondary to placental disorder. Women in both groups recruited were 
phenotypically similar in order to minimise in-utero environmental differences 
between the groups.  
5.4.2 Methodology 
 High-quality genomic DNA (500ng) from paired cord blood and placenta samples 
was extracted and cleaned up (as described in methods section 2.12) from FGR and 
control  AGA  offspring.  DNA  was  bisulphite  converted  using  the  EZ  -96  DNA 
Methylation Deep-well Kit (Zymo Research, Cambridge Biosciences, UK). Samples 
that showed >97% bi-sulphite conversion were included in the array. Chapter 5: DNA methylation in FGR offspring 
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Bisulphite-converted  samples  were  hybridised  to  the  Illumina  HumanMethylation 
450Beadchip  (Illumina,  Inc.  CA,  USA)  (Sandoval  et  al.  2011)  using  standard 
protocols (described in methods section 2.16) and arrays  were scanned using the 
Illumina iScan SQ two-colour laser scanner. 
Data produced was subject to quality control measures and probes were filtered (as 
described in methods section 2.15). 
5.4.3 Statistical Analysis  
Differentially  methylated  positions  (DMPs)  were  identified  using  t  test-based 
statistics in the Limma package provided by Bioconductor 2.11 (Smyth GK, 2004).  
Adjustment for genome-wide significance was performed using the Benjamini and 
Hochburg False Discovery Rate (FDR) with a threshold p value for DMPs of <0.05 
(Benjamini and Hochburg, 1995). 
A case/ control model was first run with all samples and then in a sub-cohort of term 
cases  and  controls  only.  Term  samples  were  defined  by  a  GA  >255  days,  the 
equivalent to a full term gestation. 
The influence of gestational age on DMPs between FGR and AGA was assessed 
using a continuous linear regression model in the Limma package, incorporating all 
samples and gestational age. Results were validated with an external dataset placenta 
tissue from the Illumina 27k methylation array (Novakovic B et al., 2011). 
To further characterize the DMPs, we utilized Marmal-aid (http://marmal-aid.org) a 
meta-analysis  tool  recently  developed.  In  Marmal-aid,  all  publicly  available 
Illumina450K data (8,531 different arrays as of April 15, 2013) is incorporated into a 
single repository and re-processed to enable customizable meta-analyses (Marmal-
aid manuscript currently under review). 
Gene Ontology (GO) pathway analysis was also performed using these DMPs. A cut 
off  p  value  <0.0001  and  over  representation  genes  (from  expected)  of  a  2  fold 
enrichment was taken as the criteria for GO pathways to be reported. 
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5.5 Results 
5.5.1 Quality Control and sample removal 
Data generated was subject to quality control checks as described in the methods 
section previously (section 2.15). Sample independent QCs of control probes 
(staining, extension, density) showed good performance (data not shown). Sample 
dependent QC’s (bisulphite conversion, specificity, negative controls and non-
polymorphic controls) also showed good performance but did result in removal of 
samples from final analysis according to whether the probes performed according to 
expected intensities. 
5.5.1.2 Bisulphite Conversion Failure 
Bisulphite converted DNA performance of Infinium I probes was assessed through 
signal intensity.  Control probes C1, C2 and C3 assess bisulphite- converted DNA 
performance of the Infinium I probes in the green channel.  Due to difference in 
extension of sequences, control probes (C1, C2 and C3) had higher signal intensity 
than unconverted control samples (U1, U2 and U3). The same pattern was observed 
in C4, C5 and C6 compared to U4, U5 and U6 in the red channel (see figure 5.1).   
Due to the Infinium II design, converted and unconverted DNA is hybridised to a 
single probe and bisulphite conversion performance is represented by higher 
intensities across all control probes (II1, II2, II3 and II4) in the red channel (data not 
shown). 
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Figure 5.1 Bisulphite control probes (C1, C2 and C3) should have higher signal intensity than unconverted control samples (U1, U2 and U3) in green channel. 
The same high signal intensity should be seen in C4, C5 and C6 compared to U4, U5 and U6 in the red channel.   
Example  of 
sample  that 
failed 
 
 
  
 BS 
conversion 
Figure 5.1a  Figure 5.1b  
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5.5.1.3 Specificity Controls - Specificity of probes I (Figure 5.2 ) which reflect high signal intensity of unmethylated interrogated C using PM 
control (reflecting a perfect A/T match) and G/T mismatch (MM control) at background signal intensity in the green channel  and in Specificity 
II  1,2,3 should be of high intensity in the red channel (data not shown).
Figure 5.2 Specificity of probe I design- high signal intensity of PM controls and low intensity of MM controls passes QC.
High signal intensity 
– PM controls 
Low signal 
intensity- MM 
controls  
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5.5.1.4 Non polymorphic Controls 
 
Figure 5.3 Non polymorphic controls -Non-polymorphic regions of the bisulphite-converted genome are used as a control to test assay 
performance by designing A, C, T and G probes within these non-polymorphic regions that can be compared across different samples. Non 
polymorphic probe performance of samples which should have high signal intensities (again the same samples are shown to have failed).  
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5.5.1.5 Negative Controls 
 
 
Figure 5.4 Negative Controls- Negative control probes are based on comparison with the average and standard deviation from 600 control 
samples available in the genome studio platform. These controls can be read in both the green and red channelsChapter 5: DNA methylation in FGR offspring 
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5.5.2 Intra-Array Normalisation 
Initially quantile normalisation was performed separately for the red and green 
channels (U unmethylated and M methylated) and the outlying tissue sample was 
removed from further analysis. However, it was quickly identified that within the red 
(Figure 5.5a) and green (Figure 5.5b) channels, tissues were clustering out separately 
(see colour figure, cord blood in green and placenta in red) so raw data was then 
quantile normalised separately for each tissue (cord blood and placenta) in order to 
adjust for inter-array variations. Final normalisation beta value patterns were 
generated for each sample and are represented visually (Figure 5.6a  placenta and 
Figure 5.6b cord blood). 
 
Figure 5.5 Samples represented in colour in red (5.5a) and green (5.5b) channels (cord blood 
green colour and placenta in red colour) it can be seen that tissues cluster out distinctly.                  Chapter 5: DNA methylation in FGR offspring 
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5.5.3 Post normalisation beta profiles 
Post separate quantile normalisation a beta profile of samples was generated in order 
to confirm homogeneity between samples analysed (Figure 5.6a and 5.6b).  
 
 
 
Figure 5.6a is the post normalisation beta profile in placenta and cord blood (in figure 5.6b) 
of each of the individual samples analysed (individually coloured).  Chapter 5: DNA methylation in FGR offspring 
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5.5.4 Probe Filtering 
Of 486,428 probes present on the array, 11,648 X and Y chromosome probes were 
removed; 1,927 were removed for not meeting the detection P-value cut-off (P=0.05) 
and 43,097 were removed due to probe cross-hybridisation. This resulted in a total of 
429,756  probes,  representing  individual  positions  of  methylation  available  for 
downstream analysis.  
 
5.5.5 Sample Identification  
Sample  identification  was  confirmed  using  a  combination  of  Y-chromosome 
methylation  profiles  in  order  to  generate  gender  matches  and  interrogation  of 
predicted single nucleotide polymorphism (SNP) probes.  SNP sites were identified 
by selecting positions where 3 individuals had a beta value difference >0.3 from the 
median in both tissues.  
 
5.5.5.1 Gender Matches 
Gender assessment through Y chromosome methylation profiling (Figure 5.7) was 
undertaken  for  pairs  of  cord  blood  and  placental  samples  in  order  to  establish 
concordance which was then cross referenced with known phenotype data of fetal 
sex at birth. In one case a gender mismatch was identified; sample 90 (female) did 
not match expected gender (which was paired with 32- male) and as a result samples 
32 and 90 were removed from analysis. Upon further investigation of initial DNA 
used it was identified that maternal DNA of the offspring had been used (labelling of 
tube was insufficient in this case). 
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Figure  5.7  Beta  methylation  profile  for  sex  chromosomes  (XX  or  XY)    successfully 
identifying gender. Sample 32 and 90 are highlighted showing discordant gender- in sample 
at top of figure the XY methylation pattern is revealed but in the bottom profile the XX 
female methylation pattern is present.  
 
5.5.5.2 Genetic Cluster Analysis 
Genetic cluster analysis of paired (umbilical cord blood and placental tissue) samples 
assessed the homogeneity of pairs in order to establish mismatches.  
Identification of a SNP methylation profile led to the discovery of around 1,800 
probes. These probes were then used to identify concordance of all placental and 
cord blood samples using a genetic clustering map (data not shown).   
Cluster analysis revealed all but three sample pairs clustered out and the rest matched 
and  identified  all  pairs  correctly  with  single  samples  forming  out-groups.  These 
outliers were correctly identified as the non- Caucasian samples run on the array. 
When plotted on an MDS plot (as described in the methods section 2.15.5) the three 
outliers can be seen in  green within the samples labelled in orange (Figure 5.8). 
These samples were not included in downstream analysis for this experiment. 
Female (XX) 
methylation pattern 
Male (XY) 
methylation pattern Chapter 5: DNA methylation in FGR offspring 
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Figure  5.8  An  MDS  plot of  the  1800  positions  identified  as  having  a  SNP  methylation 
profile.  The orange samples correspond to a separate Asian (Hitman group unpublished 
data) cohort and the three outliers in green from the FGR cohort correspond to the three 
Asian cases run additionally on the array.  
 
5.6 Final sample number analysis 
5.6.1 Maternal Characteristics 
Baseline maternal characteristics are described in table 5.1, for all mothers who had 
either placental or umbilical cord blood samples analysed (AGA mothers n=24 and 
FGR mothers n= 29, excluding 3 mothers of different ethnicity) which confirms that 
case and control maternal phenotype was similar.  
The majority of women had not given birth before and this was their first child (77% 
primiparous mothers of AGA offspring versus 86% FGR offspring). There were no 
significant  differences  between  maternal  age  [AGA  31.9±3.98  years  versus  FGR 
32.8±2.98 years] or BMI [23.7±3.5 kg/m
2 AGA versus 23.4±3.6 kg/m
2 FGR]. 
Mode of delivery did vary for cases and controls with more FGR pregnancies ending 
in delivery by caesarean section (62% versus 25% in control group) but this was 
expected as, particularly at earlier gestational ages, elective caesarean delivery may 
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be the most appropriate mode of delivery. When term deliveries were assessed then 
the rate of caesarean section in the FGR group of mothers fell to 37% (n=7 of 19 
term cord blood samples) 
  FGR mothers                      
(mean ± SD) 
Control AGA mothers                
(mean ± SD) 
  n=29  n= 24 
Maternal age (years)  32.8 ± 2.98  31.9 ± 3.98 
BMI (kgm
-2)  23.4 ± 3.6  23.7 ± 3.5 
Maternal parity  Primiparous, n=25 (86%)  Primiparous, n=21 (77%) 
Mode of delivery  Vaginal, n=11 (38%) 
Caesarean section, n=18 
Vaginal, n=18 (75%) 
Caesarean section, n=6 
Table 5.1 Maternal baseline characteristics of appropriately grown for gestational age (AGA) 
offspring and growth restricted (FGR) offspring.  
5.6.2 Offspring Samples 
A total of 56 cord-blood and 54 placenta samples were run on the array, including 49 
paired  samples  and  12  unpaired  tissue  samples  (7  cord  blood  and  5  placental 
samples). 
After QC and removal of three samples of different ethnicity, data from 45 umbilical 
blood samples (FGR n= 27 and AGA n=18) and 45 placental samples (FGR n=22 
and  AGA  n=  23)  were  available  for  further  analysis  which  included  44  paired 
samples (19 paired in cord blood and 15 in placenta) and left 7 cord blood and 12 
placental samples unpaired.  
Excluded samples meant that numbers and characteristics between offspring cord 
blood and placental samples did vary slightly (Table 5.2). 
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CORD BLOOD  All AGA 
offspring                
(mean ± SD) 
All FGR 
offspring  
(mean ± SD) 
Term FGR 
offspring       
(mean ± SD) 
       
Number of samples  18  27  19 
Birth Weight (grams)  3634 ± 369  2065 ± 770  2487 ± 420 
Customised centile (%)  51.8 ± 30.5  1.9 ± 2.3  2.6 ± 2.3 
Gestation (range) days  285 (272-299)  258 ( 202-293)  272 (256-293) 
Baby Gender  Male, n=9 
Female, n = 9 
Male, n= 9 
Female, n = 18 
Male n=7 
Female n=12 
 
 
PLACENTA 
     
Number of samples  23  22  15 
Birth Weight (grams)  3614 ± 361  2011 ± 710  2428 ± 342 
 
Customised centile (%)  47.6 ± 28.6  1.8 ± 2.3  2.3 ± 2.0 
 
Gestation (range) days  285 (266-300)  257 (202-286)  272 (256-286) 
Baby Gender  Male, n=11 
Female, n = 12 
Male, n= 9 
Female, n = 13 
Male, n=6 
Female, n = 9 
 
Table 5.2 Offspring characteristics of all cord blood samples and placental samples analysed 
as well as comparison with the term FGR samples analysed (by inclusion criteria all AGA 
samples term gestation so no difference in values than the figures presented for All AGA 
samples) 
 
In all cord blood samples, AGA offspring samples (n=18) had a mean customised 
birth centile of 51.8±30.5% and birth weight of 3634±369g versus FGR offspring 
(n=27) whose mean customised birth centile was 1.9±2.3% with a birth weight mean 
of 2065±770g. All offspring met the inclusion criteria for the study and AGA and 
FGR  offspring  customised  centiles  were  statistically  significantly  different 
(p=0.001).  There  were  more  growth  restricted  females  (67%)  than  in  the  AGA 
offspring (50%). Chapter 5: DNA methylation in FGR offspring 
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Of umbilical cord blood samples 19 of 27 FGR offspring were born at a gestation of 
255  days  or  more  which  we  defined  as  term  gestation.  Recruitment  criteria  for 
control offspring meant that all 18 AGA cord blood samples were 255 days or more 
gestation. For the term comparison these cord blood samples were used.   
The  cut-off  of  more  than  255  days  was  taken  based  on  a  pervious  study  of 
methylation differences seen in a term cohort (Banister et al., 2011) who defined a 
term  cohort  as  more  than  36  weeks  and  also  from  investigation  of  methylation 
profiles which supported a natural cut off around this gestational age. In term cord 
blood samples, data was the same for AGA offspring but for FGR offspring (n= 19) 
their  mean  customised  birth  centile  increased  to  2.6±2.3  %  and  birth  weight 
increased  to  2487±420g.  Again  in  growth  restricted  offspring  there  were  more 
females  (63%)  than  AGA  offspring.  All  statistical  differences  were  maintained 
between AGA and FGR offspring in the term samples (data not shown).  
 
In all placental samples AGA offspring samples (n=23) had a mean customised birth 
centile of 47.6±28.6% and birth weight of 3614±361g versus FGR offspring (n=22) 
whose mean customised birth centile was 1.8±2.3% with a birth weight mean of 
2011±710g. All offspring met the inclusion criteria for the study and AGA and FGR 
offspring  customised  centiles  were  statistically  significantly  different  (p=0.001). 
There were more growth restricted females (59%) than in the AGA offspring (52%). 
 
Of placental samples 15 of 22 FGR offspring were born at more than 255 days. 
Again in term placental samples, data was the same for AGA offspring but for FGR 
offspring (n= 15) their mean customised birth centile increased to 2.3±2.0% and birth 
weight increased to 2428±342g. Again in growth restricted offspring there were more 
females  (60%)  than  AGA  offspring.  All  statistical  differences  were  maintained 
between AGA and FGR offspring in the term samples (data not shown). 
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5.7 Data Analysis  
Firstly an MDS plot was plotted as a means of visualising the data. This was done for 
all  the  probes  available  (429,756).  Cord  blood  samples  can  be  seen  clustering 
separately to placental samples (Figure 5.9). 
 MDS plot were then generated for both cord blood and placental tissue with AGA 
and FGR samples annotated separately (Figure 5.10a & Figure 5.10b). When tissues 
plotted  separately  then  it  becomes  more  obvious  that  cases  (green)  and  controls 
(orange) are behaving differently in cord blood. 
 
Figure 5.9 MDS plot of cord blood in green versus placental samples in orange which show 
two tissues cluster out separately. 
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Figure 5.10 When tissues separated out in cord blood samples AGA (orange) and FGR 
(green) samples are seen to separate out (Figure 5.10a above). This pattern is not as obvious 
in placental tissue (Figure 5.10b).  
5.7.1 Analysis pipeline 
As  discussed  previously  there  were  pre-term  FGR  offspring  within  the  samples 
processed. All AGA offspring were born at term and hence did not include a pre-term 
cohort.  The approach to the analysis, therefore, took into account the possible effect 
of gestational age on methylation change. 
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Analysis was performed separately for the tissues in the following ways: 
  A case/control call between all FGR and AGA offspring 
  A term (>255 days) case/control call between FGR and AGA offspring 
  Age matched term FGR offspring versus AGA offspring  in cord blood to 
validate findings 
  A gestational age model using all samples 
  Validation of placental tissue gestational age methylation 
  Overlap between FGR and AGA call and gestational age  
  Assessment of paternal IR and offspring methylation  
 
5.8 Differentially methylated positions (DMPs) in growth restricted 
versus appropriately grown offspring 
In all FGR offspring, 553 differently methylated positions (DMPs) in cord blood and 
453 DMPs in placenta reached genome significance (adj. p <0.05) compared with all 
AGA offspring. Of these hits, in placental tissue, differences were predominantly 
hypomethylated in FGR samples (Figure 5.11 is an example) but hypermethylated in 
FGR cord blood samples. 
 
 
Figure 5.11 Example of a DMP called as hypomethylated in case FGR offspring in placenta. 
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5.9 Differentially Methylated Positions in umbilical cord blood from 
fetal growth restricted offspring at term 
From baseline data it was clear that gestational age varied in the FGR cohort with the 
presence of pre-term offspring in this group.  As no AGA offspring were born pre-
term (<255 days), gestational age was not controlled for in this original case/control 
call.  In  order  to  minimise  the  confounding  effect  of  gestational  age  in  the  next 
analysis, just FGR cases (n=19) and AGA controls (n=18) that delivered at term (≥ 
255 days) were compared.   
This analysis of genome-wide methylation differences yielded 839 DMPs in the cord 
blood  of FGR  offspring, with  the majority  (86%)  being hypermethylated (Figure 
5.12) in FGR compared to AGA offspring. Only 67% were common to the DMPs 
identified in the case/control call between all samples, suggesting that gestational age 
has independent effects on methylation in the initial call. 
Figure 5.12 Volcano plot showing differentially methylated positions in cord blood between 
growth  restricted  and  appropriately  grown  offspring  at  term  gestation.  Hypermethylated 
positions are shown in blue and hypomethylated positions in yellow. 
 
In order to identify the DMPs with a high likelihood of a functional effect, these 839 
DMPs were then stratified according to the degree of methylation difference that Chapter 5: DNA methylation in FGR offspring 
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they exhibited. Of the 839 DMPs, 304 had a beta methylation difference of >5% and 
53 DMPs had a beta methylation value difference of >10% (Table 5.3). The majority 
of DMPs with >10% beta methylation difference were hypermethylated (41/53)         
(Table 5.3  ). Of the 839 DMPs that were identified on Ref-seq annotated genes, 658 
DMPs were within 1000bp of each other and 25 DMPs co-methylated in the same 
direction. Co-methylation in the same direction was exhibited in 8/53 of the most 
differentially methylated hits including 4 co-methylated DMPs within the gene 
C5orf39 and 3 in FOXP1 and NRN1. Two DMPs were within 5 base pairs of each 
other on RIOK3, with beta methylation values of 11 and 17%. 
 
 
Hypomethylated 
positions 
         
ID  CHR  MAPINFO  UCSC_RefGene 
Beta 
value   p value 
cg23372001  6  27791640  HIST1H4J  -0.22  1.10E-10 
cg26758857  22  36649135  APOL1  -0.18  3.47E-07 
cg05533953  4  331685  ZNF141  -0.15  1.69E-10 
cg26542283  5  43040505  C5orf39  -0.15  2.77E-09 
cg07875360  5  1801344  NDUFS6;MRPL36  -0.13  4.60E-08 
ch.20.327316F  20  15628644  MACROD2  -0.12  8.34E-10 
cg01458605  3  147128679  ZIC1  -0.11  4.69E-10 
cg04410715  19  39283334 
 
-0.11  2.53E-08 
 
Table 5.3a Hypomethylated positions with beta value >10% in cord blood from FGR 
compared with AGA offspring, according to cg identifying site, gene identifier, chromosome 
number, chromosome position and beta value 
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Table 5.3b Hypermethylated positions with beta value >10% in cord blood from FGR 
compared with AGA offspring 
 
ID  CHR  MAPINFO  UCSC_RefGene 
Beta 
value  P.Value 
cg25418748  5  178977236  RUFY1  0.17  4.10E-08 
cg20796556  18  21032774  RIOK3  0.17  4.32E-08 
cg17724814  1  155881358  RIT1  0.16  8.41E-07 
cg07979357  19  14142353  IL27RA  0.15  4.30E-08 
cg01769037  6  15246613  JARID2  0.14  2.36E-07 
cg22256960  15  77711686 
 
0.14  2.70E-06 
cg19857457  18  47018947  RPL17;SNORD58A  0.14  1.92E-07 
cg27069263  2  55278118  RTN4  0.14  1.57E-05 
cg18261223  5  32711517  NPR3  0.14  2.76E-06 
cg09435090  4  17513980  QDPR  0.14  1.17E-06 
cg20684973  10  105127632  TAF5  0.14  5.18E-08 
cg00565558  7  6120396 
 
0.14  2.07E-08 
cg23802518  10  80827482  ZMIZ1  0.14  2.47E-07 
cg18036763  22  45404910  PHF21B  0.13  9.57E-08 
cg08965527  16  84178213  HSDL1;LRRC50  0.13  6.78E-08 
cg10861135  9  14345348 
 
0.13  3.31E-07 
cg00510787  6  151772946  C6orf211;RMND1  0.13  2.03E-06 
cg09747578  1  46769076  LRRC41;UQCRH  0.12  9.43E-08 
cg18022926  10  70093071  PBLD;HNRNPH3  0.12  1.24E-07 
cg10013169  6  5997028 
 
0.12  1.98E-06 
cg22276571  20  17549599  DSTN;DSTN  0.12  4.88E-07 
cg16595484  3  122512170  HSPBAP1  0.12  1.25E-06 
cg03393426  10  102986686 
 
0.12  1.07E-07 
cg04921814  1  145575587  PIAS3  0.12  2.26E-06 
cg21935083  5  131892314  RAD50  0.12  5.42E-07 
cg23653187  22  44319257  PNPLA3  0.12  8.65E-07 
cg17344340  22  46044084 
 
0.11  7.95E-06 
cg07772516  15  52107742  TMOD2;TMOD2  0.11  6.76E-06 
cg08779777  7  106505772  PIK3CG  0.11  2.62E-05 
cg21860429  6  105389544 
 
0.11  2.19E-05 
cg14555127  7  35841578  SEPT7;  0.11  4.86E-07 
cg04609859  17  46655736  HOXB4  0.11  1.45E-06 
cg21312090  8  116681727  TRPS1  0.11  2.44E-06 
cg17373554  5  72594735 
 
0.11  1.88E-05 
cg05489143  3  40498640  RPL14  0.11  8.96E-07 
cg04005701  17  1733641  RPA1;SMYD4  0.11  1.87E-07 
cg20760063  17  41277580  NBR2;BRCA1  0.11  4.40E-08 
cg06361531  16  68057779  DUS2L;DDX28  0.11  2.72E-07 
cg01013600  19  49141177  DBP;SEC1  0.11  3.42E-07 
cg25845597  6  27841122  HIST1H4L;HIST1H3I  0.11  2.00E-07 
cg14036868  2  38604442  ATL2  0.11  7.45E-07 
cg26220528  12  57623348  SHMT2  0.11  5.92E-07 
cg01147107  1  47696505  TAL1  0.11  5.12E-07 
cg16942681  18  21032779  RIOK3  0.11  6.05E-05 
cg08215925  3  71633214  FOXP1  0.11  1.02E-05 Chapter 5: DNA methylation in FGR offspring 
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5.10 Term Placenta FGR versus AGA 
When the same term analysis was performed on placental tissue (AGA n= 23, FGR 
n=15)  genome  wide  significant  DMPs  were  not  identified.  The  top  1000  non-
significant hits in the placenta were then compared with the significant term cord 
blood DMPs in order to make an assessment of whether the placenta was simply 
underpowered  to  identify  differences.  There  was  zero  overlap  between  positions, 
suggesting that the phenomenon seen in  cord blood  was  not  present  in  placental 
tissue in term growth restricted offspring rather than the placental samples being 
underpowered to identify it. 
When  p  value  distribution  for  the  two  different  tissues  is  called  in  cord  blood 
enrichment can be seen but this is not the case for placental tissue where DMPs are 
not enriched above background noise (Figures 5.13a and 5.13b) 
 Figure 5.13a. Representation of p value distribution across placental term samples Chapter 5: DNA methylation in FGR offspring 
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Figure 5.13b Representation of p value distribution across cord blood term samples shows 
enrichment 
 
Before the linear model using gestational age was run, models using birth weight 
centiles were also run. Using this variable failed to yield genome wide significant 
DMPs, as clustering together of centiles meant significance was lost. However, of the 
top 2000 non-significant results from the birth centile call when placenta and cord 
blood were compared only 21 probes are common between the two - just above what 
would be expected by chance. Again this supports the idea that methylation profiles 
between cord blood and placenta are different in growth restriction. 
 
5.11 Differentially methylated positions driven by gestational age 
To elucidate whether the 453 placenta DMPs identified in the first analysis were 
driven by differences in gestational age between experimental groups, a linear model 
was run on all samples using gestational age as a continuous variable. Across the 
gestational  age  range  (189  days  to  300  days)  in  the  placenta  there  were  20,893 
DMPs.  In  cord  blood  the  same  linear  model  yielded  76,249  DMPs  (adjusted  p< Chapter 5: DNA methylation in FGR offspring 
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0.05). Of these DMPs, 7,041 were common to both placenta and cord blood, which 
was  enriched  above  background  probability.  By  chance  you  would  expect  a 
distribution with mean ~3500 and range from 3300-3700 DMPs.  
DMPs in placenta became more methylated with advancing gestation which was also 
a characteristic of cord blood DMPs.  However, the majority of DMPs, irrespective 
of  tissue  type,  are  hypomethylated  (93%  and  68%  in  placenta  and  cord  blood, 
respectively) as the difference is likely to be driven by the preterm samples.  
 
Individual positions were plotted for all samples against gestational age. The top 
placental DMPs were plotted in this way. With advancing gestation an increasing 
trend in methylation can be seen in the top 20 positions (Figure 5.14). The clustering 
of samples towards term gestation is due to the numbers of control samples (all term 
gestation)  along  with  a  significant  proportion  of  FGR  cases  being  >255days  in 
placental samples (n=15). However, despite the small number of preterm samples the 
trend  seems  consistent  with  increasing  methylation  associated  with  advancing 
gestation across the most significant DMPs.  
 
Figure 5.14 Top 12 placental hits plotted according to gestation (days) on x-axis and beta 
methylation value showing increasing methylation status with advancing gestational age  Chapter 5: DNA methylation in FGR offspring 
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5.12 External validation of DMPs in placental tissue   
Placental results were validated using methylation data from placental tissue run on 
an Illumina HumanMethylation27 BeadChip, a precursor to the 450k array 
(Novakovic B et al., 2011) 
 
Using the same cutoff for statistical significance as our study (FDR-adjusted p<0.05) 
placental DMPs were identified between the second trimester and term groups in the 
published dataset (Novakovic B et al., 2011) and  similar placental DMPs were 
searched for between the second and third trimesters in our own cohort.  
 
There were 23,677 positions available for direct comparison between the 27k and 
450k platforms where probe type and design were identical.  825 DMPs were called 
as significant  from these positions on the 450k platform and of these, 541 (65%) 
were also identified as being significant in the independent dataset run on the 27k 
platform  (Novakovic  et  al).  There  were  519  similarly  hypomethylated  and  13 
similarly  hypermethylated  positions  in  both  datasets.  In  only  9  probes  was  the 
direction of methylation opposite between the two datasets (Figure 5.15). 
Figure 5.15   Differentially methylated positions present in placenta from our data set (450K) 
and from the data of Novakovic (27K). Hypomethylated regions common to both platforms 
(519 DMPs; yellow), hypermethylated regions (13 DMPs; blue) and mismatched direction (9 
DMPs; red).  Chapter 5: DNA methylation in FGR offspring 
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Individual positions were also correlated according to gestational age and visually 
represented in order to assess whether differences in our FGR and AGA offspring 
could be interpreted. 
 
This confirmed that in a significant number of positions the trend identified in the 
Novakovic  preterm  cohort  was  mirrored  in  FGR  and  AGA  samples  from  our 
experiments (Figures 5.16c and 5.16d below). However, anti-correlations were also 
identified where there were clear differences in FGR offspring (in green) versus AGA 
offspring  (red)  which  fell  into  the  Novakovic  controls  (in  black)  represented  by 
figure 5.16a and to some degree 5.16b. The limitation in this assessment is, however, 
the lack mid trimester samples in our cohort that would be needed to identify the 
methylation trend during this missed period of gestation (as it is conceivable that 
methylation status changed in a non-linear trajectory despite the start and end point 
making an increasing linear course most likely). 
 
Figure 5.16 (a top left, b top right, c bottom left and d bottom right) representing individual 
DMPs in placental tissue and trends of case (green), control (red) or Novakovic samples 
(black). In bottom two figures there is a correlated trend suggesting methylation is similar in 
all cohorts. In the top two examples there seems to be a hypermethylated trend in FGR cases 
as opposed to either of the other two cohorts.  
0 50 100 150 200 250 300
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
inf27k[, 5]
b
e
t
a
 
v
a
l
u
e
0 50 100 150 200 250 300
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
inf27k[, 5]
b
e
t
a
 
v
a
l
u
e
0 50 100 150 200 250 300
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
inf27k[, 5]
b
e
t
a
 
v
a
l
u
e
0 50 100 150 200 250 300
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
inf27k[, 5]
b
e
t
a
 
v
a
l
u
eChapter 5: DNA methylation in FGR offspring 
 
185 
   
5.13 Placental DMPs associated with FGR independently of 
gestational age 
By identifying 541/835 DMPs common to both our dataset and the appropriately 
grown fetal dataset by Novakovic, it is more likely that the remaining 284 DMPs 
(data not shown) unique to our FGR group, have a role independent of gestational 
age that influences fetal growth. Out of these 284 placental DMPs, the top DMP 
stratified according to adjusted p values was on FGFR1 (fibroblast growth factor 
receptor  1)  which  is  a  growth  factor  involved  in  angiogenesis  and  embryonic 
development (Bottcher RT et al., 2005). 
 
Placental DMPs identified in the original case/control model were also compared 
with the DMPs identified through the linear gestational age model. Of the 443 
DMPs, 39 (Table 5.4) were significant in the original FGR versus AGA comparison 
but did not come up in the gestational age model. Again, through exclusion, is seems 
possible that these 39 DMPs might have a role in the placenta in growth restricted 
pregnancies that is independent of gestational age. The most significant placental 
DMP of the remaining 39 DMPs  was located on latent transforming growth factor 
beta binding protein 3 (LTBP3) which encodes for a protein  which forms a complex 
with transforming growth factor beta (TGF-beta) proteins and it may play a critical 
role in controlling and directing the activity of TGFB1.  
It  is  likely  that  the  pre-term  placental  samples  power  the  initial  case/control  as 
evidenced by the lack of DMPs in the term cohort.  In combination with the placental 
DMPs identified as discordant from Novakovic, these DMPs offer novel placental 
targets to investigate and suggest key methylation differences exist between placenta 
and cord in FGR samples that are also related to gestational age and likely to be 
specific to the developing placenta as the term FGR versus AGA placentae did not 
yield significant DMPs. 
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Table 5.4 39 DMPs not present in gestational placenta age model but remaining from the 
original case/control call where a Ref-seq gene annotation has been made 
 
 
 
 
 
 
 
 
 
cg identifier  Chr  Position  Gene   adj.  p value 
cg04089426  11  65307791  LTBP3  1.34E-06 
cg02696763  1  156252642  SMG5;TMEM79  1.40E-06 
cg19883905  18  12254024  CIDEA  2.18E-06 
cg03795316  10  12110955  DHTKD1  2.56E-06 
cg23844623  11  47290730  MADD  4.50E-06 
cg05827732  3  96533699  EPHA6  5.81E-06 
cg13549444  12  7060474  PTPN6  6.16E-06 
cg13682375  5  16828148  MYO10  6.35E-06 
cg22416002  22  39713062  RPL3;RNU86  7.82E-06 
cg11031567  17  79378207  BAHCC1  9.69E-06 
cg25063733  1  43996686  PTPRFRF  1.04E-05 
cg05284727  4  1874366  WHSC1  1.27E-05 
cg03437741  1  117491966  PTGFRN  1.52E-05 
cg07137519  10  131688736  EBF3  1.57E-05 
cg00210210  6  99798738  C6orf168  2.27E-05 
cg11682350  6  33240284  VPS52;RPS18  2.35E-05 
cg14528147  1  113001201  CTTNBP2NL  3.00E-05 
cg03427058  1  1565025  MIB2  3.28E-05 
cg23496755  7  20865522  RPL23P8  3.29E-05 
cg02747671  13  39612086  C13orf23;NHLRC3  3.53E-05 
cg06915053  12  7245056  C1R  3.65E-05 
cg07130266  3  50375624  RASSF1  3.65E-05 
ch.7.2667284R  7  128843678  SMO  3.82E-05 
cg06534427  22  39713022  RPL3;RNU86;RPL3  3.99E-05 
cg17755460  1  117491905  PTGFRN  4.20E-05 
cg09005580  3  184636467  VPS8;VPS8  4.59E-05 
cg17444015  1  2322981  MORN1;RER1;MORN1  4.62E-05 
cg21113768  6  144386848  PLAGL1  4.85E-05 
cg26286901  8  22595307  PEBP4  4.92E-05 
cg08920071  1  117544781  CD101  5.18E-05 
cg09993092  6  33167743  SLC39A7;RXRB;SLC39A7  5.21E-05 
cg24780479  19  14581142  PKN1  5.26E-05 Chapter 5: DNA methylation in FGR offspring 
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 5.14 Cord blood FGR DMPs independent of gestational age 
To determine whether advancing gestation at ‘term’, between 256 - 300 days, was 
still able to influence cord blood DMPs, DMPs were identified that were present both 
in FGR offspring cord blood at term and the gestational age cord blood linear model. 
Of 839 DMPs identified in FGR cord blood at term, 121 DMPs were also called in 
the  gestational  age  cord  blood  analysis.  These  121  DMPs  were  matched  for 
gestational age between 12 FGR (mean 279.1 ± 8.3 days) and 12 AGA individuals 
(mean 280.3±  7.2 days).    The direction of methylation  is  100% correct  with  the 
overall case / control call from samples> 255 days (Figure 5.17) wwhich shows that 
the methylation differences seen in the term model persist when gestational age is 
confounded for through a matching model. This supports the idea that the 121 DMPs 
called  in  both  were  likely  to  be  driven  by  fetal  growth  restriction  rather  than 
gestational age. 
 
 
Figure 5.17 Correlation of direction methylation between the 121 DMPs in both models 
when compared in gestational age matched FGR and AGA offspring cord blood samples 
 
It is likely that these 121 DMPs have a similar influence in growth restriction to the 
other 718 DMPs in term cord blood. When these 121 are stratified according to beta 
values they reveal similar results to the overall 839 DMPs in term cord blood. 54 of 
the 121 have a beta difference greater than 5% (24% of all 839 hits which is a similar 
proportion  to  overall  number  of  DMPs  in  term  call  with  beta  difference>5%  at Chapter 5: DNA methylation in FGR offspring 
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26.8%) and 4 have a beta difference of >10% (7.5%) which is similar to the overall 
proportion  of  DMPs  with  beta  difference  >10%  (6.3%)  –  see  table  5.5  for  split 
according to hyper and hypomethylated state. 
     
5% beta value 
difference (n) 
GA 
associated 
(n/%) 
10% beta 
value 
difference (n) 
GA 
associated 
(n/%) 
  
 
           
Hypermethylated  162  48 (30%)  45  4 (8.9%) 
  
 
           
Hypomethylated 
 
63 
 
6 (9.5%) 
 
8 
 
0 (0%) 
 
 
Table 5.5Table of significance of term cord blood DMP at >5% and >10% cutoff levels and 
number of each of these that are present in the gestational age (GA) model. 
 
Term cord blood DMPs were also compared to results from a study performed on 
whole  cord  blood  of  a  separate  cohort  of  AGA  offspring  between  32-43  weeks 
gestation (Schroeder DW et al., 2011). Using the HumanMethylation27 BeadChip, 
25 DMPs were identified in whole umbilical cord blood, related to gestational age. 
None of these 25 DMPs were present in the term FGR cord blood, further supporting 
the  fact  that  methylation  differences  have  been  identified  unique  to  term  growth 
restricted offspring, not driven by gestational age. 
 
5.15 Functional assessment tools 
5.15.1 Term cord blood DMPs in relation to Marmal-aid database 
The  Marmal-aid  tool  was  used  to  gain  insight  into  the  functionality  of  the  839 
differentially  methylated  CpG  sites  that  we  discovered  in  cord  blood  from  FGR 
offspring born at term. The Marmal-aid output suggested that these DMPs are found 
in normally very stable unmethylated or lowly methylated gene loci consistent across 
all  blood  cell  types  (Figure  5.20).  Also,  these  same  positions  vary  little  in 
methylation status between tissue type and through ageing and are located in highly 
conserved, invariate regions of the genome (Figure 5.19). In contrast, the majority of 
growth  restricted  DMPs  was  hypermethylated,  forming  a  distinct  profile  in  FGR 
offspring.  
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Figure 5.18. Heat map incorporating the 839 DMPs from term cord blood. Cluster 1 (black) for the all samples plotted are the blood samples 
including AML. Cluster 2(red) is  everything  else in  Marmal-aid.  The  big blocks of  yellow  suggest fairly  consistent  methylation  across a 
largenumber of different tissues and disease states. Directionality of the differences observed coloured from red-blue   
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Figure 5.19 Heat map incorporating the 839 DMPs from term cord blood. Clusters of different cell types are recorded showing methylation status 
in relation to different cells of whole blood. The big blocks of yellow suggest fairly consistent methylation across a large number of different cell 
types. Chapter 5: DNA methylation in FGR offspring 
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5.15.2 Investigation of Gene function Associated with Epigenetic Dysregulation  
5.15.2.1 Term Cord Blood 
To investigate whether genes associated with the loci exhibiting epigenetic 
dysregulation in FGR cohort had potential functional roles, we used GO pathway 
analysis on the 839 term cod blood DMPs, which were linked to RefSeq-annotated 
genes. Using thresholds described in the methods section, 23 GO pathways were 
identified (Table 5.6) many of which contained DMPs identified with >10% beta 
value differences, strengthening and supporting a potential functional role for these 
DMPs. Several genes were differentially methylated in more than one position at 
CpG sites close together. The majority of these 23 pathways relate to regulation of 
gene transcription and expression and control of metabolic processes. Those with the 
greatest fold change suggest influence in regulation of DNA recombination and 
cellular processes. Transcription and regulation of RNA polymerase II is also 
overrepresented with fold change above 2.2. Embryonic development is present as 
well as CNS development and organ morphogenesis which are consistent with a fetal 
growth phenotype. Negative and positive regulation of metabolic processes 
(especially nucelobase containing and nitrogen compound metabolic processes) and 
regulation of gene expression are also represented in the most significant GO 
pathways. 
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Table 5.6 GO pathways identified through DMPs in cord blood 
 
 
GOBPID   Term   Exp 
Count   Count   Size   Odds 
Ratio  
GO:0006310   DNA recombination   6  18  183  3.05 
GO:0009987   cellular process   410  440  11554  2.6 
GO:0006357  
regulation of transcription from RNA 
polymerase II promoter   35  71  983  2.32 
GO:0006366  
transcription from RNA polymerase II 
promoter   42  82  1189  2.23 
GO:0009790   embryo development   27  53  768  2.15 
GO:0007417   central nervous system development   21  40  581  2.15 
GO:0045944  
positive regulation of transcription from 
RNA polymerase II promoter   20  39  570  2.09 
GO:0019219  
regulation of nucleobase-containing 
compound metabolic process   107  172  3012  2.03 
GO:0045934  
negative regulation of nucleobase-
containing compound metabolic process   28  51  781  2.01 
GO:0051171  
regulation of nitrogen compound 
metabolic process   110  174  3087  2.00 
GO:0032774   RNA biosynthetic process   103  165  2890  2.00 
GO:0010629   negative regulation of gene expression   27  50  771  1.99 
GO:2000113  
negative regulation of cellular 
macromolecule biosynthetic process   27  50  771  1.99 
GO:2000112  
regulation of cellular macromolecule 
biosynthetic process   99  159  2793  1.98 
GO:0006355  
regulation of transcription, DNA-
dependent   92  149  2580  1.98 
GO:0051172  
negative regulation of nitrogen 
compound metabolic process   28  51  790  1.98 
GO:0010468   regulation of gene expression   106  168  2987  1.97 
GO:0006351   transcription, DNA-dependent   100  160  2822  1.97 
GO:2001141   regulation of RNA biosynthetic process   92  149  2596  1.97 
GO:0009887   organ morphogenesis   24  44  682  1.97 
GO:0090304   nucleic acid metabolic process   139  208  3905  1.96 
GO:0010556  
regulation of macromolecule 
biosynthetic process   101  161  2851  1.96 
GO:0010558  
negative regulation of macromolecule 
biosynthetic process   28  51  798  1.96 
GO:0051252   regulation of RNA metabolic process   94  151  2651  1.96 Chapter 5: DNA methylation in FGR offspring 
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When individual assessment of the genes identified in the GO pathways was made it 
was  apparent  that  several  of  the  most  significant  DMPs  according  to  beta  value 
differences  were  also  frequently  present  in  the  pathways  identified  through  GO 
analysis. This  was  particularly  true  for  the  hypermethylated  positions  present  on 
TAF5; JARID2, HOXB4; TRPS1; FOXP1 as well as the hypomethylated positions on 
ZNF141 and ZIC1 (Table 5.7) and some of these will be discussed further in the 
discussion section.  
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GO term  Gene in pathway >10% beta value difference    
   Hypermethylated  Hypomethylated 
DNA recombination    IL27RA, FOXB1, RAD50    
cellular process    RIOK3; IL27RA;  RIT1; JARID2; TAF5; RAD50; 
HOXB4; TRPS1; RPL14; ATL2; FOXP1 
APOL1; ZNF141; 
MACROD2; ZIC1 
regulation of transcription from RNA 
polymerase II promoter    JARID2; HOXB4;TRPS1; FOXP1    
transcription from RNA polymerase II 
promoter   JARID2; TAF5; HOXB4; TRPS1; FOXP1  ZNF141 
embryo development    HOXB4; FOXP1  ZIC1 
central nervous system development    JARID2; FOXP1  ZIC1 
positive regulation of transcription 
from RNA polymerase II promoter   FOXP1    
regulation of nucleobase-containing 
compound metabolic process    IL27RA; JARID2; TAF5; RAD50; HOXB4; FOXP1   ZNF141; ZIC1 
negative regulation of nucleobase-
containing metabolic process    JARID2; HOXB4; FOXP1    
regulation of nitrogen compound 
metabolic process    IL27RA; JARID2; TAF5; HOXB4; TRPS1; FOXP1  ZNF141; ZIC1 
RNA biosynthetic process     TRPS1; FOXP1  ZIC1 
negative regulation of gene 
expression   JARID2; HOXB4; TRPS1; FOXP1    
negative regulation of cellular 
macromolecule biosynthetic process    JARID2;  HOXB4; TRPS1; FOXP1    
regulation of cellular macromolecule 
biosynthetic process    JARID2; HOXB4; TRPS1; FOXP1  ZNF141; ZIC1 
regulation of transcription, DNA-
dependent    JARID2; TAF5; HOXB4; TRPS1; FOXP1  ZNF141; ZIC1 
negative regulation of nitrogen 
compound metabolic process     IL27RA; JARID2; TAF5; HOXB4;TRPS1;  FOXP1  ZNF141; ZIC1 
regulation of gene expression    ZIC1; ZNF141; HOXB4; FOXP1; JARID2; TAF5  ZNF141; ZIC1 
transcription, DNA-dependent     JARID2; TAF5; HOXB4; FOXP1  ZNF141; ZIC1 
regulation of RNA biosynthetic 
process    JARID2; TAF5    
organ morphogenesis    HOXB4; FOXP1  ZIC1 
nucleic acid metabolic process     IL27RA; JARID2; TAF5; HOXB4; FOXP1  ZNF141; ZIC1 
regulation of macromolecule 
biosynthetic process    JARID2; TAF5; HOXB4; FOXP1  ZNF141; ZIC1 
negative regulation of 
macromolecule biosynthetic process     JARID2; HOXB4; TRPS1; FOXP1    
regulation of RNA metabolic process    JARID2; TAF5 ; HOXB4; FOXP1   ZNF141; ZIC1 
Table 5.7 53 DMPs with beta methylation values  above 10% and their presence in GO 
pathways identified Chapter 5: DNA methylation in FGR offspring 
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5.15.2.2 Placental DMPs in FGR not AGA pre-term samples 
GO pathway analysis was used on the 284 placental DMPs identified in in the 
validation step that associated only with the FGR cohort.  This yielded 16 pathways 
met the criteria for reporting. The majority of the pathways involved regulation of 
autophagy, response to oxidative stress and hormone stimuli (Table 5.8). 
 
GOBPID 
 
Odds 
Ratio 
 
Exp 
count 
 
Actual 
count 
 
Term 
GO:0016239  31.4  0.14  3  positive regulation of macroautophagy 
GO:0090026  31.4  0.14  3  positive regulation of monocyte chemotaxis 
GO:0010508  16.8  0.3  4  positive regulation of autophagy 
GO:0032312  12  0.4  4  regulation of ARF GTPase activity 
GO:0010506  9.78  0.72  6  regulation of autophagy 
GO:0006914  5.12  1.49  7  autophagy 
GO:0043627  4.24  2.31  9  response to oestrogen stimulus 
GO:0006979  4.08  3.5  13  response to oxidative stress 
GO:0031667  3.06  5.31  15  response to nutrient levels 
GO:0032870  3.05  6.07  17  cellular response to hormone stimulus 
GO:0043434  3.05  5.71  16  response to peptide hormone stimulus 
GO:0051270  2.85  6.07  16  regulation of cellular component movement 
GO:0009991  2.85  5.68  15  response to extracellular stimulus 
GO:0009725  2.49  10.6  24  response to hormone stimulus 
GO:0071495  2.46  8.35  19  cellular response to endogenous stimulus 
GO:0032879  2.04  18.4  34  regulation of localization 
 
Table 5.8 16 GO gene pathways identified in relation to DMPs in placental tissue  
 
5.16 Offspring methylation and Paternal IR 
This experiment was not powered to identify differences in the father through 
methylation status of offspring. None the less as paternal phenotype data was 
available for all offspring, analysis was run comparing paternal HOMA insulin 
resistance (IR) (as described previously in chapter 3) with methylation in offspring. 
Whilst no DMPs reached genome wide significance (when adjusted) for paternal IR 
range, 24 probes were found to be in common between placenta and cord blood of 
the top 100 hits. These are not necessarily changes in the same direction but most of Chapter 5: DNA methylation in FGR offspring 
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these 24 IR hits could be seen to represent a methylation profile influenced by a SNP 
(Figure 5.20) in the FGR offspring (not present in AGA controls).  
 
Figure 5.20 CpG profile in case and control offspring, called based on paternal IR that 
correlates between cord blood and placenta and shows apparent SNP profile (0,50% 
methylation) cg13723217 is on the ELAC1 gene and was one of the 24 DMPs identified in 
analysis 
 
The most striking examples were seen in methylation profiles for the five sites on 
PAX8 that were common to placenta and cord blood (Figure 5.21).  
 
Figure 5.21 represents overlapping DMPs in cord blood and placenta in case (blue/yellow) 
versus control (red/green) offspring showing SNP methylation profile (0, 50%, and 100%) in 
FGR offspring in PAX5.  Chapter 5: DNA methylation in FGR offspring 
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5.17 Influence of SNPs on methylation profiles 
Finally an assessment was made of the overall influence of SNP profiles in the data. 
Obviously from the example above, particularly where similarities between tissues 
were identified, then there was the potential for a SNP to influence the methylation 
profile seen. Position cg13723217 (Figure 5.21) is in extremely close proximity (1bp 
away) to the SNP rs60618945 on the ELAC2 gene with a minor allele frequency of 
0.5 (C/G) making the difference seen highly likely to be SNP driven.  
This (0%, 50%, 100% methylation) pattern of SNP profiles was not as evident in the 
839 term cord blood hits and there was no tissue overlap between cord and placenta 
again arguing against SNPs directly driving the methylation differences seen. 
To more comprehensively assess SNP influence, the next stage of analysis compared 
the DMPs identified in the 839 term cod blood hits with the current Illumina 
database of SNPs known to be able to influence methylation. This database is freely 
available from Illumina  
(http://support.illumina.com/downloads/infinium_hd_methylation_snp_list.ilmn) and 
contains more than 150,000 SNPs that have the potential to influence methylation. 
When this database was compared with the 839 DMPs, 221 positions were present in 
the Illumina SNP database (supplementary information) of which of the 53 positions 
with a beta value difference of >10%, 13 hypermethylated positions and 
hypomethylated positions were represented (Table 5.9). 
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Table 5.9  13 DMPs with beta methylation >10%,  identified in close proximity to a SNP – 
with information on distance away from and minor allele frequency as provided by Illumina 
(bp- base pairs away)
ID  Ch  Position 
UCSCRef 
Gene 
Beta 
value 
 p value  SNP rs 
Dist. 
(bp) 
Minor 
Allele 
Frequency 
cg09747578  1  46769076 
LRRC41;    
UQCRH 
0.12  9.43E-08 
728834261
/ 
115665648 
25/3
5 
0.33/ 
0.008 
cg01147107  1  47696505  TAL1  0.11  5.12E-07  57869712  1  0.08 
cg27069263  2  55278118  RTN4  0.14  1.57E-05  1348528  50  0.1 
cg05533953  4  331685  ZNF141  -0.15  1.69E-10  3749520  29  0.4 
cg21935083  5  131892314  RAD50  0.12  5.42E-07  2706335  43  0.04 
cg26542283  5  43040505  C5orf39  -0.15  2.77E-09 
77647328/ 
116073875  7/24 
0.05/0.00
8 
cg21312090  8  116681727  TRPS1  0.11  2.44E-06  76321771  5  0.05 
cg20684973  10  105127632  TAF5  0.14  5.18E-08  10883857  47  0.4 
cg23802518  10  80827482  ZMIZ1  0.14  2.47E-07  7087678  24  0.45 
cg26220528  12  57623348  SHMT2  0.11  5.92E-07  28365862  15  0.09 
cg08965527  16  84178213 
HSDL1;    
LRRC50 
0.13  6.78E-08 
78309971  25  0.03 
cg19857457  18  47018947  RPL17;   
SNORD58A  0.14  1.92E-07  4402665  12  0.41 
ch.20.327316  20  15628644  MACROD2  -0.12  8.34E-10  111615106  9  0.5 Chapter 5: DNA methylation in FGR offspring 
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 5.18 Discussion  
This study identified significant DNA methylation differences in offspring affected 
by fetal growth restriction secondary to placental dysfunction. In term cord blood the 
DMPs were found to be associated with pathways crucial to key cellular processes, 
particularly regulation of gene expression and transcription. Within the 53 DMPs 
with the greatest methylation differences several genes were co-methylated at more 
than one CpG site.  
 
Examples of genes that these DMPs were identified on include: FOXP1, whose gene 
in FGR offspring was hypermethylated in 3 places (beta methylation difference up to 
11%). FOXP1 is expressed in many tissues and is important for organogenesis, 
metabolism and immunity (Koon HB et al., 2007). RIOK3 was hypermethylated on 2 
CpG sites just 5 base pairs apart (beta values 11% and 17%). RIOK3 is an atypical 
protein kinase that interacts with caspase-10 and negatively regulates the 
transcription factor, NF-Kappa B (Shan J et al., 2009). Inhibition of NF-Kappa B 
reduces angiogenesis, but permits apoptosis amongst other key immune responses 
with the potential to compromise fetal growth and development. TAF5 was also 
hypermethylated (14%) in our FGR cases. TAF5 encodes transcription initiation 
factor TFIID subunit 5 (TFIID), which controls the initiation of transcription of RNA 
polymerase II and is crucial to the assembly and transcription initiation of DNA into 
mRNA. RNA polymerase II pathways featured heavily in the GO analysis of term 
hits. 
Another similarly hypermethylated position was Jumonji (JARID2), which is an 
important regulator of cardiovascular development (Toyoda M et al., 2000; Kim TG 
et al, 2004). Jumonji inhibits atrial natriuretic peptide (ANP) gene expression by 
inhibiting the transcriptional activities of GATA4 (Kim TG et al., 2004), which was 
also hypermethylated (7%) in our FGR cord blood. In pregnancy, ANP is essential 
for physiological changes at the maternal-fetal interface. Mice deficient in ANP 
show poor trophoblast invasion and impaired remodelling of the maternal spiral 
arteries (Cui Y et al., 2012), a characteristic of pregnancies affected by FGR. Chapter 5: DNA methylation in FGR offspring 
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Some genes were hypomethylated for example C5orf39 (Beta value -15%), which is 
unique to humans and was co-methylated in 4 positions. C5orf39 encodes Annexin II 
receptor, which is a novel activator of apoptosis (Xiong Y et al Apoptosis 2013; 18: 
925-939). Excessive cellular expression of Annexin II receptor, as may be the case 
when C5orf39 is hypomethylated, leads to apoptosis (Whitehead CL et al., 2013).  
Apoptosis and autophagy has been recognised in low birth weight offspring (Hung et 
al., 2012). In particular, low birth weight offspring that gain excessive weight have 
lymphocyte apoptosis, which interestingly correlates with insulin resistance (Barg E 
et al., 2012). 
Similar findings to this human study have been identified in an animal model of fetal 
growth restriction, (Thompson RF et al., 2010). Of the top genes, found to be 
differentially methylated in pancreatic islet cells of male rats at 7 weeks of age born 
growth restricted, almost half of those tested were associated together in a single 
functional network centred on important metabolic and cellular regulators. 
Furthermore, the majority of changes in the animal model occurred in evolutionarily 
conserved DNA sequences in proximity to genes regulating vascularization and 
insulin secretion (Thompson RF et al., 2010). 
 
Within  the  839  DMPs,  low-level  methylation  differences  in  2  imprinted  genes 
PLAGL1 and KCNQ1 were identified, but no evidence of IGF2/H19 involvement 
was found. Fetal growth restriction secondary to poor placental development appears 
not  to  be  primarily  controlled  by  imprinted  genes.  Indeed,  this  whole  genome 
approach has led to the discovery of novel differentially methylated genes associated 
with FGR secondary to poor placental development in humans.  
 
Fetal growth restriction often results in iatrogenic premature child-birth due to poor 
fetal development in utero. This leads to the dual problems of low birth weight and 
prematurity. In this study we attempted to dissect apart the influence of gestational 
age from impaired fetal growth by comparing placental data with other published 
datasets.  
The placenta is a dynamic system maturing in-utero with multiple roles critical to 
normal fetal development. When I compared DMPs from placentae in our cohort, Chapter 5: DNA methylation in FGR offspring 
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with the AGA offspring studied by Novakovic, 65% of DMPs correlated, supporting 
their  role  in  normal  feto-placental  development. The  35%  of  DMPs  that  did  not 
correlate  between  datasets  are  likely  to  be  associated  with  changes  in  a  growth 
restricted placenta. GO analysis of these DMPs identified differential methylation on 
genes  implicated  in  pathways  important  in  autophagy  and  response  to  oxidative 
stress  and  hormone  stimulus.  These  pathways  are  crucial  in  normal  placental 
development  (Jauniaux  E  et  al.,  2006)  and  the  presence  of  aberrant  methylation 
provides  evidence  for  a  fundamental  role  for  epigenetic  change  in  placental 
dysfunction response specifically in relation to oxygen and hormonal stimuli. A more 
targeted approach may be able to determine the  exact role of these differentially 
methylated regions in an FGR placenta.  
 
We  confirmed  previous  reports  of  genome-wide  hypomethylation  in  the  placenta 
(Gama-Sosa  MA.,  1983  &  Macaulay  EC.,  2011)  and,  as  reported  before  that  as 
pregnancy progresses, placental DNA becomes increasingly methylated (Schroeder 
DI et al ., 2013). It is plausible that certain placental genes need to methylate towards 
the  end  of  pregnancy  to  prevent  disproportionate  placental  and  fetal  growth  and 
obstructed labour. At term, we did not observe the placental methylation differences 
in FGR and AGA seen in earlier pregnancy, which supports the notion that given 
time, pathological influences give way to gestational influences. 
 
In a study that used the Infinium HumanMethylation27 BeadChip® platform, 206 
term  placentas  identified  22  methylation  loci  that  could  act  as  markers  for  poor 
growth (Banister CE et al., 2011). We did not replicate these methylation loci on the 
Infinium HumanMethylation450BeadChip®. It is possible that these DMPs might be 
influenced by gestational age. Of the 22 DMPs, 6 were present in the recalled second 
and  third  trimester  Novakovic  placental  dataset,  supporting  an  influence  of 
gestational age on these loci.  
 
One of the limitations when assessing whole cord blood methylation is the change in 
fetal circulating cell types as pregnancy progresses. As we studied whole blood, it is 
possible that some of the variation seen in cord blood DMPs was due to different cell 
type populations between individuals. Using Marmal-aid, it was seen that the 839 Chapter 5: DNA methylation in FGR offspring 
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DMPs (identified in whole cord blood) are normally unmethylated across cell types 
within whole blood. This supports the idea that cell type is not the underlying reason 
for the differences seen in growth restricted whole cord blood.  Furthermore, at term, 
gestational ages were closely matched between cases and controls and changing cell 
composition  due  to  gestation  is  unlikely  to  have  an  impact.  However,  cell 
composition is likely to play an important role in the 76,249 DMPs from cord blood 
of pre-term FGR offspring.  
 
It is unknown whether methylation differences are a cause or a consequence of fetal 
growth restriction. Having identified DMPs that are associated with FGR irrespective 
of gestational age, a more targeted approach may be able to determine the role of 
these methylated regions. The permanence of these DMPs has not been addressed in 
this  study.  However,  DMPs  in  newborn  cord  blood  at  the  moment  of  early 
independent  life,  provides  evidence  that  at  least  some  of  these  marks  have  the 
potential for persistence into later life.  Follow up studies that reassess the children 
born with FGR would determine if DMPs identified at birth have endured into later 
life and influence vulnerability to adult disease.  
 
 
 
5.19 Summary  
Using  the  HumanMethylation450  BeadChip,  839,  predominantly  hypermethylated 
DMPs were identified in DNA from umbilical cord blood of fetal growth restricted 
offspring at  term. These DMPs  were shown to  be predominantly  driven  by  fetal 
growth rather than gestational age and that these differentially methylated genes have 
fundamental  roles  in  controlling  gene  regulation  and  transcription  related  to 
important  metabolic and vascular  functions. Altered  expression of these genes  in 
utero that endures in to later life might explain the predisposition of growth restricted 
offspring to adult disease. These observations provide a robust platform for further 
studies into the functional consequences of DMPs in fetus and placenta of growth 
restricted offspring.  
   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
203 
   
 
 
 
 
 
Chapter 6 
 Genetic-Epigenetic 
interactions in Growth 
Restricted Offspring 
 
 
 
 
 
   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
204 
   
Chapter 6: Genetic-Epigenetic Interactions in Growth 
Restricted Offspring 
 
6.1 Introduction 
Recent studies have begun to explore the interplay between genetic and epigenetic 
modifications. For example, SNPs that create or destroy CpG sites clearly have the 
ability to influence methylation status (Schalkwyk LC et al., 2010). Methylation 
variation as a direct consequence of genetic variation could be the route through 
which pathology emerges. The mechanism by which many of the T2DM risk SNPs 
cause disease is unknown but differential methylation on these genes is one 
possibility which may also provide new insight into how MODY gene mutations 
influence the methylome; ultimately resulting in increased risk of T2DM and 
cardiovascular disease.  
PDX-1 is a gene that has been recognised as being associated with MODY (Naylor R 
et al., 2007).  An animal model has shown that PDX-1 silencing through differential 
methylation leads to growth restriction and T2DM (Park JH et al., 2008). It is 
possible that genetic variation could be driving epigenetic modifications in key 
regulating genes, the result of which being growth restriction and later T2DM  in the 
individual.   
 
 
In this chapter I firstly identified SNPs associated with T2DM which have the 
potential to influence methylation and T2DM risk. The aim was to correlate 
methylation change to the presence or absence in FGR offspring sampled.   
Novel/ rare genetic variants present in FGR offspring are more likely to directly 
affect function, or influence methylation, which in turn may lead to functional 
change. Therefore, the variants identified in Chapter 4 in growth restricted offspring 
are of particular interest in the search for underlying mechanisms that may be 
important in the  pathogenesis of FGR.    Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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In this chapter, therefore, I also sought to identify whether there was any evidence of 
genetic-epigenetic interactions between genetic variants identified in FGR offspring 
and DNA methylation obtained from the same FGR cohort. 
 
6.2 Hypothesis 
Genetic variants influence the state of DNA methylation in areas of the genome 
involved in control of transcription and expression of genes and regulation of 
metabolic processes. As a result, aberrant interaction can lead to poor fetal growth.  
 
6.3 Specific aims  
1.  To investigate the degree of influence of all known SNPs on differential 
methylation identified in FGR offspring. Within this aim, further characterise 
influence of risk SNPs in metabolic processes previously investigated in this 
thesis. 
2.  Investigate  any  epigenetic-genetic  interactions  with  novel/rare  candidate 
genetic variants identified of interest in FGR offspring. 
6.4 Methods 
Firstly, overlap between T2DM risk SNPs/ MODY genes and DNA methylation was  
explored using the 839 term cord blood DMPs identified.  
In order to assess the role of genetics and the influence of SNPs on methylation 
status, interaction between known SNPs in the Illumina SNP database and the 839 
term cord blood DMPs identified in table 5.10 was assessed. Exome data was  used 
where applicable to identify whether the relevant SNPs were present in the individual 
term offspring. 
Novel and rare variant calls from the 10 whole exomes of FGR offspring (identified 
as previously described in Chapter 4) were analysed using the 839 term cord blood 
DMPs as a filter in the Ingenuity Pathway Analysis. Methylation was introduced in 
the form of a 5 line bed file incorporating chromosome position as a unique 
identifier. This file was uploaded to Ingenuity software and amalgamated into the 
output.    Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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6.5 Results 
6.5.1 SNP data in relation to exome 
Of the 839 cord blood hits in FGR offspring, 221 SNPs by Illumina were identified 
that are in close proximity and could influence methylation (data not shown). A more 
structured approach was sought to assess genetic-epigenetic interactions that might 
be important in FGR. Only those methylation differences that had the greatest beta 
value difference (as identified in section 5.9) and hence had the most functional 
potential.  
Of the 53 DMPs with a beta value difference of more than 10%, 13 were present in 
the Illumina SNP list (Table 6.1).  
Next, using the exome data from individual samples, the presence of the relevant 
SNP was investigated.  Exome data from all term offspring (that were also included 
in the methylation array) were assessed. This meant that 6 of the exomes could be 
used. 
ID  CHR  MAPINFO  UCSCRef   B value   p value  SNP rs 
Distance 
From 
SNP (bp)  
MAF 
cg09747578  1  46769076 
LRRC41;    
UQCRH 
0.12  9.43E-08  728834261/ 
115665648  25/35 
0.33/ 
0.008 
cg01147107  1  47696505  TAL1  0.11  5.12E-07  57869712  1  0.08 
cg27069263  2  55278118  RTN4  0.14  1.57E-05  1348528  50  0.1 
cg05533953  4  331685  ZNF141  -0.15  1.69E-10  3749520  29  0.4 
cg21935083  5  131892314  RAD50  0.12  5.42E-07  2706335  43  0.04 
cg26542283  5  43040505  C5orf39  -0.15  2.77E-09  77647328/ 
116073875 
7/ 
24 
0.05/ 
0.008 
cg21312090  8  116681727  TRPS1  0.11  2.44E-06  76321771  5  0.05 
cg20684973  10  105127632  TAF5  0.14  5.18E-08  10883857  47  0.4 
cg23802518  10  80827482  ZMIZ1  0.14  2.47E-07  7087678  24  0.45 
cg26220528  12  57623348  SHMT2  0.11  5.92E-07  28365862  15  0.09 
cg08965527  16  84178213 
HSDL1;    
LRRC50 
0.13  6.78E-08 
78309971  25  0.03 
cg19857457  18  47018947 
RPL17;   
SNORD58A 
0.14  1.92E-07 
4402665  12  0.41 
ch.20.327316F  20  15628644  MACROD2  -0.12  8.34E-10  111615106  9  0.5 
 
Table 6.1 Thirteen DMPs within top beta value table (n=53) that were present on Illumina 
SNP list. Table includes distance of the methylation position from the SNP as well as the 
MAF- minor allele frequency of the SNP   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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However, of these 13 DMPs only 4 on the genes ZN141, SHMT2, RPL17 and 
C5orf39 were located within exomes or sequence that was captured within the exome 
dataset.  
All 6 exome samples were assessed for recognition of these 4 SNPs. None of the 
samples contained evidence of these particular SNPs. Whilst this provides some 
evidence that these SNPs are not driving methylation on these particular positions, 
further interpretation of the influence of other SNPs on the methylation profile 
cannot be made. The majority of the 839 DMPs (including a majority 44/53 of top 
hits), however, either do not have recognised SNPs within them or have been ruled 
out as being SNP driven through exome data. This provides further support that the 
methylation differences seen in term cord blood are not due to SNPs. 
6.5.2 T2DM risk SNPs identified in FGR cohort and influence on methylation 
status 
In order to assess any methylation influenced change secondary to the presence of 
T2DM risk SNPs, differential methylation in FGR offspring in relation to the 16 
T2DM SNPs identified through the exome data was investigated. None of the SNPs 
identified through exome data overlapped (within 1000bp) with the 839 DMPs 
identified in term cord blood.  There was no evidence in this cohort of T2DM risk 
SNPs influencing methylation, however, a number of T2DM risk SNPs are intronic 
and it was not possible in this study to investigate these interactions.  
6.5.3 MODY genes and methylation status 
Within the 839 term cord blood DMPs, there was no overlap with MODY gene 
variants identified in the exome data. Of the 839 DMPs, positions on PDX-1 (beta 
value difference in FGR offspring 3%), PLAGL1 (identified on two positions at 8% 
and 4% difference) and KCNQ1 (8% difference) were identified in FGR offspring 
but no new variants of interest were located on these genes. PLAGL1 and KCNQ1 
have been implicated in presentations of neonatal diabetes and are known to be 
imprinted genes.   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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6.5.4 Novel genetic variants and differential methylation  
Having explored the interaction between T2DM risk SNPs and MODY gene variants 
with DNA methylation interactions and discovering no convincing associations, the 
next stage in the analysis involved assessing potentially novel variants and the 
presence of differential methylation.   
Two approaches were undertaken with input from Ingenuity software analyst Tim 
Morewood, Dr Chiara Bacchelli (UCL) and Chris Mathews (QMUL).  
The gene on which the novel/rare variant was identified through Ingenuity Pathways 
Analysis was assessed against the 839 DMPs identified in term cord blood.  
From the first analysis within the novel gene variants, 2 differentially methylated 
positions were identified on the same gene in two instances; KDM4B and RPL14. 
The methylation position on KDM4B was located more than 100,000 bases away 
from the novel insertion but the methylation position on RPL14 was 4880bp away 
from the polymorphism identified from exome data.  
 
The 839 DMPs were then input as a text file into Ingenuity and used as a filter. 
Firstly, a window of 10000bp around each of the 839 DMPs was also generated and 
uploaded as a 5 line .BED file.  This methylation window was connected to one of 
the 71 gene variants (identified by Ingenuity in Chapter 4) if its chromosome position 
was contained within the 10000bp window.  
 
The 839 methylation positions were uploaded to Ingenuity. In this analysis one 
different filter was set in order to incorporate regions around the exome that had been 
captured (as the methylation array had more extensive coverage across the whole 
genome than just exomes) which meant that 214 variants were assessed against the 
839 methylation positions. A window of 10000bp around the methylation position 
was first used which yielded 9 hits (Table 6.2 below). The majority of these positions 
were found to be in promoter and 3’UTR regions of the genome. When a more 
stringent window of 1000bp around the variant was used then only 2 of these 
methylation positions were found to overlap a variant (CLASP1 and BCL11A) which   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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were both in promoter regions and hence not identified in the original variant 
analysis.  
Position 
Gene 
Region  Gene Symbol 
Regulatory 
Site 
File 2: 
Methyl 
10000  
bp 
distance 
File 3: 
Methyl 
1000 
33286389 
3'UTR; 
Promoter  ZBTB22; DAXX  Promoter Loss  33292028  5639 
 
33286402 
3'UTR; 
Promoter  ZBTB22; DAXX  Promoter Loss  33292028  5626 
  40503520  Exonic  RPL14 
 
40498640  4880 
  57301820  Promoter  PAICS; PPAT  Promoter Loss  57303156  1336 
  60780662  Promoter  BCL11A  Promoter Loss  60781128  466  60781128 
69599088  Promoter  NFAT5  Promoter Loss  69600792  1704 
  69599097  Promoter  NFAT5  Promoter Loss  69600792  1695 
 
1.21E+08  3'UTR  INHBB 
microRNA Binding 
Site  121116384  7410 
  1.22E+08  Promoter  CLASP1  Promoter Loss  122407280  225  60781128 
 
Table 6.2. Potentially interacting genetic variants and DMPs from cohort of FGR 
offspring. Table includes positions of gene variants and DMP and distance apart- file 
2 refers to distance of <10000bp and file 3 refers to a distance <1000bp. 
 
6.5.5 Manual annotation of 53 DMPs in FGR cord blood with 71 novel gene 
variants 
A final approach was undertaken incorporating the list of 53 most differentially 
methylated positions and 71 novel variants and performing a manual literature search 
in order to identify any potential interactions between a genetic variant and 
methylation change not previously identified through pathway analysis. 
   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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The TATA-binding protein (TBP) gene variants were identified as of interest in 
relation to the DMP identified in term cord blood TBP associated factor 5 (TAF5). 
TBP is part of the transcription factor IID (TFIID) protein, required to coordinate 
initiation of transcription by RNA polymerase II (RNAPII) by binding to the core 
promoter to position the polymerase correctly. TFIID is composed of the (TBP) and a 
group of evolutionarily conserved proteins known as TBP-associated factors or 
TAFs.  
 
6.6 Discussion 
Epigenetic modifications secondary to genetic variations offer a novel pathway for 
disease development.  In this study methylation differences seen in our FGR 
offspring term cord blood do not seem to be driven by common SNPs. There was no 
evidence of a correlation between T2DM risk SNPs or MODY gene variants with 
methylation differences. Caution must be applied to negative findings, however, due 
to the lack of whole genome comparison with the methylation array data. 
 
Novel genetic mutations identified in FGR offspring yielded limited useful insights, 
correlating loosely with some of the DMPs identified in the cord blood of FGR 
offspring. The TBP variant present in FGR offspring has the potential to be 
interacting with TAF5 and provides a plausible argument for genetic variation having 
the potential to impact methylation status. Given the important role that TAFs play in 
the control of gene transcription and expression this opens up the possibility of a 
functional effect. TAFs participate in basal transcription, serve as co-activators, 
function in promoter recognition or modify general transcription factors (GTFs) to 
facilitate complex assembly and transcription initiation (Hampsey M et al., 1998). 
The structure of GTFs is dynamic and differences in subunit composition affect 
conformation (Coleman RA et al., 2008). 
Extensive work has been undertaken to understand the interplay between TAF and 
other components in order to provide insight into how transcriptional regulation 
might help direct growth and development of organisms (Tora L et al., 2002).   Chapter 6: Genetic-epigenetic interactions in FGR offspring 
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Transcription of protein coding genes and most small nuclear RNA (snRNA) genes 
is performed by RNA polymerase II (RNAPII). Synthesis of pre mRNA by RNAPII 
involves assembly of a transcription pre initiation complex (PIC) at the promoter. 
The PIC is made of RNAPII and general transcription factors (GTFs) including 
TFIID. Recently, TAF5 has been identified as the only TAF present on the promoter 
of the snRNA genes suggesting a unique role for TAF5 in transcriptional regulation 
of snRNAs (Zaborowska J et al., 2012). 
Conformational change in TBP may be affecting the ability of TAFs to interact 
thereby influencing the ability of GTF complexes to regulate RNA polymerase II 
initiated transcription. In relation to our FGR offspring, a specific interaction with 
conformational TBP change, TAF5 methylation difference and snRNA transcription 
warrants further investigation. 
 
6.7 Summary 
This study has provided little evidence of SNP driven methylation differences 
influencing FGR phenotype. However, limited coverage of genome by using WES 
means further study is needed in order to provide convincing evidence that SNP 
driven change is not relevant in the distinct methylation profile identified in FGR 
offspring.  
Genetic variation in TBP and the TAF5 methylation change identified in the FGR 
offspring provide an interesting avenue of investigation in relation to individuals 
affected by  FGR. 
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Chapter 7: General Discussion and Future Aims  
 
 
7.1 Key findings of the research and conclusions 
 
This work has identified that men who father growth restricted offspring have a 
distinct phenotype at the time of the index pregnancy that will predispose them to 
T2DM. These findings are consistent with previous epidemiological evidence that 
shows that men with T2DM are more likely to have fathered low birth weight 
offspring (Davey Smith G, 2004 et al.; Wannamethee SG et al., 2004, and Hypponen 
E et al., 2003). 
 
Identification that men have a metabolic phenotype, characterised by insulin 
resistance and central adiposity, at the time of an affected pregnancy, provides new 
avenues of investigation into the way in which a paternal phenotype, expressed 
through a genotype may lead to FGR in his offspring.  
 
A paternal genetic influence on fetal growth is strongly suggested by the fetal insulin 
hypothesis. In my thesis, I provide direct evidence for a genetic influence on FGR.  
Rare genetic variants were identified in genes important in Maturity Onset Diabetes 
of the Young (MODY) in FGR offspring. However, transmission was not exclusively 
paternal in origin. A combined parental genetic influence along with the additive 
effects of more than one gene variant appears likely.  
The identification of MODY gene variants, did not explain the majority of fetal 
growth restriction in the cohort studied.  Furthermore, investigation of the SNPs 
common to T2DM and other insulin resistant syndromes did not provide support for 
their direct involvement in FGR; a finding consistent with other reported work. 
 
Epigenetic modifications to the genome were investigated in FGR offspring cord 
blood and placenta. FGR offspring were phenotypically homogenous, with placental 
dysfunction thought to underlie the cases recruited. Study of both the placenta and Chapter 7: General Discussion and Future Aims 
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fetus was, therefore, important in order to identify specific methylation patterns 
within each tissue that could result in a growth restricted fetus.  
DNA methylation in cord blood of term growth restricted fetuses revealed a distinct 
pattern, different to the methylation in the placenta of growth restricted individuals 
(across a range of gestational ages). The findings in my thesis support both the 
importance of epigenetic dysregulation in growth restriction and the fact that this 
dysregulation has a separate and distinct pattern in placenta and fetus.  
 
It is likely that gestation specific DNA methylation occurs in the placenta in order to 
facilitate normal fetal growth. Several reports support a recognised reproducible 
placental methylation pattern that is gestation specific (Gama Sosa et al., 1993 and 
McCauley et al., 2011), which was confirmed in my work. Deviation from a healthy 
gestation specific methylation profile may lead to a hostile placental environment 
and sub-optimal fetal growth and development. Conversely a sub-optimal in-utero 
environment might drive the placental methylation change. The design and strength 
of my study meant that mothers in both the FGR and AGA groups were selected, and 
shown, to have similar phenotypic, metabolic and vascular characteristics with no 
underlying maternal reason for FGR development, other than placental dysfunction. 
This makes it less likely that a hostile in-utero environment (per se) is the primary 
driving force behind the pathogenesis of the FGR in this cohort. This does not 
exclude the in-utero environment from playing an important role; it just supports the 
concept that in this particular presentation of FGR it is more of a consequence of 
primary genetic/epigenetic influences. 
The work in my thesis has sought to provide evidence for novel gene variants that 
could be driving the differential methylation identified in FGR offspring. 
 
The insertion on KDM4B was shown to be present in a majority of the FGR offspring 
sampled, however, further investigation revealed  it was also found in controls. 
Hence this particular variant is not likely to be of significance in my FGR cohort. 
However, the KDM4B gene is part of the JmJ complex of genes, recently identified 
as having histone demethylase activity. It is normally up-regulated in the presence of 
activated hypoxia inducible factor 1 (HIF1). Activation of HIF1 occurs in the 
presence of hypoxia in the tissues and so, during normal early placentation it is up-
regulated in response to the relatively hypoxic in-utero environment. This function Chapter 7: General Discussion and Future Aims 
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means this family of genes are still interesting candidates in FGR and may play a role 
in fetal growth in conjunction with other pathways.  
 
In normal pregnancy, extra villous trophoblast (EVT) cells invade spiral arteries and 
replace the vascular endothelial cells (Pijnenborg et al., 1980). This remodelling 
dilates spiral arteries and increases utero-placental blood flow. Despite the utero-
placental oxygen concentration being as low as 2% in early pregnancy (Jauniaux E et 
al., 2001), remodelling can occur with the appropriate response from HIF1. Failed 
remodelling and poor EVT invasion, which is the classic pathology seen in placental 
pregnancy syndromes, is therefore thought not to be directly due to oxygen 
availability, but rather the ability of the placenta to adapt to the low oxygen 
conditions. 
A placenta, unable to respond appropriately to hypoxia will develop oxidative stress 
(Burton G & Jauniaux E, 2011). Part of the response to oxidative stress involves an 
abnormal autophagy response (Hung et al., 2012). In my thesis I have shown 
placental methylation differences in genes associated with the autophagy response, 
along with response to oxidative stress and hormonal stimuli. It is plausible that 
genetic variants in the hypoxia-signalling pathway may impair the ability of a fetus 
(and placenta) to compensate for hypoxia. DNA methylation is thus altered in genes 
responsible for autophagy in the placenta thereby influencing the development of 
placental dysfunction with subsequent compromise of fetal growth. Increased 
autophagy proteins have been identified in FGR placentas (Hung et al., 2012).  My 
findings of altered placental DNA methylation of autophagy genes in FGR placentas 
and the evidence of altered autophagy protein expression shown in other studies, 
provides  a novel connection between methylation change and functional effect that 
could explain the dysregulation seen in FGR placentas.  
 
It is conceivable, that the methylation profile seen in FGR offspring cord blood is 
essentially the downstream product of the effects on the placenta during gestation. 
Persistence of cord blood (fetal) methylation differences in these offspring may 
provide a mechanism by which growth restricted individuals are more susceptible to 
adult cardio-metabolic disease. 
The identification of methylation change in TAF5 along with insertion of CAG 
sequences in TBP again opens up the possibility that genetic variants may be driving Chapter 7: General Discussion and Future Aims 
216 
   
methylation change with subsequent functional consequences. It remains to be 
proved that the methylation difference seen in term cord blood has a functional 
effect. However, if variation in TBP is the cause of the methylation difference in TAF 
seen in FGR cord blood then this may provide both the reason for the methylation 
difference and a pathway that confers increased T2DM risk in adults, affected by 
growth restriction.  
 
FGR cord blood yielded a different methylation profile to that of the placenta. It can 
be argued that the epigenetic processes occurring in the placenta are critical to 
placental function and in-utero fetal growth but that the cord blood changes seen in 
the fetus at term are the adaptive response to a poor in-utero environment and are 
more likely to influence the consequent risk of adult cardio-metabolic disease. The 
finding that cord blood methylation differences correspond to pathways important in 
gene regulation, transcription and expression, supports the concept that they have the 
potential to have a profound functional effect.  
 
 
7.2 Future Work   
This thesis has yielded many new avenues for investigation in fetal growth restriction 
(FGR). FGR is an important clinical problem to tackle; its consequences are 
significant both for short and long term outcome of affected offspring. 
 
This  work  identifies  paternity  of  FGR  offspring  as  a  novel  risk  factor  in  male 
diabetes and heart disease. Through the proxy marker of low birth weight offspring, 
fathers were identified who are at risk of developing cardio-metabolic disease later in 
life. Primary prophylaxis through altered diet and lifestyle may protect these men 
from progression towards T2DM disease development particularly if they are also 
overweight (Chae JS et al., 2012). 
It would be useful to establish whether the findings in this work hold true if the 
inclusion criteria are widened. A well-designed prospective study investigating all 
couples who have a baby born at a  <10
th customised birthweight centile would Chapter 7: General Discussion and Future Aims 
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identify whether fathers of these pregnancies have a reproducible phenotype. The 
potential for primary prevention is substantially increased if these findings can be 
applied generically to a male population who father a small baby. It would also pave 
the way for a postnatal program of referral for men, similar to that provided for 
women who suffer from gestational diabetes during their pregnancy due to their 
increased risk of subsequent diabetes development (Bellamy L et al., 2009).   
 
It remains to be known whether reproductive outcomes can be improved if a father 
loses weight before conceiving a second pregnancy. Optimising periconceptual 
paternal health is a novel concept worthy of investigation in order to minimise the 
risk of an adverse pregnancy outcome. A study investigating reproductive outcomes 
in men post interventions that reduce their risk for diabetes may provide evidence. 
Clearly, a purely genetic risk transmission from father to offspring is not likely to be 
affected by weight loss but potential trans-generational epigenetic mechanisms may 
be affected by paternal weight loss and a phenotypic study such as proposed would 
support this concept.   
 
If it proves to be the case that moderating paternal behaviour prior to conception, or 
in between pregnancies, has a positive effect on reproductive success this has far 
reaching implications in pre-conception advice that should be provided to couples. 
The finding in this thesis that men who smoked were more likely to have a growth 
restricted offspring is one example of a mechanism for which further investigation is 
warranted in order to identify if moderating this behaviour (i.e. stopping smoking)  
improves offspring birthweight. If it proves to be the case then investigation, of how 
paternal smoking translates to poor fetal growth, is warranted.   
 
The identification of rare genetic variants in FGR offspring has the potential to 
strongly support a genetic component in FGR. This finding needs further functional 
validation in order to definitively prove a role for MODY gene variants in growth 
restriction. However, the success of using WES in order to capture these genetic 
variants suggests a future role for next generation platforms in uncovering new 
avenues of investigation in FGR.  
Young adults born SGA have a different metabolic profile than those born AGA 
(Longo S et al., 2013) but MODY is not often considered. A follow up study of FGR Chapter 7: General Discussion and Future Aims 
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children is needed, specifically designed to provide evidence of whether these 
children go on to develop MODY. This could provide a novel screening opportunity 
in children who have been affected by FGR. Furthermore,  identifying FGR offspring 
with MODY gene variants and following them up as adults, whilst time consuming, 
would provide comprehensive evidence of a pluripotent phenotype in MODY which 
includes growth restriction.  
 
The DNA methylation data generated through the use of the 450K array strongly 
supports the use of next generation platforms in investigating epigenetic 
modifications in the genome. This thesis identified novel methylation patterns in 
term cord blood and placenta from growth restricted offspring. Aberrant 
hypermethylation in the cord blood corresponded to regions of the genome 
implicated in gene expression and transcription regulation. Placental hits centred on 
response to oxygen, nutrients and hormones and regulation of autophagy. These 
methylation findings need to be directly connected to functional significance. 
Knowing the pathways affected means that a functional study can be planned to 
better assess the consequences of aberrant methylation. Such a study may provide 
novel insights into ways in which FGR prevention can be achieved. If methylation is 
part of a pathway responding to genetic and/or environmental cues then interrupting 
the sequence of events that leads to aberrant methylation may affect subsequent 
outcome.  
Within my investigation of DNA methylation, changes within histones were 
apparent. It would be very useful to study histone modifications in FGR in 
conjunction with DNA methylation patterns. It is likely that the histone 
modifications together with aberrant methylation may result in FGR. 
 
Genetic variants in hypoxia signalling genes could be causing a functional defect, 
which influences the placental response to oxygen. Impaired sensing leads to altered 
DNA methylation and histone modification in placental genes related to autophagy 
and oxidative stress. Consequent fetal growth restriction occurs and is reflected in 
aberrant DNA methylation in genes regulating key cellular processes in cord blood 
seen in the neonate at birth. 
Functional studies need to be performed to assess this hypothesis and to provide 
evidence that the downstream result will be impaired fetal growth. Chapter 7: General Discussion and Future Aims 
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Other genetic variants in the hypoxia signalling pathway, particularly those 
responsible for the placental response to hypoxia, need to be investigated for their 
potential influence on epigenetic change within a placenta and subsequent effect on 
fetal growth.  
 
 
7.3 In summary  
This thesis provides evidence of a distinct paternal phenotype in FGR related to 
placental dysfunction. There is evidence for a paternal genetic effect in FGR 
offspring but this does not explain the majority of cases.  
 
Rare gene variants were identified in growth restricted offspring through whole 
exome sequencing. Distinct DNA methylation profiles were also identified in 
placenta and cord blood of FGR offspring.  These findings support the possibility 
that genetic variants in glucose sensing and/or hypoxia signalling pathways are 
driving epigenetic change at the level of the placenta which is affecting fetal growth. 
 
Placental methylation patterns correspond to pathways related to hypoxia response 
and term cord blood methylation differences were seen on genes critical in the 
regulation of gene expression and transcription. This suggests that DNA methylation 
has a crucial role to play in fetal growth.  Persistence of these epigenetic marks in 
FGR offspring would support their role in susceptibility to future T2DM. 
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APPENDIX 3 
DATABASES AND BIOINFORMATICS USED IN ASSESSMENT 
Various bioinformatic tools and databases were used in this study in order to identify 
polymorphic markers and characterise genes within the region.  The main sites used 
for this study were as follows: 
 
BLAST (www.ncbi.nlm.nih.gov/blast/) 
Ensembl Genome Browser (http://www.ensembl.org/)  
ExPASy (http://www.expasy.org). 
GDB Human Genome Database (http://www.gdb.org/) 
Gene ontology( http://www.geneontology.org) 
Mammalian Genotyping Service (http://research.marshfieldclinic.org/) 
Marmal-aid (http://marmal-aid.org) 
NCBI database (http://www.ncbi.nlm.nih.gov/) 
NCBI SNP database (http://ncbi.nlm.nih.gov/SNP/) 
OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM) 
UCSC Genome Browser (http://genome.ucsc.edu/)  
UniGene (NCBI, http://www.ncbi.nlm.nih.gov/) 
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APPENDIX 4 
SUPPLEMENTARY INFORMATION 
 
Sample ID 
Qubit 
ng/ul 
Nanodrop 
ng/ul   A260   A280   260/280   260/230  
Vole 
ul left 
Total 
ng 
187EHa  482  534.32  10.686  5.873  1.82  2.33  30  14460 
190LFa  543  578.31  11.566  6.42  1.8  2.31  30  16290 
255OAa  333  373.38  7.468  4.012  1.86  2.47  30  9990 
331MBV  341  381.68  7.634  4.256  1.79  2.27  47  16027 
337ECb  115  128.31  2.566  1.352  1.9  2.39  47  5405 
359KCb  389  413.52  8.27  4.58  1.81  2.33  47  18283 
386SSa  204  226.87  4.537  2.462  1.84  2.27  47  9588 
39NK  126  131.94  2.639  1.418  1.86  2.35  47  5922 
392DGa  255  280.26  5.605  3.047  1.84  2.36  47  11985 
395MHa  190  199.01  3.98  2.155  1.85  2.37  47  8930 
413BTa  264  274.74  5.495  2.99  1.84  2.39  47  12408 
421YDc  92.30  100.52  2.01  1.076  1.87  2.3  47  4338.1 
447VXaa  54.90  51.95  1.039  0.563  1.85  1.96  47  2580.3 
47KWaa  61.80  64.98  1.3  0.7  1.86  2.22  47  2904.6 
50STa  177  164.52  3.29  1.747  1.88  2.3  47  8319 
53ALa  119  137.22  2.744  1.492  1.84  2.29  47  5593 
56SWa  175  200.15  4.003  2.164  1.85  2.38  47  8225 
009REaa  70.60  84.7  1.694  0.921  1.84  2.21  47  3318.2 
227FBa  153.00 170.44  3.409  1.851  1.84  2.36  47  7191 
3IH  114.00 133.18  2.664  1.46  1.82  2.12  47  5358 
398IRbb  58.70  62.25  1.245  0.677  1.84  1.98  47  2758.9 
156BTa  58.30  64.19  1.284  0.701  1.83  2.23  47  2740.1 Appendix  
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156BTc  74.50  82.9  1.658  0.886  1.87  2.27  47  3501.5 
178JSa  21.10  25.12  0.502  0.29  1.73  1.97  47  991.7 
178JSb  59.60  67.8  1.356  0.732  1.85  2.06  47  2801.2 
328LBa  83.80  82.46  1.649  0.91  1.81  2.13  47  3938.6 
328LBb_2 79.10  81.92  1.638  0.896  1.83  2.23  47  3717.7 
334MVa  75.10  86.28  1.726  0.925  1.87  2.34  47  3529.7 
334MVb  81.40  90.39  1.808  0.991  1.82  2.26  47  3825.8 
95EGb  105  110.77  2.215  1.196  1.85  2.33  47  4935 
95EGc  69  69.7  1.394  0.744  1.87  2.32  47  3243 
S1 DNA Quality Check readings on case offspring samples 
 
Assay  Gene  rs 
1  ABCC8  757110 
2  ALDHIL1  1127717 
3  BMP2  235768 
4  CEL  62576769 
5  GCKR  1260326 
7  HNF1A  2464196 
9  HNF1B  141193981 
10  HNF4A  736823 
11  KCNJ11  5215 
12  KCNJ11  5218 
13  KCNJ11  5219 
14  KCNJ11  1800467 
15  NEUROD1  1801262 
16  NOTCH2  147223770 
17  PPARG  1801282 
18  SLC2A2  5400 
19  SLC30A8  1326663 
20  THADA  7578597 
21  WFS1  734312 
22  WFS1  1801214 
23  WFS1  35031397 
24  INSR   1799817 
S2 Genotyping assays designed and tested. Gene name and rs number as 
identified through dbSNP 130 and 135.Appendix  
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SNP  Gene  Population  Trait 
Risk Allele Freq 
in Controls 
OR/Beta [95% CI]  First Author. Journal; Published Year 
   ABCC8     NDM        Johansson et al. Plos One; 2013 
rs4607103  ADAMTS9  European  T2D GWAS   C[0.76]  1.09[1.06–1.12]  Zeggini et al. Nat Genet; 2008  
  
ADCY5 
  
Birth weight 
GWAS        Horikoshi M et al. Nat Genet; 2013 
  
ADRB1 
  
Birth weight 
GWAS        Horikoshi M et al. Nat Genet; 2013 
   AGPAT2     Syndrome        Johansson et al. Plos One; 2013 
rs1127717  ALDHIL1     Syndrome        Johansson et al. Plos One; 2013 
   ALMS1     Syndrome        Johansson et al. Plos One; 2013 
   APPL1     Candidate        Johansson et al. Plos One; 2013 
rs1552224  ARAP1  European  T2D GWAS  A[NR]  1.14[1.11–1.17]  Voight et al. Nat Genet; 2010  
rs243021  BCL11A  European  T2D GWAS  A[NR]  1.08[1.06–1.10]  Voight et al. Nat Genet; 2010  
rs235768  BMP2     Syndrome        Johansson et al. Plos One; 2013 
   CAV1     Syndrome        Johansson et al. Plos One; 2013 
  
CCNL1 
  
Birth weight 
GWAS        Horikoshi M et al. Nat Genet; 2013 
rs12779790 
CDC123, 
CAMK1D 
European  T2D GWAS  G[0.18]  1.11[1.07–1.14]  Zeggini et al. Nat Genet; 2008  
rs7754840  CDKAL1  European  T2D GWAS  C[0.36]  1.12[1.08–1.16]  Horikoshi M et al. Nat Genet; 2013 
rs564398 
CDKN2A, CD-
KN2B 
European  T2D GWAS  T[0.56]  1.13[1.08–1.19]  Zeggini et al. Science; 2007  
rs7018475  CDKN2B  European  T2D GWAS  ?[NR]  1.35[1.18–1.56]  Huang J et al. Eur J Hum Genet; 2012 
   CEL  62576769             
rs13292136  CHCHD9  European  T2D GWAS  C[NR]  1.11[1.07–1.15]  Voight et al. Nat Genet; 2010  
   CISD2/WFS2     Syndrome        Johansson et al. Plos One; 2013 Appendix  
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rs5945326  DUSP9  European  T2D GWAS  G[NR]  1.27[1.18–1.37]  Voight et al. Nat Genet; 2010  
   EIF2AK3     Syndrome        Johansson et al. Plos One; 2013 
   FOXA1     Candidate        Johansson et al. Plos One; 2013 
   FOXA2     Candidate        Johansson et al. Plos One; 2013 
   FOXA3     Candidate        Johansson et al. Plos One; 2013 
rs8050136  FTO  European  T2D GWAS  A[0.4]  1.23[1.18–1.32]  Zeggini et al. Science; 2007  
   FXN     Syndrome        Johansson et al. Plos One; 2013 
   GATA4     Candidate        Johansson et al. Plos One; 2013 
   GATA6     Candidate        Johansson et al. Plos One; 2013 
   HFE     Syndrome        Johansson et al. Plos One; 2013 
rs1111875  HHEX  European  T2D GWAS  C[0.52]  1.13[1.09–1.17]  Scott et al. Science; 2007  
rs1531343  HMGA2  European  T2D GWAS  C[NR]  1.1[1.07–1.14]  Horikoshi M et al. Nat Genet; 2013  
rs7957197  HNF1A  European  T2D GWAS  T[NR]  1.07[1.05–1.10]  Voight et al. Nat Genet; 2010  
rs4430796  HNF1B  European  T2D GWAS  G[NR]  1.14[1.08–1.20]  Voight et al. Nat Genet; 2010  
rs4402960  IGF2BP2  European  T2D GWAS  T[0.3]  1.14[1.11–1.18]  Scott et al. Science; 2007  
rs1799817  INSR      Candidate        Johansson et al. Plos One; 2013 
rs7578326  IRS1  European  T2D GWAS  A[NR]  1.11[1.08–1.13]  Voight et al. Nat Genet; 2010  
   ISL1     Candidate        Johansson et al. Plos One; 2013 
rs864745  JAZF1  European  T2D GWAS  T[0.5]  1.1[1.07–1.13]  Zeggini et al. Nat Genet; 2008  
rs5219/ 
5218/5215 
KCNJ11  European  T2D GWAS  T[0.46]  1.14[1.10–1.19]  Scott et al. Science; 2007  
rs231362  KCNQ1  European  T2D GWAS  G[NR]  1.08[1.06–1.10]  Voight et al. Nat Genet; 2010  
rs972283  KLF14  European  T2D GWAS  G[NR]  1.07[1.05–1.10]  Voight et al. Nat Genet; 2010  
  
LCORL 
  
Birth weight 
GWAS        Horikoshi M et al. Nat Genet; 2013 
   LMNB2     Syndrome        Johansson et al. Plos One; 2013 
   LMX1A     Candidate        Johansson et al. Plos One; 2013 Appendix  
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rs2943641  LOC64673, IRS1  European  T2D GWAS  C[0.63]  1.19[1.13–1.25]  Rung et al. Nat Genet; 2009 
rs1387153  MTNR1B  European  T2D GWAS  T[NR]  1.09[1.06–1.11]  Voight et al. Nat Genet; 2010  
   NKX2-2     Candidate        Johansson et al. Plos One; 2013 
   NKX6-1     Candidate        Johansson et al. Plos One; 2013 
rs10923931 
NOTCH2, 
ADAM30 
European  T2D GWAS  T[0.11]  1.13[1.08–1.17]  Zeggini et al. Nat Genet; 2008  
   ONECUT1/HNF6     Candidate        Johansson et al. Plos One; 2013 
   PAX6     Candidate        Johansson et al. Plos One; 2013 
   PBX1     Candidate        Johansson et al. Plos One; 2013 
rs1801282  PPARG  European  T2D GWAS  C[0.82]  1.14[1.08–1.20]  Scott et al. Science; 2007  
rs8042680  PRC1  European  T2D GWAS  A[NR]  1.07[1.05–1.09]  Voight et al. Nat Genet; 2010  
   PTF1A     Candidate        Johansson et al. Plos One; 2016 
rs7593730  RBMS1, ITGB6  European  T2D GWAS  ?[0.78]  1.11[1.08–1.16]  Qi et al. Hum Mol Genet; 2010 
rs13266634  SLC30A8  European  T2D GWAS  C[0.61]  1.12[1.07–1.16]  Scott et al. Science; 2007  
rs5400  SLC2A2     Candidate        Johansson et al. Plos One; 2013 
   SOX9     Candidate        Johansson et al. Plos One; 2013 
   SREBF1     Candidate        Johansson et al. Plos One; 2013 
rs17036101  SYN2, PPARG  European  T2D GWAS  G[0.93]  1.15[1.10–1.21]  Zeggini et al. Nat Genet; 2008  
   SYT9     Candidate        Johansson et al. Plos One; 2013 
rs7903146  TCF7L2  European  T2D GWAS  T[0.26]  1.38[1.31–1.46]  Saxena et al. Science; 2007  
rs7578597  THADA  European  T2D GWAS  T[0.9]  1.15[1.10–1.20]  Zeggini et al. Nat Genet; 2008  
rs896854  TP53INP1  European  T2D GWAS  T[NR]  1.06[1.04–1.09]  Voight et al. Nat Genet; 2010  
rs7961581  TSPAN8, LGR5  European  T2D GWAS  C[0.27]  1.09[1.06–1.12]  Zeggini et al. Nat Genet; 2008  
rs9472138  VEGFA  European  T2D GWAS  T[0.28]  1.06[1.04–1.09]  Zeggini et al. Nat Genet; 2008  Appendix  
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S3 List of a priori candidate genes and/or SNPs implicated in FGR and references 
rs1801214 
/ 734312 
WFS1  European  T2D GWAS  T[NR]  1.13[1.08–1.18]  Voight et al. Nat Genet; 2010  
rs4689388  WFS1, PPP2R2C  European  T2D GWAS  T[0.57]  1.16[1.10–1.21]  Rung et al. Nat Genet; 2009 
   ZAC     Syndrome        Johansson et al. Plos One; 2013 
rs4457053  ZBED3  European  T2D GWAS  G[NR]  1.08[1.06–1.11]  Voight et al. Nat Genet; 2010  
rs11634397  ZFAND6  European  T2D GWAS  G[NR]  1.06[1.04–1.08]  Voight et al. Nat Genet; 2010  Appendix  
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Oligo name  Sequence  Synthesis scale  Scale  Tm  Oligo length  Product size 
HNF1A_125F  TTCTCAGAACCCTCCCCTTC  0.025  DESALT  60.6  20.0  412.0 
HNF1A_125R  AAAGAGGTTTAGGTGACTGCTG  0.025  DESALT  57.7  22.0 
  HNF4A_289F  CAGCTGGAGGGCACCCACTAT  0.025  DESALT  65.8  21.0  426.0 
HNF4A_289R  TTCAGACACGTGTGTGCACTA  0.025  DESALT  58.9  21.0 
  KRT8_231F  AGACAAGGCTGGGAGTTGAGG  0.025  DESALT  63.0  21.0  438.0 
KRT8_231R  CTCCACCTTCTCCACCAACTA  0.025  DESALT  59.2  21.0 
  SAFB2_270F  GCGGGACCGTTACTGAAC  0.025  DESALT  59.1  18.0  313.0 
SAFB2_270R  CCCAAGTTCGAGGGAACC  0.025  DESALT  60.4  18.0 
  TDG_839F  CCACGCGGTACTACAGAGAC  0.025  DESALT  58.4  20.0  187.0 
TDG_839R  TTAAAAGACCCCTGCGTGC  0.025  DESALT  61.2  19.0 
  TBP_013F  ACCTGCTGTTCCACCAAGAA  0.025  DESALT  60.7  20.0  595.0 
TBP_013R  TCTGAAAACAGAGCAGGAACAT  0.025  DESALT  59.0  21.0 
  KDM4B_411F  ATGCCTCCCTTGAAGGCTG  0.025  DESALT  63.0  19.0  664.0 
KDM4B_411R  CAGGCCACTCCTAGCTTCC  0.025  DESALT  60.0  19.0 
  RPL14_520F  CTTCAGATGTAGTTGTAGGGA  0.025  DESALT  52.0  21.0  517.0 
RPL14_520R  CTATCAATCTGCCTCCTAACT  0.025  DESALT  53.0  21.0 
   
 
 
 
 
 
 
 
  S4 Primer sequence ordered for Sanger sequencing      
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Assay ID 
 
Forward  
Primer Seq. 
 
Reverse 
 Primer Seq. 
 
Reporter 1  
Sequence (VIC) 
 
Reporter 2  
Sequence 
(FAM) 
 
Context Sequence  NCBI SNP Reference 
Assay 1  C____600632_20 
       
CGTGCTCTGACCTTCTGTCCAGGGG[A/C]GATGAGGGCATTGACGTGCTTCAGC  rs757110 
Assay 2  C__11908221_20 
       
GGCTATGAACATGTGGTCTTCCACG[C/T]CTGTGAAAACAGTTGGCTCAAAGAA  rs1127717 
Assay 3  C___2244893_10 
       
CCAACTCGAAATTCCCCGTGACCAG[A/T]CTTTTGGACACCAGGTTGGTGAATC  rs235768 
Assay 4  AHVJIP0         
CCCATCCCAG 
GAGAATAAGAAGAAG 
CGGTGG 
GCACCAGGAA 
AGGACATC 
GGTCTCAAA 
AGGACATC 
GATCTCAAA 
    Assay 5  C___2862880_1_ 
       
CACAGCACCGTGGGTCAGACCTTGC[C/T]GGTGAGAGTCCAGCCGTGACAAAGG  rs1260326 
Assay 7  C___1263617_10 
       
CCTGTGCAGAGCCATGTGACCCAGA[A/G]CCCCTTCATGGCCACCATGGCTCAG  rs2464196 
Assay 9  AHS1MDK         
CTGATGCTG 
CTGGTATCTGTGA 
TGTACGCAC 
ACAAGCAGGAA 
TTTCCATCT 
GCAGTGGTG 
CATCTGCA 
ATGGTG 
    Assay 10  C__25618321_10 
       
TGTGTGCCATCTGCGGGGACCGGGC[C/T]ACGGGCAAACACTACGGTGCCTCGA  rs736823 
Assay 11  C___2991148_10 
       
GTGCAGAGTGGTGTGGGCACTTTGA[C/T]GGTGTTGCCAAACTTGGAGTAGTCC  rs5215 
Assay 12  C___2991149_20 
       
TGAAGCAGAGGCGGCCGTGGCGCAG[A/G]GCGATCACCGCATGCTTGCTGAAGA  rs5218 
Assay 13  C__11654065_10 
       
CGCTGGCGGGCACGGTACCTGGGCT[C/T]GGCAGGGTCCTCTGCCAGGCGTGTC  rs5219 
Assay 14  C__11654166_10 
       
TGGTGGTGCAGGTCGCTGGGTGCCA[C/G]GTCGTAGAGTGGGCTGTTGGCATCA  rs1800467 
Assay 15  C__11951412_10 
       
AGTGAGTCCTCCTCTGCGTTCATGG[C/T]TTCGAGGTCGTCCTCCTTCTTGTCT  rs1801262 
Assay 16  AHUAKJS         
CCCTGGATGG 
AAAATGGATAAGGAT 
AGAATGGAGG 
CACCTGTATTGAC 
CTTGTGAAC 
CATTTCAAGTG 
TGTGAACCATG 
TCAAGTG 
    Assay 17  C___1129864_10 
       
AACTCTGGGAGATTCTCCTATTGAC[C/G]CAGAAAGCGATTCCTTCACTGATAC  rs1801282 
Assay 18  C___3142148_10 
   
     AAGCCACCCACCAAAGAATGATGCA[A/G]TCATTCCACCAACTGCAAAGCTGGA 
 
rs5400 
Assay 19  C___8899319_10 
       
AGCTGGTAGGCGTAGAGATGAGTGG[A/G]CATTTTGATCCAGTGAGGGGTATTG  rs1326663 
Assay 20  C__32653841_10 
       
GCCAAAGAGATTAACTCTTTCATTG[C/T]TATTTTCAACAAATCCATTCTGCCT  rs7578597 
Assay 21  C___2401729_1_ 
       
GTCTGTAGTGTGCCCCTGCTGTTGC[A/G]CTGGTGGACCAAGGCCAGCTTCTCT  rs734312 
Assay 22  C___8841076_10 
       
CTGTCGGCCACCTGGTCGTCCTCAA[C/T]GTCAGCGTCCCGTGCCTGCTCTATG  rs1801214 
Assay 23  C__25617947_20 
       
CAAGGACTGCATCCCCTGCTCGGAG[C/G]TGGCTGTCATCACCGGCTTCTTTAC  rs35031397 
Assay 24  C___8356128_1_ 
       
GTCCCACCCCCACTGGACTCACCAC[A/G]TGATGGCAGGTGAAGCCCTTCATGA  rs1799817 
S5  ABI primers and probes for genotyping. Where customised assays were designed then ABI provide only context sequences Appendix  
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Chr  Position 
Gene 
Region  Gene Symbol  Protein Variant 
Translation 
Impact 
SIFT 
Function 
Prediction 
1  144923730  Exonic  PDE4DIP 
p.E243fs; p.E309fs; 
p.E406fs  frameshift 
1  152189055  Exonic  HRNR  p.R1684C  missense    
1  152189310  Exonic  HRNR  p.G1599S  missense    
1  152190257  Exonic  HRNR  p.V1283A  missense    
2  132238306  Exonic  TUBA3C/TUBA3D  p.C347F  missense  Damaging 
2  179419226  Exonic  TTN  p.I20676M  missense    
3  10088407  Exonic  FANCD2  p.L426fs  frameshift 
3  40503520  Exonic  RPL14  p.149_150insAAAAA  in-frame    
3  52027854  Exonic  RPL29  p.130_131insAK  in-frame    
3  73111482 
Exonic; 
Intronic  EBLN2; PPP4R2  p.R84fs  frameshift 
3  73111506 
Exonic; 
Intronic  EBLN2; PPP4R2  p.91_92insV  in-frame    
3  124951185  Exonic  ZNF148  p.*795fs  frameshift 
3  124951186  Exonic  ZNF148  p.*795fs  frameshift 
3  195505910 
Exonic; 
Intronic  MUC4  p.S4181G  missense    
3  195505925 
Exonic; 
Intronic  MUC4  p.P4176S  missense    
3  195506051 
Exonic; 
Intronic  MUC4  p.L4134F  missense    
3  195506076 
Exonic; 
Intronic  MUC4  p.Q4125H  missense    
3  195506089 
Exonic; 
Intronic  MUC4  p.A4121V  missense    
3  195507011 
Exonic; 
Intronic  MUC4  p.L3814F  missense    
3  195507324 
Exonic; 
Intronic  MUC4  p.H3709Q  missense    
3  195507605 
Exonic; 
Intronic  MUC4  p.R3616C  missense    
3  195507941 
Exonic; 
Intronic  MUC4  p.T3504P  missense    
3  195508499 
Exonic; 
Intronic  MUC4  p.A3318P  missense    
3  195508510 
Exonic; 
Intronic  MUC4  p.L3314H  missense    
3  195509861 
Exonic; 
Intronic  MUC4  p.S2864P  missense    
3  195514524 
Exonic; 
Intronic  MUC4  p.H1309Q  missense    
3  195515134 
Exonic; 
Intronic  MUC4  p.P1106H  missense    
4  1388625  Exonic  CRIPAK  p.C110fs  frameshift 
4  88537069  Exonic  DSPP  p.1085_1086insDSS  in-frame    
5  139931629 
Intronic; 
Exonic;  SRA1  p.109_110insR  in-frame    Appendix  
232 
   
ncRNA 
6  16327915  Exonic  ATXN1  p.208_209insQQQ  in-frame    
6  16327915  Exonic  ATXN1  p.208_209insQ  in-frame    
6  29912030  Exonic  HLA-A  p.D251fs  frameshift 
6  31380162 
Exonic; 
ncRNA  MICA  p.G318fs; p.A317fs  frameshift 
6  31380162 
Exonic; 
ncRNA  MICA  p.G318fs; p.A317fs  frameshift 
6  31380162 
Exonic; 
ncRNA  MICA  p.G318fs; p.A317fs  frameshift 
6  170871013  Exonic  TBP 
p.43_44insQQQ; 
p.63_64insQQQ  in-frame    
6  170871039  Exonic  TBP  p.52_53insQ; p.72_73insQ  in-frame    
6  170871047  Exonic  TBP  p.55delQ; p.75delQ  in-frame    
7  15725824  Exonic  MEOX2  p.68delH  in-frame    
7  22190123 
Splice 
Site  RAPGEF5          
7  142460779  Exonic  PRSS1  p.D218Y  missense  Activating 
8  101730036  Exonic  PABPC1  p.M158fs  frameshift 
9  40703811  Exonic 
SPATA31A6 
(includes others)  p.R490W  missense  Damaging 
9  140637837  Exonic  EHMT1  p.V280F  missense  Tolerated 
11  47857258  Exonic  NUP160  p.S349F  missense  Damaging 
11  112832341  Exonic  NCAM1  p.Q3fs  frameshift 
12  53343231 
Intronic; 
Exonic  KRT8; KRT18  p.A92P  missense  Damaging 
12  104359839 
Splice 
Site  TDG          
12  104373734  Exonic  TDG  p.I98fs  frameshift 
13  73409508 
Splice 
Site  PIBF1          
14  23548797  Exonic  ACIN1 
p.640_641insSR; 
p.600_601insSR  in-frame    
14  92537354 
Exonic; 
ncRNA  ATXN3  p.92_93insAAAAAAAAA;   in-frame    
15  100252710  Exonic  MEF2A  p.410_411delQQ;   in-frame    
16  1574650  Exonic  IFT140  p.H1015P  missense  Damaging 
16  3119304  Exonic  IL32 
p.D115fs; p.D172fs; 
p.D152fs; p.D163fs  frameshift 
17  7750177  Exonic  KDM6B  p.251_252insP  in-frame    
17  45234350  Exonic  CDC27  p.Q257Q  synonymous 
17  72541045  Exonic  CD300C  p.V35L  missense  Tolerated 
19  501701 
Intronic; 
Exonic  MADCAM1  p.234_235insTTSPEPPN  in-frame    
19  501701 
Intronic; 
Exonic  MADCAM1  p.234_235insTTSPEPPD  in-frame    
19  5144411  Exonic  KDM4B 
p.963_964insESITVSCGVGQ 
GAGGGWEHSDNLYP  in-frame    
19  5587270  Exonic  SAFB2  p.F949S  missense  Damaging 
19  9015382  Exonic  MUC16  p.G12736S  missense    Appendix  
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19  50308921  Exonic  AP2A1  p.Y824*; p.Y846*  stop gain    
19  50881824  Exonic  NR1H2 
p.173_174insT; 
p.76_77insT  in-frame    
22  28194933  Exonic  MN1  p.533_534insQ  in-frame    
22  38120180  Exonic  TRIOBP  p.540delS  in-frame    
X  135956575 
Exonic; 
Intronic; 
ncRNA  RBMX  p.P301fs  frameshift 
X  155239824 
Exonic; 
3'UTR  IL9R  p.N439S  missense  Tolerated 
X  155239827 
Exonic; 
3'UTR  IL9R  p.N440S  missense  Tolerated 
 
S6   71 gene variants identified through Ingenuity with chromosome, position, 
region, gene name, protein transcript, type of variant 
 
 
 
ID 
450k 
ID 
DNA 
(ul) 
Water 
(ul) 
PLACENTA    
Qubit 
ng/ul 
Volume 
ng/ul 
260/280  260/230 
% 
Conversion 
42FF  1  12.8  32.2  39.1  97  1.74  2.25  97.36% 
68NA  2  3.6  41.4  139  97  1.8  2.31  98.64% 
80CM  3  6.2  38.8  80.8  97  1.85  2.36  98.69% 
83AG  4  9.1  35.9  55.2  97  1.8  2.52  90.22% 
98LH  5  3.1  41.9  159  97  1.85  2.5  95.51% 
101HA  6  5.0  40.0  101  97  1.85  2.66  96.81% 
104NF  7  5.7  39.3  88.4  97  1.86  2.5  98.63% 
131JB  8  5.9  39.1  85.2  97  1.83  2.47  98.89% 
143MB  9  10.1  34.9  49.4  97  1.81  2.21  97.76% 
165EK  10  4.2  40.8  118  97  1.85  2.66  98.89% 
174NS  11  12.6  32.4  39.8  97  1.78  2.57  93.50% 
196ST  12  3.0  42.0  165  97  1.82  2.46  97.68% 
202AD  13  3.5  41.5  142  97  1.82  2.51  84.84% 
209DK  14  12.9  32.1  38.7  97  1.8  2.69  80.92% 
230DP  15  2.5  42.5  198  97  1.85  2.51  96.76% 
248IA  16  12.3  32.7  40.6  97  1.89  2.41  98.35% 
285IR  17  11.4  33.6  43.8  97  1.83  2.4  95.99% 
300PB  18  3.7  41.3  135  97  1.83  2.42  97.19% 
309FC  19  4.2  40.8  118  97  1.88  2.55  96.40% 
320AMF  20  8.9  36.1  55.9  97  1.96  2.56  96.49% 
343EE  21  19.6  25.4  25.5  97  1.94  2.8  98.51% 
359LO  22  7.7  37.3  65.1  97  1.82  2.33  98.07% Appendix  
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376AJ  23  19.6  25.4  25.5  97  1.82  2.48  97.68% 
379VMB  24  20.6  24.4  24.3  97  2.07  2.33  90.10% 
442EN  25  21.2  23.8  23.6  97  1.85  2.06  98.88% 
455MT  26  13.8  31.2  36.3  97  1.84  2.66  94.23% 
801AG  27  9.1  35.9  55  97  1.88  1.8  99.08% 
215ET  28  2.2  42.8  230  97  1.89  2.63  97.47% 
235RA  29  3.0  42.0  165  47  1.84  2.47  95.51% 
319RB  30  4.7  40.3  107  43  1.79  2.23  84.49% 
3IH  31  14.0  31.0  35.7  97  1.85  2.31  95.45% 
9RE  32  14.7  30.3  34.1  97  1.81  2.12  95.89% 
39NK  33  15.2  29.8  33  97  1.84  2.41  94.61% 
47KW  34  1.5  43.5  329  97  1.84  2.41  96.05% 
50ST  35  3.4  41.6  149  97  1.82  2.43  99.28% 
53AL  36  5.0  40.0  100  97  1.9  2.37  99.33% 
56SW  37  14.1  30.9  35.4  97  1.86  2.35  93.51% 
156BT  38  3.5  41.5  143  97  1.88  2.38  98.16% 
161SJ  39  3.2  41.8  155  97  1.87  2.4  98.76% 
184EH  40  3.4  41.6  147  97  1.84  2.58  97.81% 
190LF  41  3.0  42.0  164  97  1.82  2.48  93.37% 
254OA  42  11.1  33.9  45.2  97  1.79  2.57  98.28% 
328LBp3  43  6.7  38.3  74.2  97  1.9  2.37  96.95% 
331MVB  44  12.3  32.7  40.6  97  1.88  2.17  92.99% 
334MVa  45  13.9  31.1  36  97  1.76  2.16  99.14% 
337EC  46  9.9  35.1  50.7  97  1.86  2.77  97.37% 
359KC  47  4.2  40.8  118  97  1.88  2.5  98.90% 
385SS  48  24.4  20.6  20.5  97  1.84  2.43  97.65% 
392DG  49  6.5  38.5  77  97  1.86  2.58  96.95% 
395MH  50  45.0  0.0  7.83  97  1.8  2.27  99.95% 
398IR  51  13.9  31.1  36  97  1.84  2.09  98.60% 
413BT  52  4.5  40.5  111  97  1.84  2.55  96.99% 
421YD  53  4.8  40.2  104  97  1.86  2.58  94.13% 
427LN  54  14.2  30.8  35.2  97  1.89  2.39  97.76% 
431MZ  55  27.9  17.1  17.9  97  1.85  2.73  99.27% 
445VX  56  12.0  33.0  41.6  97  1.82  2.65  98.98% 
1008JB  57  12.8  32.2  39.1  97  1.85  2.48  92.41% 
                  433AS  13                    94.39% 
439ZH  14                    99.24% 
95EG  30                    94.38% 
164RH  11                    93% 
 
S7 DNA quality check and bisulphite conversion efficiency (% conversion) in 
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ID  450k ID 
DNA 
(ul) 
water 
(ul) 
     
CORD 
BLOOD 
  
  
Qubit 
ng/ul 
Volume 
ul 
260/280  260/230 
% 
Conversion 
42FF  58  4.5  40.5  112  97  1.84  2.34  92.83% 
68NA  59  5.3  39.7  94  97  1.85  2.35  98.32% 
80CM  60  5.7  39.3  87.3  97  1.82  2.26  98.93% 
83AG  61  5.1  39.9  97.8  97  1.83  2.27  99.40% 
98LH  62  8.6  36.4  58.1  97  1.8  2.21  98.17% 
101HA  63  10.2  34.8  48.8  97  1.81  2.16  98.06% 
104NF  64  10.2  34.8  48.8  97  1.81  2.16  98.55% 
131JB  65  8.1  36.9  61.6  97  1.82  2.24  91.26% 
143MB  66  15.9  29.1  31.5  97  1.8  2.1  96.48% 
165EK  67  7.6  37.4  66.1  97  1.9  2.42  97.72% 
174NS  68  4.3  40.7  116  97  1.82  2.32  99.09% 
196ST  69  17.9  27.1  28  97  1.97  3.43  0.09% 
202AD  70  3.1  41.9  163  97  1.84  2.41  96.58% 
209DK  71  4.4  40.6  114  97  1.84  2.43  96.23% 
230DP  72  6.1  38.9  82.3  97  1.87  2.42  97.62% 
248IA  73  2.8  42.2  176  50  1.86  2.55  96.21% 
285IR  74  3.3  41.7  152  97  1.84  2.35  99.48% 
300PB  75  2.5  42.5  204  50  1.84  2.45  97.91% 
309FC  76  4.3  40.7  117  97  1.85  2.29  98.63% 
320AMF  77  8.9  36.1  55.9  97  1.94  2.56  99.03% 
343EE  78  2.6  42.4  196  97  1.88  2.44  99.68% 
359LO  79  4.3  40.7  117  96  1.85  2.4  99.70% 
376AJ  80  2.9  42.1  174  96  1.85  2.39  99.66% 
379VMB  81  2.0  43.0  249  96  1.86  2.37  99.42% 
442EN  82  13.3  31.7  37.6  96  1.93  1.74  96.53% 
455MT  83  4.9  40.1  103  96  1.91  2.34  99.31% 
801AG  84  14.9  30.1  33.5  97  1.78  1.81  1.03% 
77KP  85  8.1  36.9  61.4  97  1.83  2.3  98.47% 
215Et  86  15.8  29.2  31.6  97  1.83  2.15  99.02% 
235RA  87  26.3  18.7  19  97  1.82  1.86  98.95% 
319RB  88  5.9  39.1  85.4  97  1.81  2.3  99.70% 
3IH  89  4.4  40.6  114  18  1.82  2.12  94.28% 
9RE  90  25.5  19.5  19.6  97  2  2.01  99.93% 
39NK  91  4.0  41.0  126  21  1.86  2.35  93.14% 
47KW  92  8.1  36.9  61.8  47  1.86  2.22  94.94% 
50ST  93  2.8  42.2  177  28  1.88  2.33  95.71% 
53AL  94  4.2  40.8  119  19  1.84  2.29  94.26% 
56SW  95  2.9  42.1  175  28  1.85  2.38  94.34% 
95EGc  96  7.2  37.8  69  47  1.87  2.32  97.24% 
156BT  97  8.6  36.4  58.3  47  1.83  2.23  94.11% 
178JSB  98  8.4  36.6  59.6  47  1.85  2.06  94.72% Appendix  
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S8 DNA quality check and bisulphite conversion efficiency (% conversion) in 
cord blood samples run on 450K array 
 
 
 
 
 
184EH  99  1.0  44.0  482  23  1.82  2.33  96.26% 
190LF  100  0.9  44.1  542  24  1.8  2.31  96.82% 
227FB  101  3.3  41.7  153  25  1.84  2.36  93.70% 
254OA  102  1.5  43.5  333  20  1.86  2.47  96.63% 
328LBb2  103  6.3  38.7  79.1  47  1.83  2.23  94.86% 
331MVB  104  1.5  43.5  341  37  1.79  2.27  94.81% 
334MVa  105  6.7  38.3  75.1  47  1.87  2.34  91.91% 
337EC  106  4.3  40.7  115  18  1.9  2.39  96.90% 
359KC  107  1.3  43.7  389  38  1.81  2.33  96.96% 
385SS  108  2.5  42.5  204  40  1.84  2.27  95.81% 
392DG  109  2.0  43.0  255  34  1.84  2.36  99.41% 
395MH  110  2.6  42.4  190  29  1.85  2.37  98.33% 
398IR  111  8.5  36.5  58.7  47  1.84  1.98  93.66% 
413BT  112  1.9  43.1  264  44.5  1.84  2.39  94.75% 
421YD  113  61.4  -16.4  8.14  97  1.77  2.02  99.13% 
431MZ  114  30.7  14.3  16.3  97  1.78  2.02  99.39% 
445VX  115  9.1  35.9  54.9  47  1.85  1.96  96.70% 
1008JB  116  45.0  0.0  7.13  147  1.77  1.58  99.73% Appendix  
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A Study looking at how parents contribute to growth of babies in the womb 
FATHER’S QUESTIONNAIRE 
 
This questionnaire asks you some questions about your health and your 
background. 
 
All answers you give are confidential and will only be seen by the 
research team 
 
We would be grateful if you would help us by answering all the 
questions.  If you have any queries about any of the questions or would 
like some help in completing this questionnaire, please contact Dr Sara 
Hillman on                 07826 631112 
THANK YOU VERY MUCH FOR YOUR HELP 
 
 
                                                   Date today: 
  
                                                                        DETAILS (number/address) 
                                                                                                                                
Preferred method of contact:   Mobile telephone                  …  
…………………………………………………... 
                                                 
Home/ Work (please delete) telephone                     
.……………………………………………… 
                                              Appendix  
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Home/ Work (please delete) email                          
.…...………………………………………….. 
                                   
Name:  ………………………………………………………………………      Date of birth:   
    
(Partner’s name: …………………………………………………………….) 
Q1. How old are you?  
 
Q2. Do you know what your weight is approximately?.....................................   And your 
height?...................................... 
 
Q3. Is this your first child with your current partner?                                      
Q3a. If no, how many children do you already have together?  
 
MEDICAL HISTORY 
Q3. Do you have any medical problems?                                                   
If yes: 
i.  Diabetes                                      Requiring insulin? 
 
ii.  Heart disease 
 
iii.  Kidney disease 
 
iv.  Haematological problems 
 
v.  Other - please state:   
……………………………………………………………………………………
……….   
Q4. Are you taking any medications?          
What:…………………………………………….. 
 
no 
 
yes 
 
yes 
 
no 
 
no 
 
yes 
 
yes 
 
no 
yes 
 
no 
 
no 
 
yes 
 
no 
 
yes 
 
yes  no 
 Appendix  
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FAMILY HISTORY 
Q5a. Do you know how much you weighed when born? 
………………………………………… 
Q5b. Were you called a ‘small’ baby?                                             
 
Q5c.  Were you born early?                                                If so, 
when?.................................................... 
 
Q5d. Were you a twin? 
 
Q6. Do you recall if your mother had high blood pressure in her pregnancy /pregnancies?      
 
Q7. Did / do either of your parents have significant health problems? 
 
If yes, can you tell us whom and what? 
……………………………………………………………………………………… 
.....................................................................................................................................................
.............................................. 
   
LIFESTYLE 
Q8.   Have you ever smoked?          
If stopped for how long and how many were you 
smoking?.............................................................................................. 
 
If yes,   How many / day 
 
Q9.  Do you drink alcohol?  
 
If yes, approximately how many glasses*/ week 
   
no 
 
yes 
 
0-5  5-
10 
10-
20 
20
+ 
yes 
 
no 
 
no 
 
yes 
 
21-69 
glasse
s 
7-20 
glasse
s 
1-6 
glasses 
1 
glass 
70
+ 
yes 
 
no 
 
yes  no 
 
N
K 
 
yes 
 
no 
 
N
K 
N
K 
yes 
 
no 
 Appendix  
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*By glass we mean a pub measure of spirits, half a pint of lager or cider, a wine glass of 
wine, etc 
Q10. If this is not your first child with this partner, has there been any significant change in 
your lifestyle between children i.e. smoking, exercise, development of disease or significant 
weight gain or loss? 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
……………………………………………………………… 
Q11. Anything else you would like to share that may be relevant? 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
……………………………………………………………… 
…………………………………………………………………………………………………
……………………………   THANK YOU  
 
 
S9 SUBJECT QUESTIONNAIRE 
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